

## Part 1, A-L

- A**
- Aabom B, Kragstrup J, Vondeling H, Bakketeig LS, Stovring H. Defining Cancer Patients As Being in the Terminal Phase: Who Receives a Formal Diagnosis, and What Are the Effects? 7411
- Aalders JG, *see* Reesink-Peters N
- Aaltonen L, *see* Eschrich S
- Aapro M, *see* Gridelli C
- Aapro MS. The Frail Are Not Always Elderly (editorial), 2121
- Aaron J, *see* Beale EA
- Aaronson N, *see* Coens C  
*see* Knols R  
*see* Madalinska JB
- Aase S, *see* Stormorken AT
- Aass N, *see* Sagstuen H
- Aass N, De Mulder PHM, Mickisch GHJ, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized Phase II/III Trial of Interferon Alfa-2a With and Without 13-*cis*-Retinoic Acid in Patients With Progressive Metastatic Renal Cell Carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951), 4172
- Abad A, *see* Sastre J
- Abati A, *see* Dudley ME
- Abbou CC, *see* Patard J-J
- Abbou M, *see* Dannenberg H
- Abbruzzese A, *see* Caraglia M
- Abbruzzese J, *see* Petrelli NJ  
*see* Thomas MB
- Abdel-Rahman WM, *see* Ollikainen M  
*see* Renkonen ET
- Abdelkefi A, Torjman L, Ladeb S, Ben Othman T, Achour W, Lakhali, Hsairi M, Kammoun L, Ben Hassen A, Ben Abdeladhim A. Randomized Trial of Prevention of Catheter-Related Bloodstream Infection by Continuous Infusion of Low-Dose Unfractionated Heparin in Patients With Hematologic and Oncologic Disease, 7864
- Abdous B, *see* Bairati I
- Abe O, *see* Noguchi S
- Abe R, *see* Noguchi S
- Abeloff M, *see* Hutchins LF  
*see* Davidson NE
- Abend M, *see* Port M
- Abergel A, *see* Barbare J-C
- Abi-Raad R, *see* Taghian AG
- Abino J-F, *see* Boulanger E
- Ablin A, *see* Castellino SM  
*see* Park ER
- Abou-Jawde RM, *see* Mekhail TM
- Aboulafia D, *see* Noy A  
*see* Gallafent JH
- Abraham S, *see* Goodin S
- Abrams J. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: A Commentary (editorial), 8564
- Abrams JR, *see* Syrjala KL
- Abrams JS, *see* Korn EL
- Abrams RA, *see* Ettinger DS
- Abramson DH, *see* Kleinerman RA  
*see* Rietschel P
- Abrott RP. Rationing and Decision Making (correspondence), 2437
- Abrott RP, Reece WHH, Enas NH, Stephens R. Randomized Phase II Studies and Their Ethics (correspondence), 9443
- Abrey LE, *see* Cloughesy TF  
*see* Shenkier TN
- Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F. Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma, 5034
- Abruzzese E, *see* Soverini S
- Abt M, *see* Camidge R
- Acharya M, *see* Ryan QC
- Acholonu S, *see* Khouri IF
- Achour W, *see* Abdelkefi A
- Achten R, *see* De Paepe P
- Açil Y, *see* Warnke PH
- Acimović L, *see* Jeremić B
- Acosta G, *see* Arroyo GF
- Adam R, *see* Bilchik AJ  
*see* Bralet M-P  
*see* Poston GJ
- Adams D, *see* Joshua AM
- Adams J, *see* Hamilton AL  
*see* O'Connor OA
- Adams MJ, Mauch P, Colan SD, Tarbell NJ, Diller L, Treves ST, Lipshultz SE. In Reply (correspondence), 3636
- Adamson PC, *see* Blaney SM  
*see* Daw NC  
*see* Lee DP
- Adang EM, Timmer-Bonte JN
- Addeo R, *see* Caraglia M
- Adegboyega PA, *see* Morgan PB
- Adelson K, *see* Melnick AM
- Adelstein DJ, *see* Urba SG
- Adelstein DJ. Induction Redux: Once More With Taxanes (editorial), 8556
- Adema GJ, *see* de Vries IJM
- Adjadj E, *see* Guibout C
- Adjei A, *see* Goetz MP  
*see* Jatoi A  
*see* Goetz MP  
*see* LoRusso PM  
*see* Ma CX
- Adjei AA, Hidalgo M. Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy, 5386
- Adjei AA, Hidalgo M. Treating Cancer by Blocking Cell Signals, 5279
- Adkins DR, *see* Pavletic SZ

- Advani RH, *see* Kuo T
- Ady-vago N, *see* Faivre S
- Afifi AA, *see* Krupski TL
- Agarwala SS. In Reply (correspondence), 3155
- Agazzi A, *see* Laszlo D
- Agelidou A, *see* Georgoulis V
- Ageno W, *see* Verso M
- Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer, 5943
- Agirre X, *see* Roman-Gomez J
- Aglietta M, *see* Grignani G  
*see* Montemurro F
- Agnelli G, *see* Verso M
- Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D, Baldini L, Morabito F, Callea V, Lombardi L, Neri A. Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing *CCND1* and Negative for 14q32 Translocations, 7296
- Agnew E, *see* Grem JL
- Agostara B, *see* Colucci G
- Agrelo R, Setien F, Espada J, Artiga MJ, Rodriguez M, Pérez-Rosado A, Sanchez-Aguilera A, Fraga MF, Piris MA, Esteller M. Inactivation of the *Lamin A/C* Gene by CpG Island Promoter Hypermethylation in Hematologic Malignancies, and Its Association With Poor Survival in Nodal Diffuse Large B-Cell Lymphoma, 3940
- Agura E, *see* Sorrow ML
- Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I Clinical Study of Pertuzumab, A Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer, 2534
- Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Titus-Ernstoff L, Skalla K, Bakitas M, Silberfarb PM. Quality of Life of Long-Term Survivors of Breast Cancer and Lymphoma Treated With Standard-Dose Chemotherapy or Local Therapy, 4399
- Ahlgren JD. Thymidylate Synthase in Nodal Metastases: Prognostic for Chemosensitivity But Not for Adjuvant Therapy? (editorial), 5452
- Ahluwalia MS, Daw HA. Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin for HER-2-Positive Operable Breast Cancer (correspondence), 7759
- Ahmad J, *see* Lalani M
- Ahmed AA, *see* Brenton JD
- Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B, Haffty BG. Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates, 17
- Ahsan H, *see* Bian Y  
*see* Pasche B
- Aikin A, *see* Blaney SM  
*see* Warren KE
- Ainsworth P, *see* Eisen A
- Aitini E, *see* Louvet C
- Ajani JA, *see* Yao JC
- Ajani JA. Carcinoma of the Esophagus: Is Biology Screaming in My Deaf Ears? (editorial), 4256
- Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I Pharmacokinetic Study of S-1 Plus Cisplatin in Patients With Advanced Gastric Carcinoma, 6957
- Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Filho SC, Majlis A, Assadourian S, Van Cutsem E. Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma, 5660
- Ajani JA. In Reply (correspondence), 38700
- Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-Based Chemoradiotherapy in Localized Gastric Carcinoma: Degree of Pathologic Response and Not Clinical Parameters Dictated Patient Outcome, 1237
- Ajzenberg C, *see* Amar L
- Akar M, *see* Oktay K
- Akazawa K, *see* Noguchi S
- Akcali Z, *see* Yildirim Y
- Akechi T, *see* Morita T
- Akhtar S, Maghfoor I. Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma, 6261
- Akhurst T, *see* Schrag D
- Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, Blumgart L, Jarnagin W, Larson SM, Fong Y. Recent Chemotherapy Reduces the Sensitivity of [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography in the Detection of Colorectal Metastases, 8713
- Akioka T, *see* Yokote T
- Akkermans J, *see* Timmer-Bonte JN
- Akyurek S, *see* Altundag K
- Al-Ali H, *see* Sorrow ML
- Al-Batran SE, *see* Rummel MJ
- Al-Kuraya K, *see* Sauter G
- Alaggio R, *see* Carli M
- Alam A, *see* Czuczman MS
- Albain KS, *see* Farray D  
*see* Gaspar LE  
*see* Pierce LJ
- Albanell J, *see* Baselga J  
*see* Montagut C  
*see* Tabernero J
- Alberg AJ, Brock MV, Samet JM. Epidemiology of Lung Cancer: Looking to the Future, 3175
- Alberola V, *see* Ramirez JL
- Albers P, *see* Lehmann J  
*see* Port M
- Albert ED, *see* Glas J
- Albert U-S, *see* Kaufman M
- Alberti D, *see* Soverini S
- Alberti L, *see* Arpin D
- Alberts DS, *see* Fruehauf JP
- Alberts S, *see* Poston GJ
- Alberts SR, *see* Witzig TE
- Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study, 9243
- Alberts SR, Sargent DJ, Gill S, Loprinzi CL. In Reply (correspondence), 654
- Albatar M, *see* Keating MJ  
*see* Wierda W
- Albritton K, *see* D'Adamo DR
- Aldana LP, *see* Onozawa M
- Aldaoud A, *see* Lenz G
- Alderfer MA, *see* Kazak AE
- Aleman BMP, *see* Raemaekers JMM
- Alemañy CA, *see* Sup SJ
- Alexander HR, *see* Pingpank JF
- Alfaro C, *see* Mazzolini G
- Algás R, *see* Zapatero A
- Alija V, *see* Martín J
- Alikhan M, Spencer HJ, Kohli M. High-Dose Interleukin-2 May Not Be Superior to Low-Dose Interleukin-2 Plus Interferon (correspondence), 6267

- Alimonti A, Ferretti G, Cognetti F. Can the Reliance of Hormone Receptor Assays of Surgical Specimens Be Explained by the Fluctuation of Estrogen Receptor, Progesterone Receptor, and HER-2 Protein Expression in Tumor Samples of Premenopausal Breast Cancer Patients? (correspondence), 8918
- Alkuzweny B, *see* Czuczman MS
- Allaf ME, *see* Link RE
- Allal AS. Preoperative Radiochemotherapy in Gastric Cancer: Another Ongoing Shift From Adjuvant to Neoadjuvant? (correspondence), 3870
- Allan SJ, *see* Panades M
- Allard WJ, *see* Cristofanilli M
- Allegra C, *see* Sargent DJ
- Allegue MJ, *see* Ortega JJ
- Allen C, *see* Ezzo J
- Allen P, *see* Sasaki R
- Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam KJ, Coit DG. In Reply (correspondence), 7237
- Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam KJ, Coit DG. Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single Institution, 2300
- Allen PK, *see* Komaki R
- Allen R, *see* Weber RW
- Allen SM, *see* Duffy CM
- Allen WL, Johnston PG. Role of Genomic Markers in Colorectal Cancer Treatment, 4545
- Alletti DG, *see* Buda A
- Alliot C. CHOP Versus CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma (correspondence), 4797
- Alliot C. Undertreatment of Breast Cancer in Elderly Women: Contribution of a Cancer Registry (correspondence), 4800
- Alliot C. Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients (correspondence), 4237
- Allison DE, *see* Agus DB
- Allmer C, *see* Philip PA
- Alloisio M, *see* Caraglia M
- Allred C, *see* Hutchins LF
- Allred DC, *see* Chang JC  
*see* Gutierrez MC  
*see* Mohsin SK
- Allweis T, *see* Stojadinovic A
- Almenar D, *see* Aparicio J
- Almohamad W, *see* Ulusakarya A
- Almonacid GV, *see* Arroyo GF
- Aloisi T, *see* Aversa F
- Alonzo TA, *see* Johnston DL
- Alonzo TA. Standards for Reporting Prognostic Tumor Marker Studies (editorial), 9053
- Altamirano E, *see* Clayman GL
- Altieri AM, *see* Ardizzoni A
- Altinbas M, *see* Ozkan M
- Altman DG, *see* McShane LM
- Altundag K, *see* Altundag O
- Altundag K, Altundag O, Atik MA. Heparin and CXCL12 Dimerization (correspondence), 7248
- Altundag K, Altundag O, Baptista MZ, Akyurek S. Heparanase Activity and Bone Loss in Postmenopausal Breast Cancer Patients (correspondence), 8916
- Altundag K, Altundag O, Morandi P, Gunduz M. CA125 Nadir Values As a Prognostic Factor in Epithelial Ovarian Cancer (correspondence), 2435
- Altundag K, Altundag O, Morandi P, Gunduz M. Targeted Therapy for Targeted Patients: Trastuzumab in Adjuvant Treatment of Non-Small-Cell Lung Cancer (correspondence), 1325
- Altundag K. Challenge in the Treatment of Estrogen-Receptor-Negative Ductal Carcinoma in Situ (correspondence), 4469
- Altundag O, *see* Altundag K
- Altundag O, Altundag K, Gunduz E. Interleukin-6 and C-Reactive Protein in Metastatic Renal Cell Carcinoma (correspondence), 1044
- Alvegard TA, *see* Ferrari S
- Alvi MM, *see* Arroyo GF
- Amabile M, *see* Soverini S
- Amado RG, *see* Hedenus M
- Amadori D, *see* Boccardo F
- Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoll-Sire P, Richard S, Rohmer V, Sadoul J-L, Strompf L, Schlumberger M, Bertagna X, Plouin P-F, Jeunemaitre X, Gimenez-Roquepio A-P. Genetic Testing in Pheochromocytoma or Functional Paraganglioma, 8812
- Amatruda TT, *see* Koyanagi K
- Ambergen T, *see* Gómez-García EB
- Ambinder RF, *see* Keegan THM
- Ambros P, *see* Vandesompele J
- Amellal N, *see* Baselga J  
*see* Chan ATC
- Amendola MA, *see* Hricak H
- Amendola MA, Hricak H, Mitchell DG, Snyder B, Chi DS, Long HJ III, Fiorica JV, Gatsonis C. Utilization of Diagnostic Studies in the Pretreatment Evaluation of Invasive Cervical Cancer in the United States: Results of Intergroup Protocol ACRIN 6651/GOG 183, 7454
- Ames M, *see* Goetz MP  
*see* Whitlock JA
- Ames P, *see* Weber RW
- Ameys L, *see* Timmerman D
- Amiel G, *see* Lotan Y
- Amin B, *see* Jatoui A
- Amin P, *see* Hussain A
- Amira N, *see* Catto JWF
- Amler LC, *see* Eberhard DA
- Amling CL, *see* Freedland SJ
- Amoroso D, *see* Boccardo F
- Amos CI, *see* Gritz ER
- Anagnostopoulos A, *see* Bamias A  
*see* Dimopoulos MA
- Anagnostopoulou O, *see* Georgoulas V
- Anaïssie E, *see* Mahfouz T  
*see* Talamo G
- Anak Ö, *see* Köhne C-H
- Anasetti C, *see* Pavletic SZ
- Anbe H, *see* Ajani JA
- Ancukiewicz M, *see* Kirsch DG  
*see* Taghian AG
- Anderlini P, *see* Khouri IF
- Anders V, *see* Bolaños-Meade J
- Andersen MH, Reker S, Stratem Pt, Gehl J, Geertsen P, Becker JC. Concomitant Administration of Interleukin-2 During Therapeutic Vaccinations Against Cancer: The Good, the Bad, or the Evil? (correspondence), 5265
- Anderson B, *see* Lutgendorf SK
- Anderson DR, *see* Couban S
- Anderson F, *see* Ho C
- Anderson H, *see* Baka S
- Anderson J, *see* Williamson D
- Anderson JR, *see* Donaldson SS
- Anderson JR, Neuberg DS. Analysis of Outcome by Response Flawed (correspondence), 8122

- Anderson KC, *see* Hideshima T  
*see* Rajkumar SV  
*see* Treon SP
- Anderson KC, Pazdur R, Farrell AT. Development of Effective New Treatments for Multiple Myeloma, 7207
- Anderson S, *see* Mamounas EP
- Anderson SE, *see* D'Adamo DR
- Anderson WF, *see* Dores GM  
*see* Jatoi I
- Andersson LC, *see* Sihto H
- Ando A, *see* Iwao-Koizumi K
- Andre F, *see* Rouzier R
- Andre F, Delaloge S, Spielmann M. In Reply (correspondence), 2116
- Andre F, Khalil A, Slimane K, Massard C, Mathieu MC, Vignot S, Assi H, Delaloge S, Spielmann M. Mitotic Index and Benefit of Adjuvant Anthracycline-Based Chemotherapy in Patients With Early Breast Cancer, 2996
- Andre T, *see* Sargent DJ
- André T, *see* Louvet C  
*see* Taïieb J
- Andreeff M, *see* Keating MJ
- Andreou P, *see* Couban S
- Andreu J, *see* Tabernero J
- Andrews MB, *see* Hainsworth JD
- Andrieu J-M, *see* Oudard S  
*see* Scotté F
- Androulakis N, *see* Georgoulas V
- Andrulis IL, *see* Wunder JS
- Andrykowski MA, Bishop MM, Hahn EA, Cella DF, Beaumont JL, Brady MJ, Horowitz MM, Sobocinski KA, Rizzo JD, Wingard JR. Long-Term Health-Related Quality-of-Life, Growth, and Spiritual Well-Being After Hematopoietic Stem-Cell Transplantation, 599
- Andrykowski MA, Schmidt JE, Salsman JM, Beacham AO, Jacobsen PB. Use of a Case Definition Approach to Identify Cancer-Related Fatigue in Women Undergoing Adjuvant Therapy for Breast Cancer, 6613
- Andrykowski MA. Depression and Survival After Hematopoietic Stem Cell Transplantation: Where Do We Go From Here? (editorial), 5878
- Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS. Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14, 3008
- Angelopolou M, *see* Molina A
- Angelucci E, *see* Gobbi PG
- Angermann C, *see* Vordermark D
- Anghelina M, *see* Eisenbeis CF
- Angtuaco E, *see* Talamo G
- Annane D, Chevret S. In Reply (correspondence), 4466
- Annema JT, Versteegh MI, Veselić M, Voigt P, Rabe KF. Endoscopic Ultrasound-Guided Fine-Needle Aspiration in the Diagnosis and Staging of Lung Cancer and Its Impact on Surgical Staging, 8357
- Ansari R, *see* Li J  
*see* Niell HB
- Anscher MS. The Irreversibility of Radiation-Induced Fibrosis: Fact or Folklore? (editorial), 8551
- Ansell SM, *see* Ghobrial IM  
*see* Martin WG  
*see* Witzig TE
- Ansell W, *see* Shamash J
- Anselmi E, *see* Vallisa D
- Antilli A, *see* Ardizzoni A
- Antimi M, *see* Papaldo P
- Antón A, *see* Hitt R  
*see* Marty M  
*see* Sastre J
- Anton-Culver H, *see* Zell JA
- Antonadou D, *see* Athanassiou H
- Antonelli P, *see* Ardizzoni A
- Aogi K, *see* Kohno N
- Aozasa K, *see* Sakane-Ishikawa E
- Aparicio J, Germà JR, del Muro XG, Maroto P, Arranz JA, Sáenz A, Barnadas A, Dorca J, Gumà J, Olmos D, Bastús R, Carles J, Almenar D, Sánchez M, Paz-Ares L, Satrustegui JJ, Mellado B, Balil A, López-Brea M, Sánchez A. Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study, 8717
- Aplenc R, *see* DeMichele A
- Apold J, *see* Stormorken AT
- Appelbaum FR, *see* Wallen H
- Aquino A, *see* Correale P
- Aranda E, *see* Sastre J
- Aranda S, *see* Yates P
- Arber DA, *see* Molina A
- Arcaini L, *see* Malcovati L  
*see* Vallisa D
- Arcari AL, *see* Vallisa D
- Ardavanis A, *see* Georgoulas V
- Ardine M, *see* Berruti A
- Ardizzoni A, *see* Gridelli C  
*see* Tiseo M
- Ardizzoni A, Favaretto A, Boni L, Baldini E, Castiglioni F, Antonelli P, Pari F, Tibaldi C, Altieri AM, Barbera S, Cacciani G, Raimondi M, Tixi L, Stefani M, Monfardini S, Antilli A, Rosso R, Paccagnella A. Platinum-Etoposide Chemotherapy in Elderly Patients With Small-Cell Lung Cancer: Results of a Randomized Multicenter Phase II Study Assessing Attenuated-Dose or Full-Dose With Lenograstim Prophylaxis—A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo di Studio Tumori Polmonari Veneto (FONICAP-GSTPV) Study, 569
- Arduini F, *see* Graziano F
- Aref A, *see* Chuba PJ
- Arenas de Pablo A, *see* Pozo-Rodríguez F
- Arenillas L, *see* López-Guillermo A
- Argani P, *see* Hansel DE
- Aricó M, *see* Pession A
- Arina A, *see* Mazzolini G
- Arlen PM, *see* Marshall JL
- Armand JP, *see* Faivre S
- Armitage JO, *see* Abrey LE  
*see* Vose JM
- Armstrong DK, *see* Santillan A
- Armstrong FD, *see* Beebe DW
- Armstrong K, *see* Rebbeck TR
- Armstrong K, Weber F, Ubel PA, Peters N, Holmes J, Schwartz JS. Individualized Survival Curves Improve Satisfaction With Cancer Risk Management Decisions in Women With *BRCA1/2* Mutations, 9319
- Armstrong SA, Look AT. Molecular Genetics of Acute Lymphoblastic Leukemia, 6306
- Arnaud JP, *see* Lutz MP
- Arndt CAS, *see* Blaney SM
- Arndt V, *see* Brenner H
- Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H. Persistence of Restrictions in Quality of Life From the First to the Third Year After Diagnosis in Women With Breast Cancer, 4945
- Arning M, *see* von der Maase H
- Arnold A, *see* Leighl NB
- Arnold A, Papanikolaou A. Cyclin D1 in Breast Cancer Pathogenesis, 4215
- Arnould L, *see* Lièvre A
- Arnulf B, *see* Femand J-P
- Aronson DC, Schnater JM, Staalman CR, Weverling GJ, Plaschkes J, Per-

- ilongo G, Brown J, Phillips A, Otte J-B, Czauderna P, MacKinlay G, Vos A. Predictive Value of the Pretreatment Extent of Disease System in Hepatoblastoma: Results From the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 Study, 1245
- Aronson N, *see* Schrag D
- Aronson WJ, *see* Freedland SJ
- Arpin D, Perol D, Blay J-Y, Falchero L, Claude L, Vuillermoz-Blas S, Martel-Lefay I, Ginetet C, Alberti L, Nosov D, Etienne-Mastroianni B, Cottin V, Perol M, Guerin J-C, Cordier J-F, Carrie C. Early Variations of Circulating Interleukin-6 and Interleukin-10 Levels During Thoracic Radiotherapy Are Predictive for Radiation Pneumonitis, 8748
- Arpino G, *see* Cui X
- Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone Receptor Status of a Contralateral Breast Cancer Is Independent of the Receptor Status of the First Primary in Patients Not Receiving Adjuvant Tamoxifen, 4687
- Arquette M, *see* Herbst RS
- Arranz JA, *see* Aparicio J
- Arranz R, *see* Rohatiner AZS
- Arroyo GF, Acosta G, Alvi MM, Raspi E, Almonacid GV, Fabián H, Freire MF. Prevalence of KIT Expression in Human Tumors: Gallbladder Cancer (correspondence), 5268
- Arshad M, Seiter K, Bilaniuk J, Qureshi A, Patil A, Ramaswamy G, Liu D. Side Effects Related to Cancer Treatment: Splenic Rupture Following Pegfilgrastim, 8533
- Arte S, *see* Renkonen ET
- Arteaga CL, *see* Baselga J
- Arthur DW, Vicini FA. Accelerated Partial Breast Irradiation As a Part of Breast Conservation Therapy, 1726
- Artibani W, *see* Patarid J-J
- Artiga MJ, *see* Agrelo R
- Artru P, *see* Taïieb J
- Artz A, *see* van Besien K
- Artz D, *see* Basch E
- Arun BK, *see* Buzdar AU
- Asad Y, *see* Banerji U
- Asaga T, *see* Kohno N
- Asaka M, *see* Onozawa M
- Asbury P, *see* LoRusso PM
- Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Hultsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF. Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies, 7660
- Ashcroft L, *see* Baka S
- Ashe M, *see* Leonard JP
- Ashley DM, *see* Mulhern RK
- Ashley S, *see* Dowsett M
- Ashley SE, *see* Smith IE
- Ashton EA, *see* Liu G
- Ashton LJ, *see* Laughton SJ
- Assaad SI, *see* Taghian AG
- Assadourian S, *see* Ajani JA  
*see* Soepenberg O
- Asselin BL, *see* Basu SK
- Assi H, *see* Andre F
- Astle J, *see* Florell SR
- Astrow AB, Mattson I, Ponet J, White M. Inter-Religious Perspectives on Hope and Limits in Cancer Treatment, 2569
- Atala J, *see* Prieto JM
- Atallah D, *see* Rouzier R
- Atasoy BM, *see* Bentzen SM
- Athanasian EA, *see* Nathan SS
- Athassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K, Karagorgis P. Randomized Phase II Study of Temozolomide and Radiotherapy Compared With Radiotherapy Alone in Newly Diagnosed Glioblastoma Multiforme, 2372
- Atherton P, *see* Goetz MP
- Atik MA, *see* Altundag K
- Atkins CD. Overestimation of the Prognostic Significance of SUV Measurement by Positron Emission Tomography for Non-Small-Cell Lung Cancer, 6799
- Atkins J, *see* Bradley JD
- Atkins MB, *see* McDermott DF
- Attal M, *see* Jourdan E
- Attia K, *see* Taghian AG
- Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA. Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti-Cytotoxic T-Lymphocyte Antigen-4, 6043
- Au AWM, *see* Chim CS
- Au GKH, *see* Lee AWM
- Au JSK, *see* Lee AWM
- Au WY, *see* Hon C
- Au WY, Hung KN, Wan TS, Ma E. Side Effects Related to Cancer Treatment: Primary Cerebral Lymphoma After Radiotherapy for Recurrent Meningioma, 8535
- Au WY, Lam P, Shek TW. Uncommon Presentations of Some Common Malignancies: Nasopharyngeal Carcinoma Followed by Secondary Acute Promyelocytic Leukemia Presenting With Respiratory Distress, 1314
- Auer H, *see* Morrison C
- Auerbach M, Ballard H. In Reply (correspondence), 652
- Auethavekiat P, Roberts JR, Biega TJ, Toney MO, Christensen RS, Belnap CM, Berenberg JL. Difficult Diagnostic Cases. Oncogenic Osteomalacia Associated With Hemangiopericytoma Localized by Octreotide Scan, 3626
- Aufdemkampe G, *see* Knols R
- Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT. Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukemia Working Party, 9219
- Aulitzky W, *see* Elter T
- Auperin A, *see* Burdett S
- Austin M, *see* Hedenus M
- Austin RM, Birdsong GG, Sidawy MK, Kaminsky DB, Benstein BD, Cibas ES, Mody DR, Guidos BJ, Moriarty AT, Rimm DL, Ehya H, Facik MS, Howell LP, Gill GW, Kurtycz DF, Powers CN, Young NA. Fine Needle Aspiration Is a Feasible and Accurate Technique in the Diagnosis of Lymphoma (correspondence), 9029
- Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF. Full Haplotype-Mismatched Hematopoietic Stem-Cell Transplantation: A Phase II Study in Patients With Acute Leukemia at High Risk of Relapse, 3447
- Aviles A, *see* Rohatiner AZS
- Avis NE, Crawford S, Manuel J. Quality of Life Among Younger Women With Breast Cancer, 3322
- Avril A, *see* MacGrogan G
- Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, Kuhn W. Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer, 7445
- Awada A, *see* Strumberg D

- Axelrod R, *see* Movsas B  
 Axtell RA, *see* Geyer JR  
 Ayanian JZ, Zaslavsky AM, Guadagnoli E, Fuchs CS, Yost KJ, Creech CM, Cress RD, O'Connor LC, West DW, Wright WE. Patients' Perceptions of Quality of Care for Colorectal Cancer by Race, Ethnicity, and Language, 6576  
 Ayav A, Habib N, Jiao LR. Portal Hypertension Secondary to <sup>90</sup>Yttrium Microspheres: An Unknown Complication, 8275  
 Ayoub J, *see* Choy H  
 Azar RJ, *see* Hansen EK  
 Azarnia N, *see* Herbst RS  
 Aziz NM, *see* Demark-Wahnefried W  
 Azon A, *see* Puig S  
 Azoulay É, *see* Darmon M  
   *see* Thiéry G  
 Azria D, Pelegrin A, Dubois J-B, Mirimanoff R-O, Ozsahin M. Radiation Therapy and Tamoxifen: Concurrent or Sequential? It's No Longer the Question! (correspondence), 4239  
 Azzouzi A-R, *see* Catto JWF
- B**
- Baak JPA, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LVAM, Vermorken JB, Janssen EAM. Prospective Multicenter Validation of the Independent Prognostic Value of the Mitotic Activity Index in Lymph Node–Negative Breast Cancer Patients Younger than 55 Years, 5993  
 Baas-Thijssen MCM, *see* Jansen SJT  
 Babar SA, *see* Rockall AG  
 Baber R, *see* Thewes B  
 Babin A, *see* Oyharcabal-Bourden V  
 Babin-Boilletot A, *see* Entz-Werlé N  
 Baccarani M, *see* Soverini S  
 Bacci G, *see* Ferrari S  
 Bach PB. Using Practical Guidelines to Assess Cancer Care Quality (editorial), 9041  
 Bacigalupo A, *see* Corradini P  
 Bacik J, *see* Kondagunta GV  
   *see* Ronnen EA  
 Bacus S, *see* Spector NL  
 Badenas C, *see* Puig S  
 Bader P, *see* Koscielniak E  
 Badger J, Uzieblo A, Srinivas S, Kang S. Double Diagnosis in Cancer Patients and Cutaneous Reaction Related to Gemcitabine: Photo Therapy Recall With Gemcitabine Following Ultraviolet B Treatment, 7224  
 Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients, 4089  
 Badruddoja MA, *see* Reardon DA  
 Baek C-H, *see* Choi JY  
 Baer MR, *see* Farag SS  
   *see* Marcucci G  
 Baetz T, *see* Canil CM  
 Bagatell R, Rumchev P, London WB, Cohn SL, Look AT, Brodeur GM, Frantz C, Joshi V, Thorner P, Rao PV, Castleberry R, Bowman LC. Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by NYCN Status and Tumor Cell Ploidy, 8819  
 Bagnoli R, *see* Maranzano E  
 Bai SA, *see* Cortes J  
 Baile WF, *see* Beale EA  
   *see* Gritz ER  
 Bainbridge T, *see* Corless CL  
 Bairati I, Meyer F, Gélinas M, Fortin A, Nabid A, Brochet F, Mercier J-P, Têtu B, Harel F, Abdous B, Vigneault E, Vass S, del Vecchio P, Roy J. Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients, 5805  
 Baird R, *see* Liu WM  
 Bajamonde A, *see* Pegram MD  
 Bajetta E, Procopio G, Celio L, Gattinoni L, Torre SD, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R. Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women, 2155  
 Bajorin DF, *see* Kondagunta GV  
   *see* Ronnen EA  
   *see* Stephenson AJ  
 Bajrovic A, *see* Rades D  
 Baka S, Ashcroft H, Anderson H, Lind M, Burt P, Stout R, Dowd J, Smith D, Lorigan P, Thatcher N. Randomized Phase II Study of Two Gemcitabine Schedules for Patients With Impaired Performance Status (Karnofsky performance status  $\leq$  70) and Advanced Non–Small-Cell Lung Cancer, 2136  
 Baka S. In Reply (correspondence), 7232  
 Baker J, *see* Gianni L  
 Baker KS, Loberiza FR Jr, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA, Camitta BM, Garcia JJ, Ho WG, Liesveld JL, Maharaj D, Marks DI, Schultz KR, Wiernik P, Zander AR, Horowitz MM, Keating A, Weisdorf DJ. Outcome of Ethnic Minorities With Acute or Chronic Leukemia Treated With Hematopoietic Stem-Cell Transplantation in the United States, 7032  
 Baker LH, *see* Chugh R  
   *see* Worden FP  
 Baker LH. Medical and Pediatric Oncology, Not Adult and Pediatric Oncology (editorial), 4003  
 Baker RI, *see* Lee AYY  
 Baker SD, *see* Dome JS  
   *see* Rudek MA  
   *see* Sparreboom A  
   *see* ten Tije AJ  
 Baker WH, *see* Kwekkeboom DJ  
 Bakitas M, *see* Ahles TA  
 Bakken K, Lund E, Eggen AE. The Impact of Hormone Replacement Therapy on the Incidence of Breast Cancer in Norway (correspondence), 3636  
 Bakker DJ, *see* van Merkesteyn R  
 Bakketeig LS, *see* Aabom B  
 Balakrishnan R, *see* Raja V  
 Balatoni Z, *see* Timár J  
 Balch CM, Soong S-J, Desmond R. In Reply (correspondence), 9428  
 Baldi A, *see* Caraglia M  
 Baldi F, *see* Caraglia M  
 Baldini E, *see* Ardizzoni A  
   *see* Mamon HJ  
 Baldini L, *see* Agnelli L  
   *see* Gobbi PG  
 Baldini L, Goldaniga M, Guffanti A, Brogna C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P. Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenström's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System, 4662  
 Balducci L, *see* Gridelli C  
 Baldus CD, *see* Marcucci G  
 Balestra D, *see* Frattini M  
 Balil A, *see* Aparicio J  
 Balis FM, *see* Blaney SM  
   *see* Warren KE

- Balkwill F, *see* Madhusudan S
- Ball G, *see* Mian S
- Ballanti S, *see* Aversa F
- Ballard-Barbash R, *see* Irwin ML
- Ballard H, *see* Auerbach M
- Balleisen L, *see* Shimabukuro-Vornhagen A
- Ballen K, *see* Pavletic SZ
- Ballman K, *see* Galanis E
- Ballova V, *see* Engert A
- Balsari A, *see* Ménard S
- Balslev E, *see* Knoop AS
- Bamberg M, *see* Budach V
- Bamia C, *see* Bamias A
- Bamias A, Kastritis E, Bamia C, Mouloupoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors, 8580
- Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I Trial of <sup>177</sup>Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer, 4591
- Bandini G, *see* Corradini P
- Banerjee M, Hryniuk W. In Reply (correspondence), 2871
- Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I. Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies, 4152
- Bang YJ, *see* Han S-W
- Banu A, *see* Oudard S
- Banu E, *see* Oudard S  
*see* Scotté F
- Baptista MZ, *see* Altundag K
- Barajas-Figueroa LJ, *see* Vogel CL
- Barajas O, *see* Gallardo J
- Barassi F, *see* Marchetti A
- Barbare J-C, Bouché O, Bonnetain F, Raoul J-L, Rougier P, Abergel A, Boige V, Denis B, Blanche A, Pariente A, Milan C, Bedenne L. Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma, 4338
- Barbera S, *see* Ardizzoni A  
*see* Maione P
- Barbui T, *see* Marchioli R
- Barcos M, *see* Dressler LG
- Bardet E, *see* Bosset J-F
- Bardou V-J, *see* Jourdan E
- Bardy-Bouxin N, *see* Chan S
- Barge RMY, *see* van Rooden CJ
- Bargetzi M, *see* Ghilmini M
- Barile-Thiem B, *see* Schwartz GK
- Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival After Recurrence of Ewing's Sarcoma Family of Tumors, 4354
- Barker MA, *see* Southey MC
- Barlogie B, *see* Greipp PR  
*see* Mahfouz T  
*see* Talamo G
- Barlow WE, *see* Herrinton LJ
- Barnadas A, *see* Aparicio J
- Barnes D, *see* Couban S
- Barnett MJ, *see* Forrest DL
- Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE, Chauncey TR, Flowers MED, Mielcarek M, Maloney DG, Storb R. Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning, 1993
- Baron JA, *see* Bian Y
- Barón MG, *see* Espinosa E
- Barone C, *see* Papaldo P
- Barosi G, *see* Massa M
- Barranco C, *see* Salar A
- Barrera E, *see* Garzotto M
- Barrett E, *see* Dark GG
- Barth NJ, *see* Augustson BM
- Bartolini S, *see* Cappuzzo F
- Barton C, *see* Baseiga J
- Barton MB, *see* Herrinton LJ
- Bartsch R, *see* Raderer M
- Basaran G, *see* Sakar B
- Basaran G, Basaran M, Onat H. Chemoradiotherapy for Localized Non-Hodgkin's Lymphoma: Lessons From Old Studies (correspondence), 3161
- Basaran M, *see* Basaran G  
*see* Sakar B
- Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, Schrag D. Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy, 3552
- Baseiga J, Carbonell X, Castañeda-Soto N-J, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. Phase II Study of Efficacy, Safety, and Pharmacokinetics of Treatment Monotherapy Administered on a 3-Weekly Schedule, 2162
- Baselga J, *see* Bell DW  
*see* Leyland-Jones B  
*see* Tabernero J
- Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero JM, Koehler MT, Rojo F. Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients With Advanced Breast Cancer, 5323
- Baselga J, Arteaga CL. Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer, 2445
- Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A. Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck, 5568
- Bashir Q, *see* Floyd JD
- Bassi S, *see* Soverini S
- Basso G, *see* Pession A
- Basso S, *see* Comoli P
- Bast RC Jr, *see* Menon U
- Bastholt L, *see* Bruzzi P
- Bastian PJ, *see* Lotan Y
- Bastús R, *see* Aparicio J
- Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of Stay and Mortality Associated With Febrile Neutropenia Among Children With Cancer, 7958
- Batchelor TT, *see* Abrey LE  
*see* Nguyen PL  
*see* Shenkier TN
- Battaglia M, *see* Boccardo F.
- Battisti S, *see* Thuret R
- Baudin E, *see* Amar L  
*see* Dromain C
- Baudis M, *see* Vandesomepele J
- Bauer J, *see* Sessa C
- Bauer P, *see* Richtig E
- Bauer S, Lang H, Schütte J, Hartmann JT. Complete Remission With Imatinib in Metastatic Gastrointestinal Stromal Tumors (correspondence), 6800

- Baughman C, *see* Hainsworth JD
- Baum M, *see* Dowsett M
- Bauman G, *see* Roa W
- Baumann M, *see* Budach V
- Baumgartner KB, *see* Irwin ML
- Baumgartner RN, *see* Irwin ML
- Bavieri M, *see* Rossi G
- Bayerdörffer E, *see* Wündisch T
- Bazan V, *see* Russo M
- Bazzan M, *see* Verso M
- Beá S, *see* López-Guillermo A
- Beacham AO, *see* Andrykowski MA
- Beale EA, Baile WF, Aaron J. Silence Is Not Golden: Communicating With Children Dying From Cancer, 3629
- Bear HD, *see* Mamounas EP
- Beart R, *see* O'Connell MJ
- Bearz A, *see* Maione P
- Bearzi I, *see* Graziano F  
*see* Scartozzi M
- Beasley V, *see* Romaguera JE
- Beattie M, *see* Powell CB
- Beauchamp CP, *see* Wunder JS
- Beaumont JL, *see* Andrykowski MA
- Beaune P, *see* Lièvre A
- Bebb G, *see* Ho C
- Beck J, *see* Lehmann J
- Beck SDW, Foster RS, Bihler R, Einhorn LH, Donohue JP. Outcome Analysis for Patients With Elevated Serum Tumor Markers at Postchemotherapy Retroperitoneal Lymph Node Dissection, 6149
- Becker H, *see* Ghadimi BM  
*see* Liersch T
- Becker JC, *see* Andersen MH  
*see* Kaufmann R
- Becker K, *see* von Rahden BHA
- Becker T, *see* Lehmann J
- Beckett LA, *see* Lara PN Jr
- Beckman JA, *see* Gornik HL
- Beckwith JB, *see* Grundy PE  
*see* Tomlinson GE
- Bedenne L, *see* Barbare J-C
- Bedor M, *see* Edelman MJ
- Beebe DW, Ris MD, Armstrong FD, Fontanesi J, Mulhern R, Holmes E, Wisoff JH. Cognitive and Adaptive Outcome in Low-Grade Pediatric Cerebellar Astrocytomas: Evidence of Diminished Cognitive and Adaptive Functioning in National Collaborative Research Studies (CCG 9891/POG 9130), 5198
- Beer TM, *see* Garzotto M
- Beeram M, Patnaik A, Rowinsky EK. Raf: A Strategic Target for Therapeutic Development Against Cancer, 6771
- Beetham PK, *see* Marshall JL
- Beex LVAM, *see* Baak JPA  
*see* Nieboer P
- Begley CE, *see* Du XL
- Beguín Y. Intravenous Iron and Recombinant Human Erythropoietin in Cancer Patients (correspondence), 651
- Begum G, *see* Augustson BM  
*see* Tauro S
- Begum S, *see* Hoque MO
- Behr TM, *see* Liersch T
- Behrens J, *see* Augustson BM
- Behringer D, *see* Chan S
- Behringer K, *see* Klimm B
- Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A. Secondary Amenorrhea After Hodgkin's Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin's Lymphoma Study Group, 7555
- Beitler JJ, *see* Gaba A
- Béjar A, *see* Zapatero A
- Belanger C, *see* Ferman J-P
- Belani CP, *see* Cella D
- Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol, 5883
- Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, Mehta M. Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Non-Small-Cell Lung Cancer, 3760
- Belghiti J, *see* Khatri VP
- Belin TR, *see* Stanton AL
- Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials, 8081
- Bell RS, *see* Wunder JS
- Bellavita R, *see* Maranzano E
- Belldregun AS, *see* Patard J-J
- Bellizzi KM, Rowland JH, Jeffery DD, McNeel T. Health Behaviors of Cancer Survivors: Examining Opportunities for Cancer Control Intervention, 8884
- Bellmunt J, *see* Tabernero J
- Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A. Sequencing of Chemotherapy and Radiation Therapy in Early-Stage Breast Cancer: Updated Results of a Prospective Randomized Trial, 1934
- Bellon JR, Harris JR. Chemotherapy and Radiation Therapy for Breast Cancer: What Is the Optimal Sequence? (editorial), 5
- Bellosillo B, *see* Salar A
- Belluco C, *see* Petricoin EF III
- Belnap CM, *see* Auethavekiat P
- Belón J, *see* Hitt R
- Beltran M, *see* Colomer R
- Belvedere O, Grossi F. To Treat or Not to Treat Advanced Non-Small-Cell Lung Cancer Patients With Impaired Performance Status? (correspondence), 7231
- Ben Abdeladhim A, *see* Abdelkefi A
- Ben Hassen A, *see* Abdelkefi A
- Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, Knol J, Dawson LA, Pan C, Lawrence TS. Phase II Trial of High-Dose Conformal Radiation Therapy With Concurrent Hepatic Artery Floxuridine for Unresectable Intrahepatic Malignancies, 8739
- Ben Othman T, *see* Abdelkefi A
- Ben-Porat L, *see* Shah NT  
*see* Zelefsky MH
- Bencsik B, *see* Timár J
- Benda JA, *see* Long HJ III
- Bendahl P-O, *see* Rydén L
- Bendandi M, *see* Mazzolini G
- Bendell JC, *see* Willett CG
- Benedetti JK, *see* Poplin EA  
*see* Sargent DJ
- Benedetto C, *see* Boccardo F

## AUTHOR INDEX

- Beneduce G, Ascierto PA  
 Beneventi S, *see* Maranzano E  
 Benítez J, *see* Honrado E  
 Benito A, *see* Mazzolini G  
 Benner A, *see* Kienle DL  
   *see* Mendrzyk F  
 Bennett CL, *see* Djulbegovic B  
   *see* Ferreira MR  
   *see* McKoy JM  
   *see* Wolf MS  
 Bennett D, *see* van Besien K  
 Bennett JE, *see* Hayman JA  
 Bennett KL, *see* Raval A  
 Benson AB III, *see* Desch CE  
   *see* Lyman GH  
   *see* Rothenberg ML  
 Benson JR. The Use of Aromatase Inhibitors in Postmenopausal Women With Hormone Receptor Positive Breast Cancer (correspondence), 6807  
 Benstein BD, *see* Austin RM  
 Bentley P, *see* Starczynski J  
 Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR, Wilson GD. Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial, 5560  
 Bentzen SM, Yarnold JR. Sequential or Concurrent Tamoxifen and Radiotherapy: To See or Not to See—*That Is the Question!* (correspondence), 6266  
 Beny A, *see* Bosset J-F  
 Benyunes M, *see* Czuczman MS  
 Bepler G, *see* Ferraro B  
 Beran M, *see* Cortes J  
   *see* Wierda W  
 Berard-Marec P, *see* Entz-Werlé N  
 Berardi R, *see* Graziano F  
   *see* Scartozzi M  
 Berber E, Pelley R, Siperstein AE. Predictors of Survival After Radiofrequency Thermal Ablation of Colorectal Cancer Metastases to the Liver: A Prospective Study, 1358  
 Berchuck A, *see* Cragun JM  
 Berd D, Mastrangelo MJ, Sato T. Calculation of Survival of Patients With Stage III Melanoma (correspondence), 9427  
 Berdel WE, *see* Kempf-Bielack B  
   *see* Koch P  
 Berenberg JL, *see* Auethavekiat P  
 Beresneva T, *see* Pingpank JF  
 Berg SL, *see* Blaney SM  
 Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB. Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children's Oncology Group, 3376  
 Berga S, *see* Scheier MF  
 Bergamini C, *see* Licitra L  
 Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival, 4330  
 Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon Cancer Survival Is Associated With Decreasing Ratio of Metastatic to Examined Lymph Nodes, 8706  
 Bergeron C, *see* Combaret V  
   *see* Valteau-Couanet D  
 Bergh J, *see* Praga C  
   *see* Sandström M  
 Berghmans T, Sculier JP. Is the Tolerance to MIP Chemotherapy Different Between English and Other European Populations? (correspondence), 6269  
 Bergmann E, *see* Weber A  
 Bergsagel KI, *see* Lynch HT  
 Bergsagel PL, Kuehl WM. Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma, 6333  
 Bergsland E, *see* Kabbinavar FF  
 Berkey BA, *see* Ettinger DS  
 Berlin J, *see* Hurwitz HI  
   *see* Rothenberg ML  
 Berman AW, *see* Low JA  
 Berman DM, *see* Dudley ME  
 Berman ML, *see* Chan JK  
 Berman S, *see* Mamon HJ  
   *see* Mayer S  
 Bermego JL, *see* Hemminki K  
 Bernard B, *see* Guillem JG  
 Bernard F, *see* Valteau-Couanet D  
 Bernardeschi P, *see* Fiorentini G  
 Bernasconi P, *see* Malcovati L  
 Berner A, *see* Subdø J  
 Bernini G, *see* Ferrari S  
 Berns AM, *see* Luiten RM  
 Berns EMJJ, *see* Jansen MPH  
 Bernsen MR, *see* de Vries IJM  
 Bernstein L, *see* Irwin ML  
   *see* Meeske KA  
 Bernstein M, *see* Berg SL  
   *see* Daw NC  
   *see* Meyers PA  
 Bernstein SH, *see* Czuczman MS  
 Bernstein V, *see* Olivotto IA  
 Bernstein ZP, *see* Czuczman MS  
 Bernuzzi P, *see* Vallisa D  
 Beroukas K, *see* Athanassiou H  
 Berrettni W, *see* Lerman C  
 Berrino F, *see* Gatta G  
 Berruti A, Generali D, Brizzi MP, Ardine M, Dogliotti L, Bottini A. Is Pathologic Complete Response a Valid Surrogate Parameter of Treatment Efficacy in HER2 Positive Breast Cancer Patients Undergoing Primary Chemotherapy Plus Trastuzumab? (correspondence), 8130  
 Berry D, *see* Buzdar AU  
   *see* Dressler LG  
   *see* Rouzier R  
 Berry S, *see* Canil CM  
 Bertaccini A, *see* Boccardo F.  
 Bertagna X, *see* Amar L  
 Bertagnolli MM. Surgical Prevention of Cancer, 324  
 Bertè R, *see* Vallisa D  
 Bertetto O, *see* Maione P  
 Berthaud P, *see* Faivre S  
 Bertherat J, *see* Amar L  
 Berthold DR, Sternberg CN, Tannock IF. Management of Advanced Prostate Cancer After First-Line Chemotherapy, 8247  
 Bertoglio S, *see* Verso M  
 Bertoni F, *see* Ferrari S  
   *see* Ghielmini M  
   *see* Laszlo D  
   *see* Martrinelli G  
 Bertoni F, Zucca E. State-of-the-Art Therapeutics: Marginal-Zone Lymphoma, 6415

- Bertrand P, *see* Ray-Coquard I
- Bertulli R, *see* Gronchi A
- see* Van Glabbeke M
- Bertz H, *see* Zeiser R
- Berzofsky JA, *see* Carbone DP
- Beslija S, *see* Zielinski C
- Besses C, *see* Salar A
- Best I. Central Role of the Research Nurse in Improving Accrual of Older Persons to Cancer Treatment Trials (correspondence), 7752
- Betcher D, *see* Meyers PA
- Betticher DC, *see* Ghielmini M
- see* Leighl NB
- Beuzebec P, *see* Oudard S
- Beyers TB, *see* Frumovitz M
- Bezjak A, *see* Brundage M
- see* Leighl NB
- see* Meyer RM
- Bhalla KN. Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies, 3971
- Bhan AK, *see* Kirsch DG
- Bhandari MS, Crook J, Hussain M. Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice? 8212
- Bhar P, *see* Gradishar WJ
- see* Ibrahim NK
- Bhat SR, Goodwin TL, Burwinkle TM, Lansdale MF, Dahl GV, Huhn SL, Gibbs IC, Donaldson SS, Rosenblum RK, Varni JW, Fisher PG. Profile of Daily Life in Children With Brain Tumors: An Assessment of Health-Related Quality of Life, 5493
- Bhatia R, Van Heijzen K, Palmer A, Komiya A, Slovak ML, Chang KL, Fung H, Krishnan A, Molina A, Nademanee A, O'Donnell M, Popplewell L, Rodriguez R, Forman SJ, Bhatia S. Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma, 6699
- Bhatia S, *see* Bhatia R
- Biakhov M, *see* Leyland-Jones B
- Bian Y, Caldes T, Wijnen J, Franken P, Vasen H, Kaklamani V, Nafa K, Peterlongo P, Ellis N, Baron JA, Burn J, Moeslein G, Morrison PJ, Chen Y, Ahsan H, Watson P, Lynch HT, de la Chapelle A, Fodde R, Pasche B. *TGFBR1\*6A* May Contribute to Hereditary Colorectal Cancer, 3074
- Bianco FJ Jr, *see* Dotan ZA
- see* Stephenson AJ
- Biankin AV, *see* Hansel DE
- Biasoli I, *see* Spector N
- Bibb J, Hromas R, Rabinowitz I. A Bayesian Approach to a Patient With a Residual Mass After Treatment for Non-Hodgkin's Lymphoma of the Thyroid, 8911
- Bicciato S, *see* Agnelli L
- see* Vacca A
- Bichsel VE, *see* Petricoin EF III
- Biddle A, *see* Dragnev KH
- Biega TJ, *see* Auethavekiat P
- Bielack SS, *see* Kempf-Bielack B
- Bierman PJ, *see* Pavletic SZ
- see* Vose JM
- Biermann JS, *see* Chugh R
- see* Worden FP
- Biesma B, Timmer-Bonte JN, *see* Hoekstra CJ
- Bigiani N, *see* Rossi G
- Bigner DD, *see* Quinn JA
- Bihrl R, *see* Beck SDW
- see* Cheng L
- Bilaniuk J, *see* Arshad M
- Bilchik AJ, *see* Kim J
- Bilchik AJ, Poston DG, Curley SA, Strasberg S, Saltz L, Adam R, Nordlinger B, Rougier P, Rosen LS. Neoadjuvant Chemotherapy for Metastatic Colon Cancer: A Cautionary Note, 9073
- Bilhartz DL, *see* Smith MR
- Bilke S, Chen O-R, Westerman F, Schwab M, Catchpoole D, Khan J. Inferring a Tumor Progression Model for Neuroblastoma From Genomic Data, 7322
- Billett A, *see* Berg SL
- Billups CA, *see* Santana VM
- see* Spunt SL
- Birch R, *see* Quinn JA
- Bird BR, *see* Hussein MAH
- Birdsong GG, *see* Austin RM
- Birgisson H, *see* Folkesson J
- Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Adverse Effects of Preoperative Radiation Therapy for Rectal Cancer: Long-Term Follow-Up of the Swedish Rectal Cancer Trial, 8697
- Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Occurrence of Second Cancers in Patients Treated With Radiotherapy for Rectal Cancer, 6126
- Bisaccia S, *see* Edelman MJ
- Bishop MM, *see* Andrykowski MA
- Bishop MR, *see* Pavletic SZ
- Bisogno G, *see* Carli M
- Bisset D, O'Byrne K, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA. Phase III Study of Matrix Metalloproteinase Inhibitor Prinomastat in Non-Small-Cell Lung Cancer, 842
- Biti GP, *see* Maranzano E
- Bitran JD, *see* Nabhan C
- Björk O, *see* Kreicbergs U
- Blackwell KL, *see* Burris HA III
- see* Spector NL
- Bladé J, *see* Greipp PR
- Blaise D, *see* Jourdan E
- Blanch J, *see* Prieto JM
- Blanchi A, *see* Barbare J-C
- Blancke CD. Gefitinib in Colorectal Cancer: If Wishes Were Horses (editorial), 5446
- Blanco R, *see* Martín J
- Blaney SM, *see* Berg SL
- see* Daw NC
- see* Tekautz TM
- Blaney SM, Balis FM, Berg S, Arndt CAS, Heideman R, Geyer JR, Packer R, Adamson PC, Jaeckle K, Klenke R, Aikin A, Murphy R, McCully C, Poplack DG. Intrathecal Mafosfamide: A Preclinical Pharmacology and Phase I Trial, 1555
- Blaney SM, Berg SL, Balis F, Poplack D. In Reply (correspondence), 7749
- Blaney SM, Boyett J, Friedman H, Gajjar A, Geyer R, Horowitz M, Hunt D, Kieran M, Kun L, Packer R, Phillips P, Pollack IF, Prados M, Heideman R. Phase I Clinical Trial of Mafosfamide in Infants and Children Aged 3 Years or Younger With Newly Diagnosed Embryonal Tumors: A Pediatric Brain Tumor Consortium Study (PBTC-001), 525
- Blank TO. Gay Men and Prostate Cancer: Invisible Diversity, 2593
- Blanke CD, *see* Sargent DJ
- Blanke CD. Whither Irinotecan? 4811
- Blankenburg T, *see* Schuette W
- Blanquicett C, *see* Saif MW
- Blazzkowsky LC, *see* Willett CG
- Blay J-Y, *see* Arpin D
- see* Negrier S
- see* Shenkier TN
- Blay JY, *see* Le Cesne A
- Bleiker E, *see* Madalinska JB
- Bley TA, *see* Zeiser R

## AUTHOR INDEX

- Bleyer A. Fellows' Forum Forgotten? (correspondence), 4237
- Bliss J, *see* Praga C
- Bliss JM, *see* Coombes RC
- Blobe GC, *see* Elliott RL
- Block AMW, *see* Farag SS
- Blohmer JU, *see* Smith IE  
*see* von Minckwitz G
- Blok MJ, *see* Gómez-García EB
- Blomgren H, *see* Öhrling K
- Bloom G, *see* Eschrich S
- Bloomfield CD, *see* Farag SS  
*see* Marcucci G
- Blum W, *see* Marcucci G
- Blume KG, *see* Sorror ML
- Blumenschein G, *see* Robert F
- Blumenschein G Jr, *see* Herbst RS
- Blumenson L, *see* Czuczman MS
- Blumenstein BA. A Comment on the Utility of Recursive Partitioning (editorial), 4254
- Blumgart L, *see* Akhurst T  
*see* Kemeny N
- Blumstein NM, *see* Juweid ME
- Board J, *see* De Preter K
- Bobrow L, *see* Purushotham AD
- Boccardo M, *see* Greipp PR
- Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganeli A, Ferraris V, Montefiore F. Evaluation of Tamoxifen and Anastrozole in the Prevention of Gynecomastia and Breast Pain Induced by Bicalutamide Monotherapy of Prostate Cancer, 808
- Boccardo F, Rubagotti A. In Reply (correspondence), 5846, 9437
- Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massida B, Distante V, Amadori D, Sismondi P. Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial, 5138
- Bociek G, *see* Vose JM
- Bockhold CA, *see* Dome JS
- Bodurka DC, *see* Frumovitz M  
*see* Lyman GH
- Boeddinghaus I, *see* Dowsett M  
*see* Smith IE
- Boerman OC, *see* Brouwers AH
- Boesen EH, Ross L, Frederiksen K, Thomsen BL, Dahlstrøm K, Schmidt G, Næsted J, Krag C, Johansen C. Psychoeducational Intervention for Patients With Cutaneous Malignant Melanoma: A Replication Study, 1270
- Boettcher H-D, *see* Josting A
- Boeving CA, *see* Kazak AE
- Boezen HM, *see* Reesink-Peters N
- Bogart J, *see* Sartor CI
- Bohidar N, *see* Warr DG
- Böhling G, *see* Ferrari S
- Boige V, *see* Barbare J-C  
*see* Dômont J  
*see* Dromain C  
*see* Ducreux M  
*see* Koscielny S  
*see* Malka D
- Boiocchi M, *see* Ferreri AJM
- Boiron J-M, *see* Jourdan E
- Bokemeyer C, *see* Köhne C-H
- Bokey EL, *see* Kohonen-Corish MRJ
- Bökkerink JPM, *see* Schellong G
- Bokma HJ, *see* Bontenbal M
- Boland PJ, *see* Nathan SS
- Bolaños M, *see* Feliu J
- Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Weintjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang GB. Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease, 2661
- Bollinger W, *see* Raja V
- Bolufer P, *see* Ortega JJ
- Bolwell BJ, *see* Baker KS
- Bomalaski JS, Ascierto PA
- Bonavida B, *see* Mizutani Y
- Bondy ML, *see* Giordano SH
- Bonenkamp JJ, *see* Hendrickx BW
- Bonetti M, *see* Gruber G
- Boneu A, *see* Valteau-Couanet D
- Boni J, *see* Chan S  
*see* Galanis E
- Boni L, *see* Ardizzoni A  
*see* Tiseo M
- Boni M, *see* Malcovati L
- Bonin M, *see* Bornhäuser M
- Boniuk M, *see* Chévez-Barrios P
- Bonmassar E, *see* Correale P
- Bonnet M-C, *see* van Baren N
- Bonnetain F, *see* Barbare J-C
- Bonnerterre J, *see* Praga C
- Bonnerterre J. In Reply (correspondence), 2873
- Bonnerterre J, Roché H, Kerbrat P, Brémond A, Fumoleau P, Namer M, Goudier M-J, Schraub S, Fargeot P, Chapelle-Marcillac I. Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial, 2686
- Bonomi P, *see* Belani CP  
*see* Hoang T
- Bonovas S, Filloussi K, Tsavaris N, Sitaras NM. Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies, 8606
- Bontenbal M, Creemers G-J, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C. Phase II to III Study Comparing Doxorubicin and Docetaxel with Fluorouracil, Doxorubicin, and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre, 7081
- Bonvalot S, *see* Le Cesne A
- Boogaerts MA, *see* Breems DA
- Book M, *see* Seidemann K
- Boon T, *see* van Baren N
- Boonstra H, *see* Madalinska JB
- Booser DJ, *see* Buzdar AU  
*see* Green MC
- Boot H, *see* Jansen EPM
- Bootsma GP, Timmer-Bonte JN
- Borchmann P, *see* Elter T  
*see* Schnell R
- Borden E, *see* Rohatiner AZS
- Bordonaro R, *see* Gobbi PG
- Borgwardt L, Højgaard L, Carstensen H, Laursen H, Nowak M, Thomsen C, Schmiegelow K. Increased Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose (FDG) Uptake in Childhood CNS Tumors Is Correlated With

- Malignancy Grade: A Study With FDG Positron Emission Tomography/  
Magnetic Resonance Imaging Coregistration and Image Fusion, 3030
- Borner M, *see* Chan S
- Bornhäuser M, *see* Hess G
- Bornhäuser M, Pursche S, Bonin M, Freiberg-Richter J, Jenke A, Illmer T, Ehninger G, Schleyer E. Elimination of Imatinib Mesylate and Its Metabolite *N*-Desmethyl-Imatinib (correspondence), 3855
- Borsellino N, *see* Colucci G
- Bos G, *see* Morrison C
- Bos MEM, *see* Klerk CPW
- Bosch CAJ, *see* Hannemann J
- Bosch F, *see* López-Guillermo A  
*see* Moreno C
- Bosl GJ, *see* Kondagunta GV  
*see* Loehrer PJ Sr  
*see* Ronnen EA  
*see* Stephenson AJ
- Bosly A, *see* Feugier P
- Bosset J-F, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L. Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results—EORTC 22921, 5620
- Bossi P, *see* Licitra L
- Botbyl J, *see* DeMichele A  
*see* Gimotty PA
- Botteman M, *see* Smith MR
- Botti C, *see* Papaldo P
- Bottini A, *see* Berruti A
- Bottomley A, *see* Coens C  
*see* Efficace F  
*see* van Meerbeeck JP
- Bouabdallah R, *see* Feugier P
- Bouchardy C, Rapiti E, Fioretta G, Vlastos G. In Reply (correspondence), 4801
- Bouché O, *see* Barbare J-C
- Boucher K, *see* Samlowski WE
- Boucher KM, *see* Florell SR
- Boucher Y, *see* Taghian AG  
*see* Willett CG
- Bouchot O, *see* Thuret R
- Bouffet E, *see* Mabbott DJ
- Boulanger E, Gérard L, Gabarre J, Molina J-M, Rapp C, Abino J-F, Cadranel J, Chevret S, Oksenhendler E. Prognostic Factors and Outcome of Human Herpesvirus 8–Associated Primary Effusion Lymphoma in Patients With AIDS, 4372
- Boulware D, *see* Eschrich S
- BouMerhi G, *see* Mekhail TM
- Bourhis J, *see* Baselga J  
*see* de Botton S
- Bourne T, *see* Timmerman D
- Bours D, *see* Oyharcabal-Bourden V
- Bouvet N, *see* Stevens MCG
- Bouvier A-M, *see* Lièvre A
- Bouzy J, *see* Valteau-Couanet D
- Bowden C, *see* Lee AYY
- Bower JE, *see* Stanton AL
- Bower JE. Prevalence and Causes of Fatigue After Cancer Treatment: The Next Generation of Research (editorial), 8280
- Bower M, *see* Stebbing J
- Bower M, Nelson M, Young AM, Thirlwell C, Newson-Davis T, Mandalia S, Dhillon T, Holmes P, Gazzard BG, Stebbing J. Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma, 5224
- Bower M, Powles T, Stebbing J, Thirlwell C. Potential Antiretroviral Drug Interactions With Cyclophosphamide, Doxorubicin, and Etoposide (correspondence), 1328
- Bowers DC, McNeil DE, Liu Y, Yasui Y, Stovall M, Gurney JG, Hudson MM, Donaldson SS, Packer RJ, Mitby PA, Kasper CE, Robison LL, Oeffinger KC. Stroke As a Late Treatment Effect of Hodgkin's Disease: A Report From the Childhood Cancer Survivor Study, 6508
- Bowitz-Lothe IM, *see* Stormorken AT
- Bowman LC, *see* Bagatell R
- Bown N, *see* Vandesompele J
- Bowne WB, *see* Allen PJ
- Boyages J, *see* Coombs NJ
- Boyd AP, *see* Choy H
- Boyd CE, *see* McKoy JM
- Boyd J, *see* Spentzos D
- Boyd J. Genetic Basis of Familial Endometrial Cancer: Is There More to Learn? (editorial), 4570
- Boyden J, *see* Hamilton AL
- Boyer MJ, *see* Fulham MJ
- Boyett J, *see* Blaney SM  
*see* Mulhern RK
- Boyett JM, *see* Geyer JR
- Boyle FM, Robinson E, Dunn SM, Heinrich PC. Multidisciplinary Care in Cancer: The Fellowship of the Ring, 916
- Bozas G, *see* Bamias A
- Bozonnat M-C, *see* Fournel P
- Brach A, *see* Ferrari S
- Bradding P, *see* Welsh TJ
- Bradley JD, Paulus R, Graham MV, Ettinger DS, Johnstone DW, Pilepich MV, Machtay M, Komaki R, Atkins J, Curran WJ. Phase III Trial of Postoperative Adjuvant Paclitaxel/Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small-Cell Lung Cancer: Promising Long-Term Results of the Radiation Therapy Oncology Group—RTOG 9705, 3480
- Brady MF, Young RC. In Reply (correspondence), 927
- Brady MJ, *see* Andrykowski MA
- Brady MS, *see* Jimenez RE
- Brahimi N, *see* Ulusakarya A
- Braile L, *see* Schwartz GK
- Bralet M-P, Paule B, Adam R, Guettier C. Loss of Epidermal Growth Factor Receptor Expression in Lymph Node and Liver Metastases of Colon Carcinoma (correspondence), 5844
- Brambilla E, *see* Rossi G  
*see* Travis WD
- Bramwell V, *see* Parulekar WR
- Bramwell VHC, *see* Levine MN
- Branagan AR, *see* Treon SP
- Brandman J, *see* Smith MR
- Brandt K, *see* Hricak H
- Brandwein J, *see* Feldman EJ
- Brannigan BW, *see* Bell DW
- Branscheid D, *see* Kempf-Bielack B
- Braun HJ, *see* Bontenbal M
- Braun S, *see* Winer EP
- Braun S, Naume B. Circulating and Disseminated Tumor Cells, 1623
- Brawley OW, Kramer BS. Cancer Screening in Theory and in Practice, 293
- Braybrooke JP, *see* Madhusudan S
- Breathnach OS, *see* Hussein MAH
- Bredee JP, *see* Warnke PH
- Bredeson C, *see* Sorrow ML
- Breems DA, Van Putten WLJ, Huijgens PC, Ossenkoppele GJ, Verhoef GEG, Verdonck LF, Vellenga E, De Greef GE, Jacky E, Van der Lelie J, Boogaerts MA, Löwenberg B. Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse, 1969
- Bregni M, *see* Corradini P

## AUTHOR INDEX

- Breiger D, *see* Geyer JR
- Breining D, *see* Gaba A
- Breitsprecher R, *see* Koch P
- Brem H, *see* Quinn JA
- Bremer TM, *see* Spector NL
- Bremnes R, *see* Mykletun A  
*see* Sagstuen H
- Bremnes Y, *see* Lønning PE
- Brémond A, *see* Bonnetterre J
- Brendel E, *see* Strumberg D
- Brenin DR, *see* Schroen AT
- Brennan MF, Ferrone CR, *see* Allen PJ
- Brenner B, *see* Klimstra DS  
*see* Leonard GD
- Brenner H, *see* Arndt V
- Brenner H, Arndt V. Long-Term Survival Rates of Patients With Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period Analysis, 441
- Brenner H, Hakulinen T. Long-Term Survival and Cure of Patients Diagnosed With Breast Cancer Age 50 Years (correspondence), 1585
- Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application? 7350
- Breslow NE, *see* Dome JS  
*see* Grundy PE  
*see* Tomlinson GE
- Bressac-de Paillerets B, *see* Amar L
- Brett I, *see* Noy A
- Breuer K, *see* Behringer K
- Brewster K, *see* Halbert CH
- Bria E, *see* Ferretti G
- Brichard B, *see* Vandesompele J
- Brichard VG, *see* van Baren N
- Bridges MW, *see* Scheier MF
- Briffaux A, *see* Bosset J-F
- Brinkschmidt C, *see* Vandesompele J
- Brisbay S, *see* Bueso-Ramos C
- Brisson C, *see* Drolet M
- Brisson J, *see* Drolet M
- Bristow RE, *see* Santillan A
- Britt TL, *see* Vickers KS
- Brizzi MP, *see* Berruti A
- Broadbush RR, *see* Soliman PT
- Broadwater G, *see* Dressler LG  
*see* Petros WP
- Broadwater R, *see* Dye DW
- Brochet F, *see* Bairati I
- Brock MV, *see* Alberg AJ
- Brockmann J, *see* Koch P
- Broderson J, Thorsen H, Cockburn J. Validity of Short-Term Consequences of Cancer Prevention and Screening Activities? (correspondence), 244
- Brodeur GM, *see* Bagatell R  
*see* George RE  
*see* London WB
- Brodowicz T, *see* Zielinski C
- Broeckeaert B, *see* Maltoni M
- Brogliola C, *see* Baldini L  
*see* Gobbi PG
- Broglio K, *see* Cristofanilli M  
*see* Goy A  
*see* Hennessy BT
- Broglio KR, *see* Romaguera JE
- Broniscer A, *see* Tekautz TM
- Brooks JD, *see* Patel DA
- Brooks SL, *see* Castellino SM
- Brosjö O, *see* Ferrari S
- Brotchi J, *see* Lefranc F
- Brouet JC, *see* Femand J-P
- Broughton L, *see* Jayson GC
- Brouwers AH, Mulders PFA, de Mulder PHM, van den Broek WJM, Buijs WCAM, Mala C, Joosten FBM, Oosterwijk E, Boerman OC, Corstens FHM, Oyen WJG. Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With <sup>131</sup>I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma, 6540
- Brouwers M, *see* Browman GP
- Brouwers P, *see* Mulhern RK
- Browman GP, *see* Winer EP
- Browman GP, Makarski J, Robinson P, Brouwers M. Practitioners As Experts: The Influence of Practicing Oncologists “in-the-Field” on Evidence-Based Guideline Development, 113
- Browman GP. Standards of Proof, Standards of Practice, and Proof of Standards: A Tale of Two Trials (editorial), 2583
- Brown A, *see* Mamounas EP  
*see* Tan-Chiu E
- Brown J, *see* Aronson DC
- Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MKB, Rudd RM, Spiro SG, Stephens RJ, Waller D, West P, Peake MD. Assessment of Quality of Life in the Supportive Care Setting of the Big Lung Trial in Non-Small-Cell Lung Cancer, 7417
- Brown JE, *see* Coleman RE
- Brown JJ, *see* Hricak H
- Brown JR, DuBois RN. COX-2: A Molecular Target for Colorectal Cancer Prevention, 2840
- Brown JR, Freedman AS. In Reply (correspondence), 8121
- Brown JR, Yeckes H, Friedberg JW, Neuberger D, Kim H, Nadler LM, Freedman AS. Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin’s Lymphoma, 2208
- Brown K, *see* Czuczman MS
- Brown M, *see* Van Glabbeke M
- Brown ML, *see* Harlan LC
- Brown R, *see* Feldman EJ
- Brown S, *see* Hotte SJ
- Brown TD, *see* Dômont J
- Browning D, *see* Solomon MZ
- Broxson E, *see* Geyer JR
- Bruce JN, *see* Komotar RJ
- Bruera E, *see* Nayak S
- Bruera E. Improving the Care of Terminally Ill Cancer Patients and Their Families (editorial), 7378
- Bruera E, Sala R, Rico MA, Moyano J, Centeno C, Willey J, Palmer JL. Effects of Parenteral Hydration in Terminally Ill Cancer Patients: A Preliminary Study, 2366
- Brufsky A, *see* Low JA
- Brugge WR. Endoscopic Techniques to Diagnose and Manage Biliary Tumors, 4561
- Brugiere L, *see* Entz-Werlé N
- Brundage M, *see* Canil CM  
*see* Lukka H
- Brundage M, Feldman-Stewart D, Leis A, Bezjak A, Degner L, Velji K, Zetes-Zanatta L, Tu D, Ritvo P, Pater J. Communicating Quality of Life Information to Cancer Patients: A Study of Six Presentation Formats, 6949
- Brunelli C, *see* Maltoni M
- Brunet-Vidal J, *see* Puig S
- Brünnler G, *see* Glas J

## AUTHOR INDEX

- Bruno B, *see* Sorror ML
- Bruweleit M, *see* Loges S
- Bruzek L, *see* LoRusso PM
- Bruzzi P, *see* Sobrero A
- Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, Fountzilias G, Paul J, Rosso R, Venturini M. Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients, 5117
- Bryant J, *see* Mamounas EP  
*see* Tan-Chiu E  
*see* Winer EP
- Bubley GJ, *see* Koon HB
- Bucana C, *see* Mathew P
- Buchanan DR, O'Mara AM, Kelaghan JW, Minasian LM. Quality-of-Life Assessment in the Symptom Management Trials of the National Cancer Institute-Supported Community Clinical Oncology Program, 591
- Buchanan DR, White JD, O'Mara AM, Kelaghan JW, Smith WB, Minasian LM. Research-Design Issues in Cancer-Symptom-Management Trials Using Complementary and Alternative Medicine: Lessons from the National Cancer Institute Community Clinical Oncology Program Experience, 6682
- Buchanan G, *see* Fouladi M
- Buchanan MR, *see* Mann GB
- Buchholz TA, *see* Buzdar AU  
*see* Cristofanilli M  
*see* Gonzalez-Angulo A  
*see* Hennessy BT  
*see* Pratt DA
- Buckley DL, *see* Jayson GC
- Buckner JC, *see* Galanis E  
*see* Mahoney MR
- Bucvalas JC, *see* Gross TG
- Buda A, Fossati R, Colombo N, Fei F, Floriani I, Alletti DG, Katsaros D, Landoni F, Lissoni A, Malzoni C, Sartori E, Scollo P, Torri V, Zola P, Mangioni C. Randomized Trial of Neoadjuvant Chemotherapy Comparing Paclitaxel, Ifosfamide, and Cisplatin With Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous Cell Cervical Carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study, 4137
- Budach V, Stuschke M, Budach W, Baumann M, Geismar G, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke K-D. Hyperfractionated Accelerated Chemoradiation With Concurrent Fluorouracil-Mitomycin Is More Effective Than Dose-Escalated Hyperfractionated Accelerated Radiation Therapy Alone in Locally Advanced Head and Neck Cancer: Final Results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 Prospective Randomized Trial, 1125
- Budach W, *see* Stahl M
- Budd GT, *see* Cristofanilli M  
*see* Jones SE
- Budman D, *see* Dressler LG
- Budman DR, *see* Schwartz GK
- Bueno R, *see* Mamon HJ
- Buesa JM, *see* Martín J
- Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, Rosner G, Garcia-Manero G. Protein Expression of a Triad of Frequently Methylated Genes, *p73*, *p57<sup>Kip2</sup>*, and *p15*, Has Prognostic Value in Adult Acute Lymphocytic Leukemia Independently of Its Methylation Status, 3932
- Bugat R, *see* Conroy T
- Buijs C, *see* Nieboer P
- Buijs WCAM, *see* Brouwers AH
- Bujan-Boza WA, *see* Baker KS
- Bukowski R, *see* Mekhail TM
- Bulanhagui CA, *see* Ribas A
- Bull SB, *see* Wunder JS
- Büller HR, *see* Klerk CPW
- Bullinger L, Valk PJM. Gene Expression Profiling in Acute Myeloid Leukemia, 6296
- Bulten J, *see* Hendrickx BW
- Bultz BD, Carlson LE. Emotional Distress: The Sixth Vital Sign in Cancer Care (correspondence), 6440
- Bundy BN, *see* Lanciano R  
*see* Long HJ III
- Bunjes D, *see* Hess G
- Bunn PA Jr, *see* Bach PB  
*see* Cappuzzo F  
*see* Hirsch FR  
*see* Thienelt CD
- Bunn PA Jr. Platinums in Lung Cancer: Sufficient or Necessary? (editorial), 2882
- Bunnell C, *see* Stearns V
- Bunnell CA, *see* Burstein HJ  
*see* Meyerhardt JA
- Buosi R, *see* Montemurro F
- Burack R, *see* Tu P-h
- Burch KA. Home to Benin, 7226
- Burdett S, Stewart L, Auperin A, Pignon J-P. Chemotherapy in Non-Small-Cell Lung Cancer: An Update of an Individual Patient Data Meta-Analysis (correspondence), 924
- Burger PC, *see* Tu P-h
- Burkhardt B, *see* Seidemann K
- Burn J, *see* Bian Y
- Burnell M, *see* Couban S
- Burns BF, *see* Meyer RM
- Burris H III, *see* Spector NL
- Burris HA III, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL. Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients with Metastatic Carcinomas, 5305
- Burstein HJ, *see* Lyman GH  
*see* Punglia RS  
*see* Schrag D  
*see* Winer EP
- Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of Pegfilgrastim and Darbepoetin Alpha As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy, 8340
- Burstein HJ, Winer EP. HER2 or Not HER2: That Is the Question (editorial), 3656
- Burt BM, *see* Akhurst T
- Burt P, *see* Baka S
- Burtness B, *see* Ahn PH
- Burtness B. Cetuximab and Cisplatin for Chemotherapy-Refractory Squamous Cell Cancer of the Head and Neck (editorial), 5440
- Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study, 8646
- Burton E, *see* Couban S
- Burwinkle TM, *see* Bhat SR
- Burzykowski T, *see* Collette L
- Busam KJ, *see* Allen PJ  
*see* Jimenez RE

## AUTHOR INDEX

- Busby-Earle RMC, *see* Stirling D
- Busby EM, *see* Divers SG
- Busby L, *see* Samlowski WE
- Buske C, *see* Hiddemann W
- Buskin SE, *see* Gallafent JH
- Butler D, *see* Grote T
- Butow PN, *see* Hagerty RG
- Butrynski JE, *see* Hawkins DS
- Butterfield RM, *see* Emmons KM
- Buttitta F, *see* Marchetti A
- Büttner R, *see* Tasci S
- Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M. Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer, 6674
- Butzal M, *see* Loges S
- Butzow R, *see* Ollikainen M
- Buys CHCM, *see* Westra JL
- Buys S, *see* Phillips K-A
- Buyse M, *see* Sargent DJ
- Buyuk E, *see* Oktay K
- Büyükcelik A, *see* Utkan G
- Buzdar AU, *see* Cristofanilli M  
*see* Gonzalez-Angulo A  
*see* Green MC  
*see* Hennessy BT  
*see* Rouzier R
- Buzdar AU, Cuzick J. Optimum Use of Aromatase Inhibitors in the Adjuvant Treatment of Early Breast Cancer (correspondence), 8544
- Buzdar AU, Hunt KK, Berry D, Hortobagyi GN. In Reply (correspondence), 6804, 8131
- Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer, 3676
- Buzdar AU, Theriault RL, Hunt KK, Hortobagyi GN. In Reply (correspondence), 7760
- Buzzi F, *see* Boccardo F
- Buzzoni R, *see* Bajetta E
- Byhardt R, *see* Movsas B  
*see* Ettinger DS
- Byrd JC, *see* Bolaños-Meade J  
*see* Marcucci G  
*see* Raval A
- C**
- Caan BJ, *see* Rock CL
- Cabanillas F, *see* Goy A  
*see* Romaguera JE
- Cacciani G, *see* Ardizzoni A
- Cadeddu JA, *see* Lotan Y
- Cadranel J, *see* Boulanger E
- Cagnoni PJ, *see* Choy H
- Cahn JY, *see* de Botton S
- Caillet H, *see* Dromain C
- Cairncross JG, *see* Roa W
- Cairo MS, *see* Baker KS
- Calabrese L, *see* Laszlo D  
*see* Martrinelli G
- Calabresi F, *see* Papaldo P
- Calabuig S, *see* Martín J
- Calais G, *see* Bosset J-F
- Calandra G, *see* Devine S
- Caldas C, *see* Brenton JD
- Caldes T, *see* Bian Y
- Caldwell CB, *see* Mamounas EP
- Calero F, *see* Espinosa E
- Calero-García R, *see* Pozo-Rodríguez F
- Caligiuri MA, *see* Marcucci G
- Calingaert B, *see* Cragun JM
- Calkins A, *see* Lanciano R
- Callea V, *see* Agnelli L  
*see* Baldini L  
*see* Vallisa D
- Calvert AH, *see* Dark GG
- Calvert AH. Fishing for New Drugs (editorial), 7780
- Calvert VS, *see* Petricoin EF III
- Calvo FA, *see* Zapatero A
- Calzone KA, Prindiville SA, Jourkiv O, Jenkins J, DeCarvalho M, Wallerstedt DB, Liewehr DJ, Steinberg SM, Soballe PW, Lipkowitz S, Klein P, Kirsch IR. Randomized Comparison of Group Versus Individual Genetic Education and Counseling for Familial Breast and/or Ovarian Cancer, 3455
- Camacho LH, *see* Ribas A
- Cameron DA, *see* Evans TRJ  
*see* Langley RE
- Cameron T, *see* Dark GG
- Camidge R, Reigner B, Cassidy J, Grange S, Abt M, Weidekamm E, Jodrell D. Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Cancer, 4719
- Camilo ME, *see* Ravasco P
- Camitta BM, *see* Baker KS
- Campana D, *see* Pui C-H
- Campanelli R, *see* Massa M
- Campbell KJ, *see* Nyman DW
- Campbell M, *see* Banerji U
- Camphausen K, Citrin D, Krishna MC, Mitchell JB. Implications for Tumor Control During Protection of Normal Tissues With Antioxidants (editorial), 5455
- Campiglio M, *see* Ménard S
- Camplese PP, *see* Marchetti A
- Campo E, *see* Fernández V  
*see* López-Guillermo A  
*see* Moreno C
- Campos H, *see* Meyerhardt JA
- Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C, Hirte H. Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer, 5597
- Campoy A, *see* Puig S
- Camps C, *see* Ramirez JL
- Canellos GP. Chemotherapy Alone for Early Hodgkin's Lymphoma: An Emerging Option (editorial), 4574
- Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group, 455
- Cannistra SA, *see* Spentzos D
- Cannistra SA. In Reply (correspondence), 2863
- Cannon-Albright LA, *see* Florell SR
- Cantor A, *see* Eschrich S

## AUTHOR INDEX

- see* Ferraro B  
 Cantore M, *see* Fiorentini G  
 Cao D, *see* van Besien K  
 Cao H, *see* Le Q-T  
 Cao Y, Tsien CI, Shen Z, Tatro DS, Haken RT, Kessler ML, Chenevert TL, Lawrence TS. Use of Magnetic Resonance Imaging to Assess Blood-Brain/Blood-Glioma Barrier Opening During Conformal Radiotherapy, 4127  
 Capanna R, *see* Ferrari S  
 Capanna T, *see* Goodin S  
 Capdeville R, *see* Peng B  
 Capocaccia R, *see* Gatta G  
 Capote FJ, *see* Ortega JJ  
 Capp A, *see* Thewes B  
 Cappuzzo F, *see* Travis WD  
 Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR. Increased *HER2* Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients, 5007  
 Caputo A, *see* von Minckwitz G  
 Caraceni A, *see* Maltoni M  
 Caraglia M, Montella L, Addeo R, Costanzo R, Faiola V, Del Prete S, Baldi F, Baldi A, Abbruzzese A, Alloisio M. Conditions Suggesting Lymphoma. Mediastinal Liposarcoma in a Patient With Previous Testicular Cancer, 3844  
 Carbone A, *see* Gruber G  
 Carbone D, *see* Meyerson M  
 Carbone DP, *see* Herbst RS  
 Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, Maher VE, Stipanov M, Contois D, Johnson BE, Pendleton CD, Seifert B, Carter C, Read EJ, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA. Immunization With Mutant *p53*- and *K-ras*-Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome, 5099  
 Carbonell X, *see* Baseiga J  
 Carcangiu M, *see* Gianni L  
 Carde P. The Chemotherapy/Radiation Balance in Advanced Hodgkin's Lymphoma: Overweight Which Side? (editorial), 9058  
 Cardillo A, *see* Colleoni M  
 Cardoso F, *see* Chan S  
 Carducci MA, *see* Rudek MA  
     *see* Sausville EA  
     *see* ten Tije AJ  
 Carducci MA. What Is More Exciting? The Activity of Docetaxel in Early Prostate Cancer or the Successful Collaboration Between Urologists and Medical Oncologists to Complete a Study in Early Prostate Cancer? (editorial), 3304  
 Carey D, *see* Divers SG  
 Carey LA, *see* Brenton JD  
 Carles J, *see* Aparicio J  
     *see* Hitt R  
 Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, De Sio L, Koscielniak E, Scotti G, Treuner J. Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group, 8422  
 Carlini P, *see* Ferretti G  
     *see* Papaldo P  
 Carlson LE, *see* Bultz BD  
 Carmichael J, *see* Langley RE  
 Carminati O, *see* Comoli P  
 Carotti A, *see* Aversa F  
 Carpenter M, *see* Saif MW  
 Carr DB, *see* McNicol E  
 Carr KL, *see* Ajani JA  
 Carr RA, *see* Hoekstra R  
 Carrascosa L, *see* Ang KK  
 Carrato A, *see* Sastre J  
 Carreras E, *see* Prieto JM  
 Carrie C, *see* Arpin D  
     *see* Oyharcabal-Bourden V  
 Carrington B, *see* Jayson GC  
 Carroll AJ, *see* Farag SS  
     *see* Marcucci G  
 Carroll KJ, *see* Collette L  
 Carroll M, *see* Faynsod M  
 Carroll PR, *see* Cooperberg MR  
     *see* Stewart AJ  
     *see* Zhou P  
 Carroll RR, *see* Vogel CL  
 Carson K, *see* McKoy JM  
 Carson KR, *see* Wolf MS  
 Carson WE. Getting Melanoma Cells to Stimulate With Frequency (editorial), 8929  
 Carson WE III, *see* Eisenbeis CF  
 Carstensen H, *see* Borgwardt L  
 Carston M, *see* Pavletic SZ  
 Carteni G, *see* Colucci G  
 Carter C, *see* Carbone DP  
     *see* Green MC  
 Carter J, *see* Paramasivan S  
 Carter NP, *see* Mendrzyk F  
 Carulla J, *see* Tabernero J  
 Caruso M, *see* Colucci G  
 Casado A, *see* Martín J  
 Casado E, *see* Feliu J  
 Casali C, *see* Rossi G  
 Casali PG, *see* Fiore M  
     *see* Gronchi A  
     *see* Van Glabbeke M  
 Casanova M, *see* Carli M  
     *see* Ferrari A  
 Cascinu S, *see* Graziano F  
 Cascinu S, *see* Scartozzi M  
 Casey B, *see* van Besien K  
 Casillas J, *see* Castellino SM  
 Casiraghi O, *see* Faivre S  
 Cassidy J, *see* Camidge R  
 Cassidy P, *see* Samlowski WE  
 Cassileth BR, Vickers AJ. High Prevalence of Complementary and Alternative Medicine Use Among Cancer Patients: Implications for Research and Clinical Care (editorial), 2590  
 Castagnetti F, *see* Soverini S  
 Castañeda-Soto N-J, *see* Baseiga J  
 Castel T, *see* Puig S  
 Castellino SM, Casillas J, Hudson MM, Mertens AC, Whitton J, Brooks SL, Zeltzer LK, Ablin A, Castleberry R, Hobbie W, Kaste S, Robison LL, Oeffinger KC. Minority Adult Survivors of Childhood Cancer: A Comparison of Long-Term Outcomes, Health Care Utilization, and Health-Related Behaviors From the Childhood Cancer Survivor Study, 6499  
 Castello G, Ascierto PA  
 Castiglione-Gertsch M, *see* Colleoni M  
     *see* Gruber G  
 Castiglioni F, *see* Ardizzoni A  
 Castillo R, *see* Grote T  
     *see* Jatoi A  
 Castle PE, *see* McGlynn KA  
 Castleberry R, *see* Bagatell R

- see Castellino SM
- Castleberry RP, *see* George RE
- see London WB
- Castro AA, *see* Clark OAC
- Castro M. Resisting a Fundamentalist Policy (correspondence), 3645
- Casty A, *see* Taghian AG
- Casuccio A, *see* Mercadante S
- Catalano P, *see* Sun W
- Catalano PJ, *see* Berger AC
- see Haller DG
- see Sargent DJ
- Catalano V, *see* Graziano F
- Catalona WJ, *see* D'Amico AV
- Catania S, *see* Ferrari A
- Catchpole D, *see* Bilke S
- Catena L, *see* Bajetta E
- Catot S, *see* Ramirez JL
- Catto JWF, Azzouzi A-R, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M, Handy FC. Promoter Hypermethylation Is Associated With Tumor Location, Stage, and Subsequent Progression in Transitional Cell Carcinoma, 2903
- Cavalli F, *see* Abrey LE
- Cavalloni G, *see* Grignani G
- Cavanna L, *see* Gobbi PG
- see Vallisa D
- Cavazza A, *see* Rossi G
- Cazorla A, *see* Honrado E
- Cazzola M, *see* Malcovati L
- Cecchetto G, *see* Carli M
- Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, Horcher E, Neuenschwander S, Tomà P, Rizzo A, Michon J, Holmes K. Surgical Risk Factors in Primary Surgery for Localized Neuroblastoma: The LNESG1 Study of the European International Society of Pediatric Oncology Neuroblastoma Group, 8483
- Cedermark B, *see* Folkesson J
- Cefalo G, *see* Ferrari A
- Cejas P, *see* Espinosa E
- Celio L, *see* Bajetta E
- Cella D, *see* Monk BJ
- see Wenzel L
- Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial, 2946
- Cella DF, *see* Andrykowski MA
- Centeno C, *see* Bruera E
- Ceresoli GL, *see* Cappuzzo F
- Cerny T, *see* D'Addario G
- see Ghilmini M
- Cervantes A, *see* Hitt R
- Cervek J, *see* Zielinski C
- Cesana B, *see* Praga C
- Cesarman E, *see* Leonard JP
- Chachoua A, *see* Hamilton AL
- Chacón M, *see* Chacón R
- Chacón M, Roca E, Huertas E, Loria FS, Domenichini E. Dramatic Responses to Therapy in Rare Tumors: Pathologic Complete Remission of Metastatic Gastrointestinal Stromal Tumor After Imatinib Mesylate, 1580
- Chacón M, Roca E, Huertas E, Loria FS, Domenichini E. Complete Remission With Imatinib in Metastatic Gastrointestinal Stromal Tumors (correspondence), 6801
- Chacón R, Tossen G, Loria FS, Chacón M. Dramatic Responses to Therapy in Rare Tumors: Response in a Patient With Metastatic Adrenal Cortical Carcinoma With Thalidomide, 1579
- Chadburn A, *see* Leonard JP
- Chahinian P, *see* Lilenbaum RC
- Chaib C, *see* Hitt R
- Chakravarti A, *see* Nguyen PL
- Chalchal HI, *see* Witzig TE
- Chamberlain MC. Mafosfamide: A New Intra-CSF Chemotherapy? (correspondence), 7748
- Chamberlain MC. Neoplastic Meningitis, 3605
- Chamberlain MC, Recht LD, Glantz M. Regarding "Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial" (correspondence), 1587
- Chamberlain MC, Sloan A, Vrionis F. Systematic Review of the Diagnosis and Management of Malignant Extradural Spine Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group (correspondence), 7750
- Chambers A, *see* Loblaw DA
- Chamness GC, *see* Chang JC
- see Mohsin SK
- Chamontin B, *see* Amar L
- Champlin RE, *see* Khouri IF
- Chan ATC, *see* Ma BBY
- see Mok TSK
- Chan ATC, Hsu M-M, Goh BC, Hui EP, Liu T-W, Millward MJ, Hong R-L, Whang-Peng J, Ma BBY, To KF, Mueser M, Amellal N, Lin X, Chang AY. Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma, 3568
- Chan C, *see* Kohonen-Corish MRJ
- Chan DDN, *see* Chan W-M
- Chan HLY, *see* Mok TSK
- Chan HM, *see* Zelefsky MH
- Chan JK, Lin SS, McMeekin DS, Berman ML. Patients With Malignancy Requiring Urgent Therapy. Tumor Lysis Syndrome Associated With Chemotherapy in Ovarian Cancer, 6794
- Chan JM, Gann PH, Giovannucci EL. Role of Diet in Prostate Cancer Development and Progression, 8152
- Chan KK, *see* Marcucci G
- Chan R. Randomized Trial of 30 Versus 20 Gy in the Adjuvant Treatment of Stage I Testicular Seminoma: A Report on Medical Research Council Trial TE18, European Organisation for Research and Treatment of Cancer Trial 30942 (ISRCTN18525328) (correspondence), 6806
- Chan RHW, *see* Chim CS
- Chan S, *see* Marty M
- Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger H-J, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L. Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer, 5314
- Chan W-M, Liu DTL, Pang C-P, Lam DSC, To KF, Choi TPCL, Choy KW, Wong C-Y, Chan DDN. Pediatric Malignancies. Hypermethylation in Orbital Alveolar Rhabdomyosarcoma, 4790
- Chan YM, Lee PWH, Fong DYT, Fung ASM, Wu LYF, Choi AYY, Ng TY, Ngan HYS, Wong LC. Effect of Individual Psychological Intervention in Chinese Women With Gynecologic Malignancy: A Randomized Controlled Trial, 4913
- Chanan-Khan A, *see* Czuczman MS
- Chandler WF, *see* Chugh R
- Chang AY, *see* Chan ATC
- Chang H, *see* Jaksic W
- Chang J, Couture F, Young S, McWatters K-L, Lau CY. Weekly Epoetin

- Alfa Maintains Hemoglobin, Improves Quality of Life, and Reduces Transfusion in Breast Cancer Patients Receiving Chemotherapy, 2597
- Chang JC, *see* Mohsin SK
- Chang JC, Weiss H, Mohsin S. Apoptosis Induction by the Core Biopsy Procedure (correspondence), 7240
- Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham Y-L, Kalidas M, Elledga R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P. Patterns of Resistance and Incomplete Response to Docetaxel by Gene Expression Profiling in Breast Cancer Patients, 1169
- Chang K-J, *see* Chen C-N
- Chang KL, *see* Bhatia R
- Chang M, *see* Laver JH
- Chang R, *see* Pingpank JF
- Chang S, *see* Cloughesy TF
- Chang YS, *see* Lee H-Y
- Chansky K, *see* Gaspar LE
- Chao Y, *see* Ajani JA
- Chap, LI, *see* Miller KD
- Chapelle-Marcillac I, *see* Bonnetterre J
- Chapman PB, *see* Giaccone G  
*see* Rietschel P  
*see* Su YB
- Chappell R, *see* Lee AWM
- Chapuis PH, *see* Kohonen-Corish MRJ
- Chapusot C, *see* Lièvre A
- Charachon A, *see* Lévy M
- Charbe O, *see* Amar L
- Charbonneau C, *see* Campos S
- Charles M, *see* Hardy J
- Charles W, Joseph G, Hunis B, Rankin L. Problems in Colon Cancer and a Child With Renal Lymphoma. Metastatic Colon Cancer to the Testicle Presenting As Testicular Hydrocele, 5256
- Charnsangavej C, *see* Liu G
- Chaastagner P, *see* Oyharcabal-Bourden V  
*see* Valteau-Couanet D
- Chatelut E, *see* Chevreau C
- Chatis P, *see* Koon HB
- Chatzidaki D, *see* Georgoulas V
- Chauhan D, *see* Hideshima T
- Chaumette M-T, *see* Lévy M
- Chauncey TR, *see* Baron F  
*see* Sorror ML
- Chauvenet AR, *see* McLean TW
- Chauvin F, *see* Ray-Coquard I
- Chavaudra J, *see* Guibout C
- Cheewakriangkrai R, Litwin A, Nava ME, Ramnath N. Unusual Thoracic Problems in Patients With Malignancies. Malignant Mesothelioma in a Patient With Long-Standing Pulmonary Alveolar Proteinosis, 2858
- Chella A, *see* Marchetti A
- Chemerynsky I, *see* Mar Fan HG
- Chen BE, *see* Kramer JL
- Chen C, *see* Jaksic W
- Chen C-H, *see* Chen JJW
- Chen C-N, Lin J-J, Chen JJW, Lee P-H, Yang C-Y, Kuo M-L, Chang K-J, Hsieh F-J. Gene Expression Profile Predicts Patient Survival of Gastric Cancer After Surgical Resection, 7286
- Chen C-Y, *see* Wang Y-C
- Chen E, *see* Knox JJ
- Chen EX, *see* Hotte SJ  
*see* Zia MI
- Chen EY, *see* Le Q-T
- Chen H, *see* D'Adamo DR
- Chen H-N, *see* Dotan ZA
- Chen H-Y, *see* Chen JJW
- Chen I, *see* Galsky MD
- Chen J-T, *see* Wang Y-C
- Chen JJW, *see* Chen C-N
- Chen JJW, Lin Y-C, Yao P-L, Yuan A, Chen H-Y, Shun C-T, Tsai M-F, Chen C-H, Yang P-C. Tumor-Associated Macrophages: The Double-Edged Sword in Cancer Progression, 953
- Chen L-m, *see* Powell CB
- Chen M-H, *see* D'Amico AV  
*see* Stewart AJ  
*see* Zhou P
- Chen MS Jr, *see* Lara PN Jr
- Chen O-R, *see* Bilke S
- Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW. Pivotal Study of Iodine-131-Labeled Chimeric Tumor Necrosis Treatment Radioimmunotherapy in Patients With Advanced Lung Cancer, 1538
- Chen T, *see* Rubin EH
- Chen WY, *see* Kroenke CH
- Chen X-F, *see* Zhang H-T
- Chen Y, *see* Bian Y  
*see* Chen S  
*see* Pasche B
- Chenevert TL, *see* Cao Y
- Cheng C, *see* Pui C-H
- Cheng JD, *see* Ang KK  
*see* Berger AC
- Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrl R, Gardner TA. The Combined Percentage of Gleason Patterns 4 and 5 Is the Best Predictor of Cancer Progression After Radical Prostatectomy, 2911
- Cheng SH, Huang AT. Comments on Concurrent and Adjuvant Chemotherapy for Nasopharyngeal Carcinoma: A Mist of Mysterious Results (correspondence), 2864
- Cheragwandi SA, Timmer-Bonte JN
- Chernozemsky I, *see* Zielinski C
- Cheson, BD. Individualizing Therapy for the Hematologic Malignancies: The Stuff of Genes and Dreams (editorial), 6283
- Cheson BD, *see* Juweid ME
- Cheson BD, Haller D, Horning SJ. Serving Interests in Hematologic Malignancies in the *Journal of Clinical Oncology*, 3666
- Chessin DB, *see* Guillem JG
- Cheung AM, Tomlinson G, Goss PE. Bone Loss With Exemestane—Is the Jury Still Out? (correspondence), 9433
- Cheung N-KV, *see* Kushner BH
- Cheung S, *see* Jayson GC
- Cheung W, *see* Chim CS
- Cheung Y-B, Goh C, Thumboo J, Khoo K-S, Wee J. In Reply (correspondence), 8542
- Cheung Y-B, Goh C, Thumboo J, Khoo K-S, Wee J. Variability and Sample Size Requirements of Quality-of-Life Measures: A Randomized Study of Three Major Questionnaires, 4936
- Chévez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C, Hurwitz MY, Hurwitz RL. Response of Retinoblastoma With Vitreous Tumor Seeding to Adenovirus-Mediated Delivery of Thymidine Kinase Followed by Ganciclovir, 7927
- Chevreau C, Thomas F, Couteau C, Dalenc F, Mourey L, Chatelut E. Ototoxicity of High-Dose Carboplatin (correspondence), 3649
- Chevret S, *see* Annane DJ  
*see* Boulanger E  
*see* de Botton S  
*see* Ferman J-P
- Chhanabhai M, *see* Sehn LH
- Chi DS, *see* Hricak H
- Chi KN, *see* Canil CM

## AUTHOR INDEX

- Chianese-Bullock K, *see* Slingluff CL Jr
- Chiang SS, *see* Yao JC
- Chiao JH, *see* Kelly WK
- Chiaramondia M, *see* Tiseo M
- Chiechi C, *see* Lara PN Jr
- Chièze S, *see* Faivre S
- Child JA, *see* Augustson BM  
*see* Greipp PR
- Chim CS, Loong F, Ma ESK, Cheung W, Chan RHW, Ooi GC. Plasma Cell Problems: Extramedullary Cardiac Plasmacytoma Presenting With Cardiac Tamponade, 3140
- Chim CS, Ooi GC, Loong F, Au AWM, Lie AKW. Side Effects and Good Effects From New Chemotherapeutic Agents. Bortezomib in Primary Refractory Plasmacytoma, 2426
- Chintagumpala M, *see* Chévez-Barríos P  
*see* Mulhern RK
- Chisesi T, *see* Gobbi PG  
*see* Rohatiner AZS
- Chlebowski RT, *see* Winer EP
- Chlebowski RT. Obesity and Early-Stage Breast Cancer (editorial), 1345
- Chmielewski L, *see* Mintzer DM
- Cho CD, *see* Kuo T
- Cho D, Kocher O, Tenen DG, Halmos B, Lee JC, Myerson ML, Janne PA. Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer. Mutation of the Epidermal Growth Factor Receptor in an Elderly Man With Advanced Gefitinib-Responsive, Non-Small-Cell Lung Cancer, 235
- Cho E, Rosner BA, Feskanich D, Colditz GA. Risk Factors and Individual Probabilities of Melanoma for Whites, 2669
- Cho KH, *see* Han J-Y
- Cho MJ, *see* Roh J-L
- Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M. Dignity Therapy: A Novel Psychotherapeutic Intervention for Patients Near the End of Life, 5520
- Choe JK, *see* Nagaria NC
- Choi AYY, *see* Chan YW
- Choi E, *see* O'Connor OA
- Choi IS, *see* Han S-W
- Choi JY, Lee KS, Kwon OJ, Shim YM, Baek C-H, Park K, Lee, K-H, Kim B-T. Improved Detection of Second Primary Cancer Using Integrated [<sup>18</sup>F] Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Initial Tumor Staging, 7654
- Choi PCL, *see* Chan W-M
- Chomienne C, *see* de Botton S
- Chong G, Cunningham D. Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer (editorial), 9063
- Choo R, *see* Lukka H
- Choo SP, Lim DWT, Lo CPL, Koong HN, Tao M, Lim CH. Variable Problems in Lymphomas. Burkitt's Lymphoma Presenting With Central Airway Obstruction, 8112
- Chopin DK, *see* Patard J-J
- Chopra R, *see* Feldman EJ  
*see* Tauro S
- Chow KU, *see* Rummel MJ
- Choy DTK, *see* Chua DTT
- Choy H, *see* Belani CP
- Choy H, Nabid A, Stea B, Scott C, Roa W, Kleinberg L, Ayoub J, Smith C, Souhami L, Hamburg S, Spanos W, Kreisman H, Boyd AP, Cagnoni PJ, Curran WJ. Phase II Multicenter Study of Induction Chemotherapy Followed by Concurrent Efavoxiral (RSR13) and Thoracic Radiotherapy for Patients With Locally Advanced Non-Small-Cell Lung Cancer, 5918
- Choy KW, *see* Chan W-M
- Chretien P, *see* Timár J
- Chrischilles E, *see* Swenson WT
- Christakis N, *see* Maltoni M
- Christensen RS, *see* Auethavekiat P
- Christensen VJ, *see* Harris EER
- Christian B, *see* Feugier P
- Christiansen H, *see* Vandesompele J  
*see* Weber A
- Christou A, *see* Georgoulas V
- Chu E, *see* Kelly WK
- Chua DTT, *see* Lee AWM
- Chua DTT, Ma J, Sham JST, Mai H-Q, Choy DTK, Hong M-H, Lu T-X, Min H-Q. Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III Trials, 1118
- Chua EJ, *see* Wee J
- Chua ET, *see* Wee J
- Chua YJ, Cunningham D. Adjuvant Treatment for Resectable Pancreatic Cancer, 4532
- Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A. Bilateral Risk for Subsequent Breast Cancer After Lobular Carcinoma-In-Situ: Analysis of Surveillance, Epidemiology, and End Results Data, 5534
- Chugh R, *see* Worden FP
- Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, Leu KM, Chandler WF, Baker LH. Phase II Study of 9-Nitro-Camptothecin in Patients With Advanced Chordoma or Soft Tissue Sarcoma, 3597
- Chundru S, *see* Morgan PB
- Chung DC, *see* Willett CG
- Chung DH, *see* Han S-W
- Chung EJ, *see* Ryan QC
- Chung KY, *see* Saltz LB
- Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry, 1803
- Church C, *see* Hinds PS
- Cibas ES, *see* Austin RM
- Ciceri F, *see* Corradini P
- Ciernik IF, *see* Carbone DP
- Cigolari S, *see* Maione P
- Cilloni D, *see* Soverini S
- Cincotta M, *see* Chan S
- Cindolo L, *see* Patard J-J
- Cinieri S, *see* Pruneri G
- Cirera E, *see* Prieto JM
- Ciroidi M, *see* Thiéry G
- Cirrincione C, *see* Peters WP
- Ciruelos E, *see* Colomer R
- Citrin D, *see* Camphausen K
- Clark GM, *see* Arpino G  
*see* McShane LM
- Clark JH, *see* McDermott DF
- Clark JW, *see* Hamilton AL  
*see* Willett CG
- Clark K, *see* Gianni L
- Clark LGO, *see* Clark OAC
- Clark MA, Ascierto PA, *see* Duffy CM
- Clark MM, *see* Vickers KS
- Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B. Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials, 4198
- Clark OAC, Lyman GH, Djulbegovic B. In Reply (correspondence), 8537
- Clark PI, *see* Thatcher N

AUTHOR INDEX

- Clarke CA, *see* Keegan THM  
 Clarke-Pearson DL, *see* Cragun JM  
 Clarke S, *see* Joshua AM  
 Clarke SJ, *see* Joshua AM  
   *see* Sharma R  
   *see* Vardy J  
 Clasen H, *see* Koch P  
 Claude L, *see* Arpin D  
 Clavarino A, *see* Yates P  
 Claviez A, *see* Schellong G  
 Claviez A, Tiemann M, Lüders H, Krams M, Parwaresch R, Schellong G, Dörrfel W. Impact of Latent Epstein-Barr Virus Infection on Outcome in Children and Adolescents With Hodgkin's Lymphoma, 4048  
 Clawson S, *see* Johnson PWM  
 Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, Prieto VG, Altamirano E, Tucker SL, Strom SS, Kripke ML, Lippman SM. Mortality Risk From Squamous Cell Skin Cancer, 759  
 Clegg LX, *see* Harlan LC  
 Clemens M, *see* Baseiga J  
 Clemons M, *see* Gainford MC  
   *see* Simmons C  
   *see* Verma S  
 Cleverly A, *see* Schwartz GK  
 Clifford SC, *see* Ellison DW  
 Clift SM, *see* Luiten RM  
 Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebt SM, Prados M. Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study, 6647  
 Cmelak A, *see* Robbins KT  
 Coates AS, *see* Colleoni M  
   *see* Gruber G  
   *see* Stewart BW  
 Cobleigh MA, *see* Miller KD  
   *see* Winer EP  
 Cochran AJ, *see* Lyman GH  
 Cockburn J, *see* Broderick J  
 Codony J, *see* Montagut C  
 Cody HS III, *see* Lyman GH  
 Coens C, *see* Giaccone G  
 Coens C, Bottomley A, Efficace F, Flechtner H, Aaronson N. Variability and Sample Size Requirements for Health-Related Quality-of-Life Measures: Understanding the Challenges Facing Investigators (correspondence), 8541  
 Coffey RJ, *see* Rothenberg ML  
 Cogliatti S, *see* Ghilmini M  
 Cognetti F, *see* Alimonti A  
   *see* Ferretti G  
   *see* Marty M  
 Cogswell J, *see* Nagaria NC  
 Cohen AM, *see* Guillem JG  
 Cohen HJ, *see* Kimmick GG  
 Cohen KS, *see* Willett CG  
 Cohen RB, *see* Cohen SJ  
 Cohen SJ, Cohen RB, Meropol NJ. Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep, 5374  
 Cohn SL, *see* Bagatell R  
   *see* George RE  
   *see* London WB  
 Coiffier B, *see* Feugier P  
 Coiffier B. State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma, 6387  
 Coindre J-M, *see* Guillou L  
 Coit DG, *see* Allen PJ  
   *see* Kammula US  
 Cola LR, *see* Suntharalingam M  
 Colan SD, *see* Adams MJ  
   *see* Lipshultz SE  
 Colditz GA, *see* Cho E  
 Cole B, *see* Ahles TA  
 Coleman M, *see* Fisher RI  
   *see* Leonard JP  
 Coleman R, *see* Dark GG  
 Coleman RE, *see* Evans TRJ  
 Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R. Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid, 4925  
 Colevas AD, *see* Galsky MD  
   *see* Hussain M  
 Colgan JP, *see* Martin WG  
 Colleoni M, *see* Curigliano G  
   *see* Dellapasqua S  
 Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G, Luini A, Intra M, Veronesi P, Galimberti V, Torrisi R, Cardillo A, Goldhirsch A, Viale G. Size of Breast Cancer Metastases in Axillary Lymph Nodes: Clinical Relevance of Minimal Lymph Node Involvement, 1379  
 Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenski C-M, Lindtner J, Er<sup>9</sup>een D, Snyder R, Collins J, Fey MF, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience, 1390  
 Collette L, *see* Bosset J-F  
   *see* Sargent DJ  
 Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH. Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals, 6139  
 Collier A, *see* Halbert CH  
 Collier MA, *see* Bissett D  
 Colligan T, *see* DeMichele A  
 Collin F, *see* Le Cesne A  
 Collini P, *see* Ferrari A  
   *see* Fiore M  
   *see* Gronchi A  
 Collins J, *see* Colleoni M  
   *see* Gruber G  
 Collins JM. Imaging and Other Biomarkers in Early Clinical Studies: One Step at a Time or Re-Engineering Drug Development? (editorial), 5417  
 Collins WP, *see* Timmerman D  
 Colombi M, *see* Baldini L  
 Colombo N, *see* Buda A  
   *see* Sessa C  
 Colomer D, *see* López-Guillermo A  
   *see* Moreno C  
 Colomer R, Beltran M, Dorcas J, Cortes-Funes H, Hornedo J, Valentin V, Vargas C, Mendiola C, Ciruelos E. It Is Not Time to Stop Progesterone Receptor Testing in Breast Cancer (correspondence), 3868  
 Colomo L, *see* López-Guillermo A  
 Colozza M, Larsimont D, Piccart MJ. Progesterone Receptor Testing: Not the Right Time to Be Buried (correspondence), 3867  
 Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni

- G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E. Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale, 4866
- Colvin OM, *see* Petros WP
- Colvin S, *see* Scheier MF
- Comandone A, *see* Ferrari S
- Combaret V, *see* De Preter K  
*see* Vandesompele J
- Combaret V, Bergeron C, Noguera R, Iacono I, Puisieux A. Circulating MYCN DNA Predicts MYCN-Amplification in Neuroblastoma (correspondence), 8819
- Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of Fractionated Stereotactic Reirradiation in Recurrent Gliomas: Long-Term Results in 172 Patients Treated in a Single Institution, 8863
- Come SE, *see* Bellon JR  
*see* Burstein HJ
- Comeri G, *see* Boccardo F.
- Comin-Anduix B, *see* Ribas A
- Commandeur S, *see* van Doorn R
- Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S. Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes, 8942
- Conconi A, *see* Martrinelli G
- Conde E, *see* Ortega JJ
- Conley BA, *see* Sargent DJ
- Conlon KC. Intraductal Papillary Mucinous Tumors of the Pancreas, 4518
- Connors JM, *see* Forrest DL  
*see* Meyer RM  
*see* Sehn LH  
*see* Shankier TN
- Connors JM. State-of-the-Art Therapeutics: Hodgkin's Lymphoma, 6400
- Conrad B, *see* Kaufman M
- Conrad E, *see* Meyers PA
- Conrad EU, *see* Wunder JS
- Conrad EU III, *see* Hawkins DS
- Conroy T, Paillot B, François E, Bugat R, Jacob J-H, Stein U, Nasca S, Metges J-P, Rixe O, Michel P, Magherini E, Hua A, Deplanque G. Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study, 1228
- Conte D, *see* Sozzi G
- Conte PF, *see* Marty M
- Conti B, *see* Spinola M
- Conti F, *see* Papaldo P
- Conti G, *see* Boccardo F.
- Contois D, *see* Carbone DP
- Cook G, *see* Tauro S
- Cook M, *see* Tauro S  
*see* Weber RW
- Cook R, *see* Coleman RE  
*see* Smith MR
- Coombes RC, *see* Praga C
- Coombes RC, Bliss JM, Hall E. Safety of Exemestane in the Intergroup Exemestane Study (correspondence), 3171
- Coombs NJ, Boyages J. Multifocal and Multicentric Breast Cancer: Does Each Focus Matter? 7497
- Cooper DL, *see* Smith BD
- Cooper M, *see* Tabernero J
- Cooperberg MR, Moul JW, Carroll PR. The Changing Face of Prostate Cancer, 8146
- Copelan EA, *see* Pavletic SZ
- Copie-Bergman C, *see* Lévy M
- Coppes MJ, *see* Grundy PE
- Coppola D, *see* Eschrich S
- Corbett-Hemeyer J. Inter-Religious Perspectives on Hope and Limits in Cancer Treatment: One Buddhist Chaplain's Response to the Case (correspondence), 8140
- Cordier J-F, *see* Arpin D
- Cordio S, *see* Colucci G
- Corless CL, *see* McArthur GA
- Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib, 5357
- Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Greshenwald JE, Ross MI, Du XL. Population-Based Assessment of Surgical Treatment Trends for Patients With Melanoma in the Era of Sentinel Lymph Node Biopsy, 6054
- Cormier Y, *see* Butts C
- Cornelis M, *see* Poston GJ
- Cornelisse CJ, *see* Sieben NLG
- Corradini P, *see* Vacca A
- Corradini P. In Reply (correspondence), 2110
- Corradini P, Zallio F, Mariotti J, Farina L, Bregni M, Valagussa P, Ciceri F, Bacigalupo A, Doderò A, Lucese M, Patriarca F, Rambaldi A, Scimé R, Locasciulli A, Bandini G, Gianni AM, Tarella C, Olivieri A. Effect of Age and Previous Autologous Transplantation on Nonrelapse Mortality and Survival in Patients Treated With Reduced-Intensity Conditioning and Allografting for Advanced Hematologic Malignancies, 6690
- Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, La Placa M, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G. Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients, 8950
- Corry J, *see* Rischin D
- Corstens FHM, *see* Brouwers AH
- Cortelazzo S, *see* Baldini L
- Cortés-Funes H, *see* Baselga J  
*see* Colomer R  
*see* Hitt R
- Cortes J, *see* Issa J-PJ  
*see* Keating MJ  
*see* Wierda W
- Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients With Acute Leukemias and High-Risk Myelodysplastic Syndromes, 2805
- Cortes J, Kantarjian H. New Targeted Approaches in Chronic Myeloid Leukemia, 6316
- Cortesi E, *see* Papaldo P
- Coscas Y, *see* Oudard S
- Cosimi AB, *see* Livestro DP
- Cosio MG, *see* Montalban C
- Cosio S, Gadducci A
- Costa A, *see* Ménard S
- Costa DB, Parker JA, Schumer ST. Modern Treatment of Lung Cancer. Non-Metastatic Bilateral F-18 Fluorodeoxyglucose Avid Adrenal Glands in Non-Small-Cell Lung Cancer, 7740
- Costa E, *see* Cecchetto G
- Costa SD, *see* von Minckwitz G
- Costanzo R, *see* Caraglia M

AUTHOR INDEX

- Cote RJ, Laird PW, Datar RH. Promoter Hypermethylation: A New Therapeutic Target Emerges in Urothelial Cancer (editorial), 2879
- Cotroneo A, *see* Joshua AM
- Cottin V, *see* Arpin D
- Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, MacLeod D, Burton E, Andreou P, Anderson DR. Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer, 4063
- Couch FJ, *see* Goetz MP
- Coulie PG, *see* van Baren N
- Couriel D, *see* Khouri IF
- Couteau C, *see* Chevreau C
- Couture F, *see* Chang J
- Cowan D, *see* Dressler LG
- Cox JD, *see* Das P  
*see* Sasaki R
- Cox K, *see* Dressler LG
- Coze C, *see* Valteau-Couanet D
- Crabtree D, *see* Raja V
- Craddock C, *see* Tauro S
- Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer, 3668
- Craig FE, *see* Keegan THM
- Crandon A, *see* Paramasivan S
- Crane CH, *see* Ajani JA  
*see* Yao JC
- Crane CH, Sargent DJ. In Reply (correspondence), 934
- Crawford B, *see* Powell CB
- Crawford ED, *see* Hussain M
- Crawford J, *see* Leigh NB
- Crawford S, *see* Avis NE
- Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial, 8802
- Creaser C, *see* Mian S
- Creech CM, *see* Ayanian JZ
- Creemers G-J, *see* Bontenbal M
- Cress RD, *see* Ayanian JZ
- Creutzberg CL. Lymphadenectomy in Apparent Early-Stage Endometrial Carcinoma: Do Numbers Count? (editorial), 3653
- Cricellari D, *see* Colleoni M
- Crino L, *see* Cappuzzo F
- Cristofami R, Gadducci A
- Cristofanilli M, *see* Buzdar AU  
*see* Gonzalez-Angulo A  
*see* Green MC
- Cristofanilli M, Gonzalez-Angulo A, Hortobagyi G. In Reply (correspondence), 6796
- Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau S-W, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN. Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes, 41
- Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LWMM. Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer, 1420
- Crivellari D, *see* Gruber G
- Croghan G, *see* Goetz MP
- Cronin M, *see* Gianni L
- Crook J, *see* Bhandari MS
- Croop JM, *see* Daw NC
- Crosby K, *see* Koon HB
- Cross SS, *see* Catto JWF
- Crosta C, *see* Martrinelli G
- Crowley J, *see* Hirsch FR
- Crowley JJ, *see* Gaspar LE  
*see* Greipp PR  
*see* Williamson SK
- Crown J, *see* Evans TRJ
- Cruickshank S, *see* Weber RW
- Crump M, *see* Peters WP
- Cuccurullo F, *see* Marchetti A
- Cuellar F, *see* Puig S
- Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy, 7721
- Cui Y, *see* Fuqua SAW
- Cullen J, *see* Stearns V
- Cullen J. In Reply (correspondence), 244
- Cullen MH, *see* Johnson PWM
- Cunningham AJ, Edmonds CVI. Possible Effects of Psychological Therapy on Survival Duration in Cancer Patients (correspondence), 5263
- Cunningham CC, *see* O'Brien SM
- Cunningham D, *see* Chong G  
*see* Chua YJ
- Cupples LA, *see* Larson PS
- Cuppone F, *see* Ferretti G
- Curriel-Lewandrowski C, *see* Li FP
- Curigliano G, *see* DePas T  
*see* Noberasco C  
*see* Sessa C
- Curigliano G, Colleoni M, Mandala M, De Pas T, Spitaleri G, de Braud F, Goldhirsch A. Prophylaxis for Venous Thromboembolism in Cancer Patients With a Central Vein Catheter: New Tones for an Old Song (correspondence), 7243
- Curley S, *see* Poston GJ
- Curley SA, *see* Bilchik AJ  
*see* Ellis LM
- Curley SA. One Surgeon's Unabashedly Biased View on Liver Resection (editorial), 8286
- Curley T, *see* Galsky MD  
*see* Kelly WK
- Curran WJ, *see* Bradley JD  
*see* Choy H
- Curran WJ Jr, *see* Belani CP  
*see* Ettinger DS
- Cusi MG, *see* Correale P
- Cussenot O, *see* Catto JWF
- Cuzick J, *see* Buzdar AU  
*see* Dowsett M
- Cuzick J. Aromatase Inhibitors for Breast Cancer Prevention, 1636
- Cypess AM, *see* Mayer S
- Czauderna P, *see* Aronson DC
- Czene K, *see* Prochazka M
- Czito BG, *see* Willett CG
- Czuczman MS, Koryzna A, Stewart C, Mohr A, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH. Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma, 694
- Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR. Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma, 4390

- D**
- Daban A, *see* Bosset J-F
- Dachman A, *see* Kindler HL
- D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H, Maki RG. Phase II Study of Doxorubicin and Bevacizumab for Patients for Metastatic Soft-Tissue Sarcomas, 7135
- D'Addario G, *see* Giaccone G
- D'Addario G, Pintilie M, Leigh NB, Feld R, Cerny T, Shepherd FA. Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature, 2926
- D'Addario G, Pintilie M, Shepherd FA. In Reply (correspondence), 6277
- Daenen SMG, *see* Nijhuis CO
- Daggy JK, *see* Cheng L
- Dahele M, Wall L. Optimizing End Points and Outcomes in Cancer-Associated Wasting (correspondence), 2871
- Dahl AA, *see* Mykletun A  
*see* Thorsen L
- Dahl GV, *see* Bhat SR
- Dahl O, *see* Mykletun A  
*see* Sagstuen H
- Dahlstrøm K, *see* Boesen EH
- Dahut WL, *see* Figg WD
- Dai DL, Martinka M, Li G. Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases, 1473
- Dai G, *see* Marcucci G
- Daidone MG, *see* Frattini M
- Dakhil S, *see* Jatoi A
- Dakhil SR, *see* Alberts SR  
*see* Galanis E  
*see* Witzig TE
- Dale D, *see* Townsley C
- Dalenc F, *see* Chevreau C
- Daley FM, *see* Bentzen SM
- Dalley D, *see* Thewes B
- Dall'ó E, *see* Sessa C
- Dalton J, *see* Tekautz TM
- Dalton VM, *see* Lipshultz SE
- Daly MB, *see* Rebbeck TR
- Daly-Schweitzer N, *see* Guibout C
- D'Amico AV, *see* Lee AK  
*see* Stewart AJ  
*see* Zhou P
- D'Amico AV, Chen M-H, Roehl KA, Catalona WJ. Identifying Patients at Risk for Significant Versus Clinically Insignificant Postoperative Prostate-Specific Antigen Failure, 4975
- Dammacco F, *see* Vacca A
- Damon LE, *see* Muss HB
- Dancey J, *see* Galanis E
- Dancey JE, *see* Daw NC  
*see* Quinn JA
- Danenbergh KD, *see* Vallböhmer D
- Dang NH, *see* Goy A  
*see* Romaguera JE
- D'Angelica M, *see* Kemeny N
- D'Angio GJ, *see* Evans AE  
*see* Grundy PE  
*see* Tomlinson GE
- Daniel JJ, *see* Kohonen-Corish MRJ
- Daniels MS, *see* Soliman PT
- Dannenbergh AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention, 254
- Dannenbergh H, van Nederveen FH, Abbou M, Verhofstad AA, Kommitho P, de Krijger RR, Dinjens WNM. Clinical Characteristics of Pheochromocytoma Patients With Germline Mutations in *SDHD*, 1894
- Danova M, *see* Bruzzi P
- Dansin E, *see* Fournel P
- Dao M, *see* Lutgendorf SK
- Daponte A, *see* Ascierto PA
- Dar AR, *see* Meyer RM
- Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA. Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group, 1859
- Darmon M, *see* Thiéry G
- Darmon M, Azoulay E. Prognosis of Acute Monocytic Leukemia (French-American-British Classification M5) (correspondence), 1327
- Das P, Ha CS, Cox JD. Radiotherapy and Hodgkin's Lymphoma (correspondence), 8914
- Dastugue N, *see* Jourdan E
- Datar RH, *see* Cote RJ
- Daugherty C, *see* van Besien K
- Daugherty CK, *see* Helft PR
- Daurés J-P, *see* Fournel P
- Davidoff AM, *see* Santana VM
- Davids L, *see* Stebbing J
- Davidson B, *see* Subdó J
- Davidson N, *see* Gradishar WJ
- Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD. Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node-Positive, Steroid Hormone Receptor-Positive Breast Cancer: Results From INT 0101 (E5188), 5973
- Davies F, *see* Augustson BM
- Davies K, *see* Jayson GC
- Davis AM, *see* Wunder JS
- Davis IR, *see* Sathya JR
- Davis J, *see* Ho C
- Davis JA, *see* Crawford SC
- Davis JP, *see* Komotar RJ
- Davis JR, *see* Ewer MS  
*see* Hennessy BT
- Davis M, *see* Butts C
- Davis M. Gender Differences in *p*-Glycoprotein: Drug Toxicity and Response (correspondence), 6439
- Davis MP, *see* Yavuzsen T
- Davis MP. Eicosapentaenoic Acid: The Answers Are Not All In (correspondence), 3854
- Davis MP, Walsh D, Lagman R. In Reply (correspondence), 2112
- Davis S, *see* Lara PN Jr
- Davis T, *see* Sanderson K
- Davis TC, *see* Ferreira MR
- Davy M, *see* Paramasivan S
- Daw HA, *see* Ahluwalia MS
- Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, Reaman GH, Adamson PC. Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children's Oncology Group Study, 6172
- Dawkins F, *see* Okuno S  
*see* ten Tije AJ
- Dawney A, *see* Menon U
- Dawson LA, *see* Ben-Josef E
- Dawson MA, Spencer A. Successful Use of Haploidentical Stem-Cell

- Transplantation With KIR Mismatch As Initial Therapy for Poor-Risk Myelodysplastic Syndrome, 4473
- Dawson N, *see* Hussain A
- Day AG, *see* Parulekar WR
- Daya D, *see* Sathya JR
- Dayes IS, *see* Sathya JR
- de Alwis DP, *see* Schwartz GK
- De Angelis V, *see* Maranzano E
- DeAngelis LM, *see* Abrey LE  
*see* Cloughesy TF
- Deangelis LM, *see* Muss HB
- De Angelo D, *see* Feldman EJ
- Deapen D, *see* Katz SJ
- de Azambuja E, *see* Puglisi F
- De Baere T, *see* Dromain C  
*see* Malka D
- Debén G, *see* Ortega JJ
- De Bernardi B, *see* Cecchetto G
- De Bie S, *see* Vandesompele J
- Debiec-Rychter M, *see* McArthur GA
- Debled M, *see* MacGrogan G
- de Boer AC, *see* Bontenbal M
- de Boer JP, *see* Westra JL
- Debois M, *see* Lutz MP
- de Bont ESJM, *see* Nijhuis CO
- de Boo TM, Timmer–Bonte JN
- de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, Guerci A, San Miguel J, de la Serna J, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P. Autologous and Allogeneic Stem-Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated With All-*Trans*-Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group, 120
- De Braud F, *see* Curigliano G  
*see* De Pas T  
*see* Noberasco C  
*see* Sessa C
- Debruyne C, *see* Giaccone G  
*see* van Meerbeeck JP
- Debus J, *see* Combs SE
- DeCarvalho M, *see* Calzone KA
- de Castro G Jr, *see* Puglisi F
- D’cruz AK, *see* Pantvaidya GH
- Deck R, *see* Weber RW
- De Conciliis C, *see* Ferreri AJM
- De Conno F, *see* Maltoni M
- DeConti RC, *see* Gibson MK
- Deeg HJ, *see* Wallen H
- Dees EC, *see* Burris HA III  
*see* Spector NL
- Dees EC, Watkins PB. Role of Cytochrome P450 Phenotyping in Cancer Treatment (editorial), 1053
- de Gast GC, *see* Luiten RM
- De Geest K, *see* Lutgendorf SK
- Degner L, *see* Brundage M
- Degos L, *see* de Botton S
- de Graeff A, *see* van der Lee ML
- de Gramont A, *see* Louvet C  
*see* Sargent DJ  
*see* Taïieb J
- De Greef GE, *see* Breems DA
- de Herder WW, *see* Kwekkeboom DJ
- de Jong D, *see* Westra JL
- de Jong D. Molecular Pathogenesis of Follicular Lymphoma: A Cross Talk of Genetic and Immunologic Factors, 6358
- de Jong FA, Engels FK, Mathijssen RHJ, van Zuylen L, Verweij J, Peters RPH, Sparreboom A. Medicinal Cannabis in Oncology Practice: Still a Bridge Too Far? 2886
- de Jong FA, Engels FK, Mathijssen RHJ, van Zuylen L, Verweij J, Peters RPH, Sparreboom A. In Reply (correspondence), 7756
- de Jonge M, Verweij J. The Epothilone Dilemma (editorial), 9048
- deJonge MJA, *see* Soepenberg O
- De Juan A, *see* Martín J
- de Kraker J, Pritchard-Jones K. Treatment of Wilms Tumor: An International Perspective (correspondence), 3156
- de Krijger RR, *see* Dannenberg H
- de la Chapelle A, *see* Bian Y  
*see* Marcucci G
- DeLaCruz A, *see* Galsky MD
- Delalogue S, *see* Andre F  
*see* Rouzier R
- Delaney SM, *see* Quinn JA
- DeLaney TF, *see* Jaggi R
- Delanian S, Porcher R, Rudant J, Lefaix J-L. Kinetics of Response to Long-Term Treatment Combining Pentoxifylline and Tocopherol in Patients With Superficial Radiation-Induced Fibrosis, 8570
- de Laroche G, *see* Ray-Coquard I
- de las Morenas A, *see* Larson PS
- de las Peñas R, *see* Ramirez JL
- de la Serna J, *see* de Botton S  
*see* Ortega JJ
- De La Taille A, *see* Patarid J-J
- Delbaldo C, *see* Faivre S
- Del Cerro P, *see* van Besien K
- Delchier J-C, *see* Lévy M
- Delemer B, *see* Amar L
- DeLeo M, *see* Grote T
- Delfau-Larue M-H, *see* Lévy M
- Delhoume J-Y, *see* Fournel P
- Deliliers GL, *see* Gobbi PG
- De Lima M, *see* Khouri IF
- Della Porta MG, *see* Malcovati L
- Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A. Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer, 1736
- Dellon ES, Shaheen NJ. Does Screening for Barrett’s Esophagus and Adenocarcinoma of the Esophagus Prolong Survival? 4478
- Dell’Oro S, *see* Ferreri AJM
- Delmas-Marsalet B, *see* Ulusakarya A
- Del Mastro L, *see* Bruzzi P
- del Muro XG, *see* Aparicio J
- Delperro J-R, *see* Ducreux M
- Del Prete S, *see* Caraglia M
- Del Prever AB, *see* Ferrari S
- De Luca A, *see* Normanno N
- DeLuca P, *see* LoRusso PM
- del Valle F, *see* Koch P
- Del Vecchio MT, *see* Correale P
- del Vecchio P, *see* Bairati I
- De Marinis F, *see* Gridelli C
- Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the Crest of the Teachable Moment: Promoting Long-Term Health After the Diagnosis of Cancer, 5814
- de Mascarel I, *see* MacGrogan G
- DeMatteo R, *see* Kemeny N
- de Menezes RX, *see* van Doorn R
- Demeter J, *see* Ferreri AJM
- Demetri GD, *see* Garcia-Carbonero R

## AUTHOR INDEX

- see* Li FP  
*see* McArthur GA  
 DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L, Klein-Cabral M, Foulkes A, Gimotty P, Glick J, Weber B, Stadtmauer E, Rebbeck TR. Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort, 5552  
 De Miranda S, *see* Thiéry G  
 Demonty G, *see* Puglisi F  
 Demonty G. Treatment Guidelines for Adjuvant Breast Cancer Are Moving Towards Double Standards: One for the Rich and One for the Poor, 9436  
 Dempfle A, *see* Wündisch T  
 De Mulder PHM, *see* Aass N  
*see* Brouwers AH  
 Denham J, *see* Rischin D  
 Denis B, *see* Barbare J-C  
 Dent OF, *see* Kohonen-Corish MRJ  
 De Paepe A, *see* De Preter K  
*see* Vandesompele J  
 De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, Praet M, De Wolf-Peeters C. Large Cleaved and Immunoblastic Lymphoma May Represent Two Distinct Clinicopathologic Entities Within the Group of Diffuse Large B-Cell Lymphomas, 7060  
 De Pas T, *see* Curigliano G  
*see* Noberasco C  
 De Pas T, de Braud F, Spaggiari L, Pelosi G. In Reply (correspondence), 7748  
 De Pas T, Putzu C, Pelosi G, Curigliano G, Noberasco C, Zampino G, Fazio N, Formica V, Spaggiari L, de Braud F. Target-Treatment and Patients' Selection: Can We Still Neglect the Timing of Tissue Collection? (correspondence), 6274  
 De Petris L, *see* Gridelli C  
 Depierre A, *see* Leighl NB  
 De Placido S, *see* Pignata S  
 Deplanque G, *see* Conroy T  
 De Preter K, *see* Vandesompele J  
 De Preter K, Speleman F, Combaret V, Lunec J, Board J, Pearson A, De Paepe A, Van Roy N, Laureys G, Vandesompele J. No Evidence for Correlation of *DDX1* Gene Amplification With Improved Survival Probability in Patients With *MYCN*-Amplified Neuroblastomas (correspondence), 3167  
 de Prijck L, *see* Aass N  
 De Rosa V, Ascierto PA  
 Desai N, *see* Gradishar WJ  
*see* Ibrahim NK  
*see* Nyman DW  
 Desai NB, *see* Dragnev KH  
 Desai S, *see* Laver JH  
 Desch C, *see* Lilienbaum RC  
 Desch CE, *see* Neuss MN  
 Desch CE, Benson AB III, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ. Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline, 8512  
 Deschênes L, *see* Dorval M  
 De Sio L, *see* Carli M  
 Desjardins A, *see* Quinn JA  
*see* Reardon DA  
 Desmond KA, *see* Wyatt GE  
 Desmond R, *see* Balch CM  
 Desschênes L, *see* Drolet M  
 Desta Z, *see* Goetz MP  
 de Toledo JS, *see* Orbach D  
 Detre S, *see* Dowsett M  
*see* Gutierrez MC  
 Detry MA, *see* Keating MJ  
 De Turk PB, *see* Gallafent JH  
 de Vathaire F, *see* Guibout C  
 Devesa SS, *see* Dores GM  
*see* Jatoi I  
*see* McGlynn KA  
 Devidas M, *see* Berg SL  
*see* Pappo AS  
 De Vincentis G, *see* Scopinaro F  
 Devine S, Gazitt Y, Calandra G. In Reply (correspondence), 3872  
 de Vivo A, *see* Soverini S  
 de Vos FYFL, *see* Hoekstra R  
 de Vries EGE, *see* Hoekstra R  
*see* Nieboer P  
*see* Reesink-Peters N  
 de Vries-Hospers HG, *see* Nijhuis CO  
 de Vries IJM, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen M-JP, Ruiter DJ, Figdor CG, Punt CJA, Adema GJ. Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome, 5779  
 Dewhirst MW, *see* Jones EL  
 de Wit M, *see* Schuch G  
 De Wolf-Peeters C, *see* De Paepe P  
 DeYoung BR, *see* Yao M  
 Dezube BJ, *see* Huang W-Y  
*see* Koon HB  
*see* Noy A  
 Dhaliwal K, *see* Fennell DA  
 Dhillon T, *see* Bower M  
 Dhillon VS, *see* Kohonen-Corish MRJ  
 Diaconescu R, *see* Baron F  
 Diaslo RB, *see* Saif MW  
 Díaz-Rubio E, *see* Sastre J  
 Dibble SL, *see* Ezzo J  
 DiBlasio CJ, *see* Stephenson AJ  
 Dicke K, *see* Herbst RS  
 Dicker AP, Rodeck U. Predicting the Future From Trials of the Past: Epidermal Growth Factor Receptor Expression and Outcome of Fractionated Radiation Therapy Trials (editorial), 5437  
 Dickler M, *see* Miller KD  
 Di Cosimo S, *see* Papaldo P  
 Diehl V, *see* Behringer K  
*see* Engert A  
*see* Josting A  
*see* Klimm B  
*see* Re D  
*see* Schnell R  
*see* Shimabukuro-Vornhagen A  
 Diem H, *see* Schmid C  
 Dietlein M, *see* Schnell R  
 Dietrich P-Y, *see* van Baren N  
 Dietze O, *see* Filipits M  
 Diez O, *see* Honrado E  
 Difilippantonio MJ, *see* Ghadimi BM  
 Di Filippo F, *see* Papaldo P  
 DiGiovanna MP, *see* Ahn PH  
*see* Mohsin SK  
 DiGiovanna MP, Stern DF, Edgerton SM, Thor AD. In Reply (correspondence), 8119  
 DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D II, Thor AD. Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients, 1152

## AUTHOR INDEX

- DiGiuseppe JA, *see* Keegan THM
- Dignam JJ. Early Viewing of Noninferiority Trials in Progress (editorial), 5461
- Dijkman R, *see* van Doorn R
- Dijoud F, *see* Entz-Werlé N
- Di Lauro L, *see* Papaldo P
- Diller L, *see* Adams MJ  
*see* George RE
- Dilts DM. Practice Variation: The Achilles' Heel in Quality Cancer Care (editorial), 5881
- Di Maio M, *see* Gridelli C  
*see* Pignata S
- Di Mari A, *see* Tralongo P
- Dimitrijevic S, *see* McArthur GA
- Dimopoulos MA, *see* Bamias A
- Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and Management of Waldenström's Macroglobulinemia, 1564
- Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Papadimitriou C, Sfikakis PP. Extent of Damage and Repair in the *p53* Tumor-Suppressor Gene After Treatment of Myeloma Patients With High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predict Clinical Outcome, 4381
- D'Incalci M, *see* Sessa C
- Ding CL, *see* Leonard JP
- Ding K, *see* Meyer RM
- Ding M, *see* Cormier JN
- Dinjens NM, *see* Dannenberg H
- Dinney CP, *see* Leibovici D
- Di Paola E, *see* Le Cesne A
- DiPaola RS, *see* Goodin S
- DiPersio JF, *see* Khoury HJ
- Di Pietro G, *see* Vacca A
- Dirkzwager-Kiel MM, *see* Jansen MPH
- Dische S, *see* Bentzen SM
- Di Seri M, *see* Colucci G
- Disis ML, *see* Salazar LG
- Disis ML, Lysterly HK. Global Role of the Immune System in Identifying Cancer Initiation and Limiting Disease Progression (overview), 8923
- Disis ML. Molecular Targeting With Cancer Vaccines, 4840
- Di Somma FC, *see* Verso M
- Dispenzieri A, *see* Kumar S
- Distante V, *see* Boccardo F
- di Tomaso E, *see* Willett CG
- Di Tonno P, *see* Boccardo F
- Dittrich C, *see* Chan S
- Dittrich I, *see* Schuette W
- Divers SG, Spencer SA, Carey D, Busby EM, Hyatt MD, Robert F. Phase I/IIa Study of Cisplatin and Gemcitabine As Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Gemcitabine and Paclitaxel for Locally Advanced Non-Small-Cell Lung Cancer, 6664
- Divine M, *see* Ferman J-P
- Dixon JM, *see* Dowsett M  
*see* Smith IE
- Dizon DS, *see* Aghajanian C
- Djulgovic B, *see* Clark OAC  
*see* Glasmacher A
- Djulgovic B, Frohlich A, Bennett CL. Acting on Imperfect Evidence: How Much Regret Are We Ready to Accept? (editorial), 6822
- Djurfeldt MS, *see* Meyer RM
- Dmitrovsky E, *see* Dragnev KH
- Do K-A, *see* Wierda W
- Dobrzynski D, *see* Kondagunta GV
- Dodaro L, *see* Noberasco C
- Dodero A, *see* Corradini P
- Dodwell D, *see* Leyland-Jones B
- Dogliani C, *see* Ferreri AJM
- Dogliotti L, *see* Berruti A  
*see* von der Maase H
- Dogu GG, *see* Ozkan M
- Doherty J, *see* Burstein HJ
- Doherty MM, *see* Michael M
- Döhner H, *see* Kienle DL
- Dolan ME, *see* Quinn JA
- Dolan NC, *see* Ferreira MR  
*see* Wolf MS
- Dolan S, *see* Couban S
- Dolcetti R, *see* Ferreri AJM
- Doll DC, *see* Floyd JD  
*see* Sachs BA
- Dombret H, *see* de Botton S
- Domchek S, *see* Halbert CH  
*see* Rebbeck TR
- Döme B, *see* Timár J
- Dome J, *see* Tomlinson GE
- Dome JS, Bockhold CA, Li SM, Baker SD, Green DM, Perlman EJ, Hill DA, Breslow NE. High Telomerase RNA Expression Level Is an Adverse Prognostic Factor for Favorable-Histology Wilms' Tumor, 9138
- Domenichini E, *see* Chacón M
- Domenichini I, *see* Cappuzzo F
- Dómont J, Pawlik TM, Boige V, Rose M, Weber J-C, Hoff PM, Brown TD, Zorzi D, Morat L, Pignon J-P, Rashid A, Jaeck D, Sabatier L, Elias D, Tursz T, Soria J-C, Vauthey J-N. Catalytic Subunit of Human Telomerase Reverse Transcriptase Is an Independent Predictor of Survival in Patients Undergoing Curative Resection of Hepatic Colorectal Metastases: A Multicenter Analysis, 3086
- Donadio A, *see* Kondagunta GV
- Donadio M, *see* Montemurro F
- Donahue B, *see* Geyer JR
- Donaldson GW, Moynour CM. Learning to Live With Missing Quality-of-Life Data in Advanced-Stage Disease Trials (editorial), 7380
- Donaldson J, *see* Sehn LH
- Donaldson M, *see* Grundy PE
- Donaldson SS, *see* Bhat SR  
*see* Bowers DC
- Donaldson SS, Anderson JR. Rhabdomyosarcoma: Many Similarities, a Few Philosophical Differences (editorial), 2586
- Donato ML, *see* Khouri IF
- Donehower RC, *see* Philip PA
- Donelan K, *see* Jagsi R
- Dong Li, *see* Talamo G
- Dong Q, *see* Leibovici D
- Donohue JH, *see* Alberts SR  
*see* Frost MH
- Donohue JP, *see* Beck SDW
- Donohue K, *see* Czuczman MS
- Doorduijn JK, Sonneveld P. In Reply (correspondence), 4799
- Dorca J, *see* Aparicio J
- Dorcas J, *see* Colomer R
- Doren S, *see* Marshall JL
- Dores GM, Anderson WF, Devesa SS. Cutaneous Lymphomas Reported to the National Cancer Institute's Surveillance Epidemiology, and End Results Program: Applying the New WHO-European Organisation for Research and Treatment of Cancer Classification System (correspondence), 7246
- Dörffel W, *see* Claviez A  
*see* Schellong G
- Dorfman RF, *see* Keegan THM
- Dörken B, *see* Thuss-Patience PC

## AUTHOR INDEX

- Dorsey B, *see* Hussain A
- Dorssers LCJ, *see* Jansen MPHM
- Dorval M, Guay S, Mondor M, Mâsse B, Falardeau M, Robidoux A, Deschênes L, Maunsell E. Couples Who Get Closer After Breast Cancer: Frequency and Predictors in a Prospective Investigation, 3588
- Dorval T, *see* van Baren N
- Dosik M. Withholding Information From Study Participants in Clinical Trials: Ethical Considerations (correspondence), 4468
- Dotan ZA, *see* Stephenson AJ
- Dotan ZA, Bianco FJ Jr, Rabbani F, Eastham JA, Fearn P, Scher HI, Kelly KW, Chen H-N, Schöder H, Hricak H, Scardino PT, Kattan MW. Pattern of Prostate-Specific Antigen (PSA) Failure Dictates the Probability of a Positive Bone Scan in Patients With an Increasing PSA After Radical Prostatectomy, 1962
- Douer D, Tallman MS. Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies, 2396
- Douglas L, *see* Canil CM
- Douglas V, *see* Gordan LN
- Douillard J-Y, *see* Leigh NB
- Dourthe LM, *see* Oudard S
- Doval D, *see* Ibrahim NK
- Dowd I, *see* Baka S
- Dowell JE, Shen Y, Harford WV, Lai WS. Difficult Diagnostic Cases. Melanoma in African Americans, 3622
- Dowell JM, *see* Reardon DA
- Dowlati A, *see* Burris HA III  
*see* Spector NL
- Downey E, *see* Raja V
- Downie FP, *see* Mar Fan HG
- Downing JR, *see* Pui C-H
- Dowsett M, *see* Gutierrez MC  
*see* Smith IE  
*see* Urruticoechea A
- Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study, 7512
- Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE. Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists, 2477
- Doyle GV, *see* Cristofanilli M
- Doyle JJ, Neugut I, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: Population-Based Study, 8597
- Doyle LA, *see* Edelman MJ
- Doyle-Lindrud S, *see* Goodin S
- Doz F, *see* Oyharcabal-Bourden V
- Drach J, *see* Raderer M
- Dragani TA, *see* Spinola M
- Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoll V, Rigas JR, Dmitrovsky E. Bexarotene and Eriotinib for Aerodigestive Tract Cancer, 8757
- Dranitsaris G, *see* Gainford MC  
*see* Verma S
- Dranoff G. CTLA-4 Blockade: Unveiling Immune Regulation (editorial), 662
- Dravet F, *see* Rouanet P
- Drayson MT, *see* Augustson BM
- Dréno B, *see* van Baren N
- Drenth JPH, *see* van Kouwen MCA
- Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF. Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients, 4287
- Drew D, *see* Hinds PS
- Dreyer ZE, *see* Perkins JL
- Dreyfus F, *see* Ferman J-P
- Dreyling M, Hiddemann W, *see* Hiddemann W  
*see* Lenz G
- Driver JA, *see* Floyd SR
- Drolet M, Maunsell E, Brisson J, Brisson C, Mâsse B, Deschênes L. Not Working 3 Years After Breast Cancer: Predictors in a Population-Based Study, 8305
- Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duviollard P, Elias D, Schlumberger M, Sigal R, Baudin E. Detection of Liver Metastases From Endocrine Tumors: A Prospective Comparison of Somatostatin Receptor Scintigraphy, Computed Tomography, and Magnetic Resonance Imaging, 70
- Dryden I, *see* Mian S
- du Bois A, *see* von Minckwitz G
- Du M-Q, *see* Wündisch T
- Du XL, *see* Cormier JN
- Du XL, Lairson DR, Begley CE, Fang S. Temporal and Geographic Variation in the Use of Hematopoietic Growth Factors in Older Women Receiving Breast Cancer Chemotherapy: Findings From a Large Population-Based Cohort, 8620
- Dubois J-B, *see* Azria D
- DuBois RN, *see* Brown JR  
*see* Dannenberg AJ
- Dubs A, Taverna C. In Reply (correspondence), 3650
- Ducreux M, *see* Dromain C  
*see* Louvet C  
*see* Malka D
- Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Hussein F, Quenet F, Viret F, Jacob J-H, Boige V, Elias D, Delperro J-R, Luboinski M. Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the Fédération Nationale des Centres de Lutte Contre le Cancer, 4881
- Ducreux MP, *see* Lutz MP
- Duda DG, *see* Willett CG
- Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Garcia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma, 2346
- Duensing A, *see* Li FP
- Duet M, Huy PTB, Wassef M, Lioté F. Plasma Cell Problems: Plasmacytoma Mimicking a Paraganglioma of the Skull Base: Diagnostic Value of Somatostatin Receptor Scintigraphy, 3143
- Duffy CM, Allen SM, Clark MA. Discussions Regarding Reproductive Health for Young Women With Breast Cancer Undergoing Chemotherapy, 766
- Duffy SW, *see* Purushotham AD
- Dufmats M, *see* Sederholm C
- Dühmke E, *see* Engert A
- Dührsen U, *see* Lenz G
- Duk JM, *see* Reesink-Peters N
- Dulko D, *see* Basch E
- Dumetrescu O, *see* O'Connor OA
- Dumez H, *see* Soepenberg O
- Dummer R, *see* Kaufmann R
- Duncan PJ, *see* Ettinger DS

- Dunn BK, Wickerham DL, Ford LG. Prevention of Hormone-Related Cancers: Breast Cancer, 357
- Dunn JA, *see* Augustson BM
- Dunn R, *see* Chugh R
- Dunn RL, *see* Miller DC
- Dunn SM, *see* Boyle FM
- Dupont J, *see* Aghajanian C
- Durand F, *see* Boccardo F.
- Durand J-B, *see* Ewer MS
- Durand M, *see* MacGrogan G
- Durando A, *see* Montemurro F
- Durie BGM, *see* Greipp PR
- Durini E, *see* Colucci G
- Dürk H, *see* Rummel MJ
- Dutcher JP, *see* McDermott DF
- Duvic M, *see* Clayman GL
- Duvillard P, *see* Dromain C
- Dwight-Johnson M, *see* Ell K
- Dye DW, Broadwater R, Lamps LW. Uncommon Malignancies. Gastric Choriocarcinoma, 6251
- E**
- Earl H, *see* Evans TRJ
- Earle CC, *see* Steyerberg EW
- Eary JF, *see* Hawkins DS
- Eastham JA, *see* Dotan ZA  
*see* Saranchuk JW  
*see* Stephenson AJ
- Eaton LA, *see* Long HJ III
- Ebbs SR, *see* Dowsett M  
*see* Smith IE
- Eberhard DA, *see* Herbst RS
- Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisano D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non-Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib, 5900
- Eccles DM, *see* Stirling D
- Eckardt A, *see* Baselga J
- Eckhardt SG, *see* Ellis LM
- Eckles RE, *see* Helft PR
- Edan C, *see* Oyharcabal-Bourden V
- Edelman MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, Bedor M, Bisaccia S. Phase II Trial of the Novel Retinoid, Bexarotene, and Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer, 5774
- Eder JP, *see* Hamilton AL
- Edge SB, *see* Lyman GH  
*see* Winer EP
- Edgerton SM, *see* DiGiovanna MP
- Edler D, *see* Öhrling K
- Edler L, *see* Combs SE
- Edmonds CVI, *see* Cunningham AJ
- Edwards CG, *see* Marcucci G
- Edwards DL, *see* Hainsworth JD
- Eeles R, *see* Rebbeck TR
- Efficace F, *see* Coens C
- Efficace F, Bottomley A. Toward a Clearer Understanding of the Prognostic Value of Health-Related Quality-of-Life Parameters in Breast Cancer (correspondence), 1335
- Eggen AE, *see* Bakken K
- Eggermont AMM, *see* Keilholz U  
*see* Pawlik TM
- Egorin MJ, *see* Koon HB  
*see* Reardon DA
- Ehmann WC, *see* Feldman EJ
- Ehninger G, *see* Bornhäuser M
- Ehya H, *see* Austin RM
- Eich HT, *see* Josting A  
*see* Klimm B  
*see* Shimabukuro-Vornhagen A
- Eichler H-G, *see* Geling O
- Eidtmann H, *see* von Minckwitz G
- Eiermann W, *see* Chan S  
*see* Kaufman M
- Eifel P, *see* Frumovitz M
- Eifel PJ. Chemoradiotherapy for Cervical Cancer: What Next? (editorial), 8277
- Eimermacher H, *see* Lenz G
- Einhorn LH, *see* Beck SDW  
*see* Li J
- Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hählen K, Göbel U, Klingebiel T, Ludwig W-D, Henze G. Long-Term Outcome in Children with Relapsed ALL by Risk-Stratified Salvage Therapy: Results of Trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87, 7942
- Eisen A, *see* Rebbeck TR
- Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA. Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study, 7491
- Eisen RN, *see* Hollister D Jr
- Eisen TG, *see* Rudd RM
- Eisenbeis CF, Lesinski GB, Anghelina M, Parhar R, Valentino D, Liu J, Nadella P, Sundaram P, Young DC, Sznol M, Walker MJ, Carson WE III. Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12, 8835
- Eisenberg PD, *see* Neuss MN  
*see* Warr DG
- Eisenberger M, *see* Ryan CJ
- Eisenhauer EA, *see* Dark GG
- Eisinger F, Huiart L, Sobol H. The Choice of Bilateral Prophylactic Mastectomy (correspondence), 1330
- Ejlertsen B, *see* Knoop AS
- El-Naggat AK, *see* Clayman GL
- El-Serafi M, *see* Köhne C-H  
*see* Lutz MP
- Elashoff RM, *see* Koyanagi K
- Elder DE, *see* Gimotty PA
- Elias D, *see* Dômont J  
*see* Dromain C  
*see* Ducreux M
- Elion G, *see* Kurtzberg J
- Elkin E, *see* Saranchuk JW
- Ell K, Sanchez K, Vourlekis B, Lee P-J, Dwight-Johnson M, Lagomasino I, Muderspach L, Russell C. Depression, Correlates of Depression, and Receipt of Depression Care Among Low-Income Women With Breast or Gynecologic Cancer, 3052
- Ellard S, *see* Dark GG
- Elledge R, *see* Chang JC  
*see* Mohsin SK

## AUTHOR INDEX

- Ellershaw C, *see* Stevens MCG
- Ellerton J, *see* Niell HB
- Elliott P, *see* Hamilton AL
- Elliott RL, Blobe GC. Role of Transforming Growth Factor Beta in Human Cancer, 2078
- Ellis LM, *see* Hicklin DJ
- Ellis LM, Curley SA, Grothey A. Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumab, 4853
- Ellis LM, Eckhardt SG. Integrating Molecular Oncology Into Clinical Practice: Antiangiogenic Therapy, 937
- Ellis MJ, *see* Burris HA III  
*see* Cristofanilli M  
*see* Spector NL
- Ellis MJ. Neoadjuvant Endocrine Therapy for Breast Cancer: More Questions Than Answers, 4842
- Ellis N, *see* Bian Y
- Ellis P, *see* Butts C  
*see* Harries M
- Ellis PA, *see* Ring AE
- Ellis PM, *see* Hagerty RG
- Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC.  $\beta$ -Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee, 7951
- Elmore JG, *see* Herrinton LJ
- Élő J, *see* Tímár J
- Eloubeidi MA, *see* Saif MW
- Elsaleh H, Iacopetta B. Re: Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? (correspondence), 653
- Elsayed Y, *see* Ryan QC
- Elson P, *see* Mekhail TM  
*see* Sup SJ
- Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A. Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial, 7024
- Eltorky MA, *see* Morgan PB
- Ely SF. Potential Risk of a Common Hereditary Thrombophilia and Adjuvant Chemotherapy for Low-Stage Breast Cancer (correspondence), 4242
- Emami B, *see* Nagda SN
- Emanuel EJ. Depression, Euthanasia, and Improving End-of-Life Care (editorial), 6456
- Emmanouilides C, *see* Czuczman MS  
*see* Treon SP
- Emmons KM, *see* Park ER
- Emmons KM, Puleo E, Park E, Gritz ER, Butterfield RM, Weeks JC, Mertens A, Li FP. Peer-Delivered Smoking Counseling for Childhood Cancer Survivors Increases Rate of Cessation: The Partnership for Health Study, 6516
- Enas NH, *see* Abratt RP
- Endo N, *see* Ogose A
- Endoh H, *see* Mitsudomi T
- Eng C, *see* Weber F
- Engelhart S, *see* Glasmacher A
- Engelman JA, *see* Jänne PA
- Engels FK, *see* de Jong FA
- Engert A, *see* Behringer K  
*see* Elter T  
*see* Josting A  
*see* Klimm B  
*see* Schnell R  
*see* Shimabukuro-Vornhagen A
- Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Dühmke E, Müller-Hermelink K, Diehl V. Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin's Study Group, 5052
- Engstrom C, *see* Hussain A
- Enke C, *see* Vose JM
- Ennis M, *see* Goodwin PJ
- Ensley J, *see* Gibson MK
- Ensley JF, *see* Urba SG
- Ensminger WD, *see* Ben-Josef E
- Ensminger WD. A Role for Hepatic-Directed Chemotherapy in Colorectal Liver Metastases, 4815
- Ensor CM, *see* Ascierto PA
- Entz-Werlé N, Marcellin L, Gaub M-P, Guerin E, Schneider A, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone M-D, Jeanne-Pasquier C, Terrier P, Dijoud F, Oudet P, Lutz P, Babin-Boilletot A. Prognostic Significance of Allelic Imbalance at the *c-kit* Gene Locus and *c-kit* Overexpression by Immunohistochemistry in Pediatric Osteosarcomas, 2248
- Enzinger PC, *see* Meyerhardt JA
- Epplein M, Koon KP, Ramsey SD, Potter JD. Genetic Services for Familial Cancer Patients: A Follow-Up Survey of National Cancer Institute Cancer Centers, 4713
- Epstein AL, *see* Chen S
- Er O, *see* Ozkan M
- Erasmus J, *see* Sasaki R
- Erban J, *see* Jones SE
- Erdi YE, *see* Schöder H
- Erikstein B, *see* Lønning PE
- Erlichman C, *see* Goetz MP  
*see* Okuno S  
*see* Philip PA
- Ernst DS, *see* Canil CM
- Ernst MF, *see* Voogd A
- Ernst TJ, *see* Kurtzberg J
- Ernstoff MS, *see* McDermott DF
- Ernstoff MS. Self-Recognition and Tumor Response to Immunotherapy (editorial), 5875
- Erzen D, *see* Colleoni M
- Escalante CP, *see* Geraci JM
- Eschner W, *see* Schnell R
- Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhöffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular Staging for Survival Prediction of Colorectal Cancer Patients, 3526
- Escrig V, *see* Hitt R
- Escudero P, *see* Feliu J  
*see* Martín J
- Escudier B, *see* Negrier S  
*see* van Baren N
- Eser B, *see* Ozkan M
- Eskandarian S, *see* Wunder JS
- Eskens FALM, *see* Hoekstra R  
*see* Soepenbergh O
- Espada J, *see* Agrelo R
- Espina B, *see* Lim ST
- Espina V, *see* Petricoin EF III
- Espinal A, *see* Prieto JM
- Espinosa E, Fresno Vara JA, Redondo A, Sánchez JJ. In Reply (correspondence), 9440
- Espinosa E, Vara JAF, Redondo A, Sánchez JJ, Hardisson D, Zamora P, Pastrana FG, Cejas P, Martínez B, Suarez A, Calero F, Barón MG. Breast

- Cancer Prognosis Determined by Gene Expression Profiling: A Quantitative Reverse Transcriptase Polymerase Chain Reaction Study, 7278
- Esseltine D, *see* O'Connor OA
- Esser J-P, *see* Kwekkeboom DJ
- Esserman L. Integration of Imaging in the Management of Breast Cancer (editorial), 1601
- Esserman LJ, *see* Petricoin EF III
- Essner R, *see* Kang JC
- Esteller M, *see* Agrelo R
- Esterni B, *see* Jourdan E
- Estes NC, *see* Poplin EA
- Esteve J, *see* Moreno C
- Estey E, *see* Cortes J
- Etienne-Mastroianni B, *see* Arpin D
- Etienne P-L, *see* Lutz MP
- Ettinger DS, *see* Bradley JD  
*see* Okuno S
- Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran WJ Jr, Movsas B, Byhardt RW. Study of Paclitaxel, Etoposide, and Cisplatin Chemotherapy Combined With Twice-Daily Thoracic Radiotherapy for Patients With Limited-Stage Small-Cell Lung Cancer: A Radiation Therapy Oncology Group 9609 Phase II Study, 4991
- Etzell J, *see* Sanchez R
- Evans, DGR, *see* Stirling D
- Evans AE, D'Angio GJ. Age at Diagnosis and Prognosis in Children With Neuroblastoma (editorial), 6443
- Evans DG, *see* Rebbeck TR
- Evans MT, *see* Fennell DA
- Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RCF, Mansi JL. Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study, 2988
- Evans WE, *see* Pui C-H
- Evans WK, *see* Singh S
- Evelhoch JL, *see* Liu G
- Ewer M, *see* Tan-Chiu E
- Ewer MS, *see* Buzdar AU
- Ewer MS, Lippman SM. Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity, 2900
- Ewer MS, Voolteich MT, Durand J-B, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment, 7820
- Exner GU, *see* Kempf-Bielack B
- Extra J-M, *see* Marty M
- Eychmueller S, *see* Maltoni M
- Ezzo J, Vickers A, Richardson MA, Allen C, Dibble SL, Issell B, Lao L, Pearl M, Ramirez G, Roscoe JA, Shen J, Shivnan J, Streitberger K, Treish I, Zhang G. Acupuncture-Point Stimulation for Chemotherapy-Induced Nausea and Vomiting, 7188
- F**
- Fabbri LM, *see* Rossi G
- Fabi A, *see* Ferretti G  
*see* Papaldo P
- Fabian CJ, Kimler BF. Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer, 1644
- Fabián H, *see* Arroyo GF
- Fabre-Guillevin E, *see* Scotté F
- Fabris S, *see* Agnelli L
- Facciolongo N, *see* Rossi G
- Facik MS, *see* Austin RM
- Faderl S, *see* Cortes J  
*see* Keating MJ  
*see* Wierda W
- Fagerlin A, *see* Katz SJ
- Faggiuolo R, *see* Montemurro F
- Faghih M, *see* Strumberg D
- Fagnoni F, *see* Ménard S
- Fahey VD, *see* Mann GB
- Faiola V, *see* Caraglia M
- Fairclough L, *see* Wright J
- Fairlamb DJ, *see* Brown J
- Fairley C, *see* Sanchez R
- Faivre J, *see* Lièvre A
- Faivre S, Chièze S, Delbaldo C, Ady-vago N, Guzman C, Lopez-Lazaro L, Lozahic S, Jimeno J, Pico F, Armand JP, Martin JAL, Raymond E. Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies, 7871
- Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P. Imatinib Mesylate Can Induce Objective Response in Progressing, Highly Expressing KIT Adenoid Cystic Carcinoma of the Salivary Glands (correspondence), 6271
- Falardeau M, *see* Dorval M
- Falchero L, *see* Arpin D
- Falcinelli F, *see* Aversa F
- Falzetti F, *see* Aversa F
- Fanelli FR, *see* Laviano A
- Fanelli M, *see* Gasparini G
- Fang S, *see* Du XL
- Fantus IG, *see* Goodwin PJ
- Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PRK, Stamberg J, Baer MR, Block AMW, Vardiman JW, Koltz JE, Schiffer CA, Larson RA, Bloomfield CD. Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study, 482
- Fargeot P, *see* Bonnetterre J  
*see* Praga C
- Fargeot P. In Reply (correspondence), 4238
- Faries MB, *see* Kang JC
- Farina L, *see* Corradini P
- Farinha P, Gascoyne RD. Molecular Pathogenesis of Mucosa-Associated Lymphoid Tissue Lymphoma, 6370
- Farma J, *see* Berger AC
- Faroux R, *see* Louvet C
- Farray D, Mirkovic N, Albain KS. Multimodality Therapy for Stage III Non-Small-Cell Lung Cancer, 3257
- Farrell AT, *see* Anderson KC
- Farrell K, *see* Hamilton AL
- Farsi F, *see* Ray-Coquard I
- Fassas A, *see* Mahfouz T
- Faust J, *see* Ajani JA
- Fava M, *see* Soverini S
- Favaretto A, *see* Ardizzoni A  
*see* Maione P
- Fawaz A, *see* de Botton S
- Fayad L, *see* Goy A  
*see* Khouri IF  
*see* Romaguera JE
- Faynsod M, Wagman LD, Longmate J, Carroll M, Leong LA. Improved Hepatic Toxicity Profile of Portal Vein Adjuvant Hepatic Infusional Chemotherapy, 4876
- Fazio N, *see* DePas T
- Fearn P, *see* Dotan ZA

- Fearn PA, *see* Zelefsky MH  
 Fears TR, *see* Strouse JJ  
 Federico M, *see* Gobbi PG  
 Feelders RA, *see* Kwekkeboom DJ  
 Feeley KM, *see* Catto JWF  
 Fegan C, *see* Moreton P  
   *see* Starczynski J  
 Fegueux N, *see* Jourdan E  
 Fehrenbacher L, *see* Herbst RS  
   *see* Hurwitz HI  
   *see* Mamounas EP  
   *see* Miller KD  
   *see* Tan-Chiu E  
 Fei F, *see* Buda A  
 Feig B, *see* Ajani JA  
 Feig BW, *see* Yao JC  
 Feijó E, *see* Mazzolini G  
 Feith M, *see* von Rahden BHA  
 Feld R, *see* D'Addario G  
   *see* Knox JJ  
   *see* Singh S  
 Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D. Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia, 4110  
 Feldman-Stewart D, *see* Brundage M  
 Feleppa F, *see* Mann GB  
 Felici A, *see* Ferretti G  
 Felicini R, *see* Aversa F  
 Felicioni L, *see* Marchetti A  
 Felip E, *see* Giaccone G  
   *see* Tabernero J  
 Feliu J, Escudero P, Llosa F, Bolaños M, Vicent J-M, Yubero A, Sanz-Lacalle, J-J, Lopez R, Lopez-Gómez L, Casado E, Gómez-Reina M-J, González-Baron M. Capecitabine As First-Line Treatment for Patients Older Than 70 Years With Metastatic Colorectal Cancer: An Oncopaz Cooperative Group Study, 3104  
 Fenaux P, *see* de Botton S  
 Feng L, *see* Lee JJ  
   *see* Lu C  
 Fengler R, *see* Einsiedel HG  
 Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R. Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials, 184  
 Fenton RG, *see* Badros AZ  
 Ferguson W, *see* Meyers PA  
 Fermand J-P, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P. High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe, 9227  
 Fermé C, *see* Feugier P  
 Fernandez ID, *see* Basu SK  
 Fernández-Rodríguez R, López de Argumedo G, Mañé JM, Muñoz A, Ferreiro J, Fuente N, López-Vivanco G. High-Dose Interleukin-2 in Metastatic Renal Cell Carcinoma (correspondence), 6797  
 Fernández V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of Mantle-Cell Lymphoma: All Oncogenic Roads Lead to Dysregulation of Cell Cycle and DNA Damage Response Pathways, 6364  
 Fernö M, *see* Rydén L  
 Ferrajoli A, *see* Cortes J  
   *see* Wierda W  
 Ferrando J, *see* Montagut C  
 Ferrari A, *see* Carli M  
 Ferrari A, Casanova M, Collini P, Meazza C, Luksch R, Massimino M, Cefalo G, Terenziani M, Spreafico F, Catania S, Gandola L, Gronchi A, Mariani L, Fossati-Bellani F. Adult-Type Soft Tissue Sarcomas in Pediatric-Age Patients: Experience at the Istituto Nazionale Tumori in Milan, 4021  
 Ferrari F, *see* Correale P  
 Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Sæter G. Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups, 8845  
 Ferrarini M, *see* Tiseo M  
 Ferraris V, *see* Boccardo F.  
 Ferraro B, Bepler G, Sharma S, Cantor A, Haura EB. *EGR1* Predicts *PTEN* and Survival in Patients With Non-Small-Cell Lung Cancer, 1921  
 Ferrás F, *see* Maione P  
   *see* Tralongo P  
 Ferrazzi E, *see* Timmerman D  
 Ferreira MR, *see* Wolf MS  
 Ferreira MR, Dolan NC, Fitzgibbon ML, Davis TC, Gorby N, Ladewski L, Liu D, Rademaker AW, Medio F, Schmitt BP, Bennett CL. Health Care Provider-Directed Intervention to Increase Colorectal Cancer Screening Among Veterans: Results of a Randomized Controlled Trial, 1548  
 Ferreiro J, *see* Fernández-Rodríguez R  
 Ferrell B. Dignity Therapy: Advancing the Science of Spiritual Care in Terminal Illness (editorial), 5427  
 Ferrell BR. Late Referrals to Palliative Care (editorial), 2588  
 Ferrera P, *see* Mercadante S  
 Ferreri AJM, *see* Abrey LE  
   *see* Martrinelli G  
   *see* Shankier TN  
 Ferreri AJM, Ponzoni M, Guidoboni M, De Conciliis C, Resti AG, Mazzi B, Lettini AA, Demeter J, Dell'Oro S, Doglioni C, Villa E, Boiocchi M, Dolcetti R. Regression of Ocular Adnexal Lymphoma After *Chlamydia Psittaci*-Eradicating Antibiotic Therapy, 5067  
 Ferretti G, *see* Alimonti A  
   *see* Papaldo P  
 Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandala M, Papaldo P, Nistico C, Fabi A, Cuppone F, Gelibter A, Terzoli E, Cognetti F. Low-Molecular-Weight Heparin Versus Oral Anticoagulant Therapy for the Long-Term Treatment of Symptomatic Venous Thromboembolism: Is There Any Difference in Cancer-Related Mortality? (correspondence), 7248  
 Ferrone CR, Kattan MW, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL. Validation of a Postresection Pancreatic Adenocarcinoma Nomogram for Disease-Specific Survival, 7529  
 Feskanich D, *see* Cho E  
 Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte, 4117  
 Feun LG, Ascierto PA  
 Fey C, *see* Hollister D Jr  
 Fey M, *see* de Botton S  
 Fey MF, *see* Colleoni M

- see Ghielmini M  
 see Gruber G  
 Ficarella R, *see* Graziano F  
 Ficarra V, *see* Patard J-J  
 Fidler IJ, *see* Mathew P  
 Fiedler W, *see* Loges S  
   *see* Schuch G  
 Fiegler H, *see* Mendrzyk F  
 Fields S, *see* Stojadinovic A  
 Fietkau R, *see* Koch P  
   *see* Rödel C  
 Fieux F, *see* Thiéry G  
 Figdor CG, *see* de Vries IJM  
 Figg WD, *see* Pingpank JF  
   *see* Ryan QC  
 Figg WD, Retter A, Steinberg SM, Dahut WL. In Reply (correspondence), 2113  
 Figlin RA, *see* Patard J-J  
 Figueras J, *see* Poston GJ  
 Filho SC, *see* Ajani JA  
 Filie AC, *see* Dudley ME  
 Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R. Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group, 1161  
 Filloussi K, *see* Bonovas S  
 Fimmers R, *see* Kuhl CK  
 Finazzi G, *see* Marchioli R  
 Fini A, *see* Boccardo F  
 Fink K, *see* Cloughesy TF  
   *see* Grote T  
 Finke J, *see* Zeiser R  
 Finkelstein DM, *see* Nguyen PL  
 Finlay JL, *see* Geyer JR  
 Finucane DM, *see* Czuczman MS  
 Fiore J, *see* Leonard JP  
 Fiore JM, *see* Leonard JP  
 Fiore M, *see* Gronchi A  
 Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG, Gronchi A. Dermatofibrosarcoma Protuberans Treated at a Single Institution: A Surgical Disease With a High Cure Rate, 7669  
 Fiorentini G, Rossi S, Bernardeschi P, Cantore M, Guadagni S. Is There a New Drug Beyond Floxuridine for Intra-Arterial Hepatic Chemotherapy in Liver Metastases From Colorectal Cancer? (correspondence), 2105  
 Fioretta G, *see* Bouchardy C  
 Fiorica JV, *see* Hricak H  
   *see* Long HJ III  
 Fisch MJ, *see* Li J  
   *see* Moynihan T  
 Fischer T, *see* Hess G  
   *see* Schnell R  
 Fischer U, *see* Loges S  
 Fischman AJ, *see* Willett CG  
 Fisher B, *see* Canil CM  
   *see* Mamounas EP  
 Fisher C, *see* Peoples GE  
   *see* Williamson D  
 Fisher CJ, *see* McLean TW  
 Fisher GA, *see* Kuo T  
 Fisher PG, *see* Bhat SR  
 Fisher R, *see* Rischin D  
 Fisher RI, *see* Rohatiner AZS  
 Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelentz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M. Totipotomab and Iodine-131 Totipotomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphoma, 7565  
 Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma, 8447  
 Fisher RI. Mantle Cell Lymphoma: At Last, Some Hope for Successful Innovative Treatment Strategies (editorial), 657  
 Fisher SG, *see* Basu SK  
 Fishkin E, *see* Grote T  
 Fishman DA, *see* Petricoin EF III  
 Fitch T, *see* Okuno S  
   *see* Philip PA  
 Fitch TR, *see* Ma CX  
   *see* Witzig TE  
 Fitzgerald C, *see* Sehn LH  
 FitzGerald DJP, *see* Kreitman RJ  
 FitzGerald TJ, *see* Sartor CI  
 Fitzgibbon ML, *see* Ferreira MR  
 Fitzner KA, *see* Wolf MS  
 Fitzpatrick F, *see* Samlowski WE  
 Fiveash J, *see* Saif MW  
 Flaherty LE, *see* McDermott DF  
   *see* Muss HB  
 Flamant F, *see* Stevens MCG  
 Flanagan AM, *see* Sieben NLG  
 Flatt SW, *see* Rock CL  
 Flaws JA, *see* Badros AZ  
 Flechtner H, *see* Coens C  
 Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular Extension of Pelvic Lymph Node Metastases From Urothelial Carcinoma of the Bladder Is an Independent Prognostic Factor, 2358  
 Fleming TR. Objective Response Rate As a Surrogate End Point: A Commentary, 4845  
 Flentje M, *see* Vordermark D  
 Fletcher JA, *see* Li FP  
   *see* McArthur GA  
 Fletcher SW, *see* Herrinton LJ  
 Fleuren GJ, *see* Sieben NLG  
 Flieder DB, *see* Travis WD  
 Flockhart DA, *see* Goetz MP  
 Flood W, *see* Burtness B  
 Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, Zone JJ, Samlowski WE, Leachman SA. Population-Based Analysis of Prognostic Factors and Survival in Familial Melanoma, 7168  
 Floriani I, *see* Buda A  
 Flotte TJ, *see* Livestro DP  
 Flowers MED, *see* Baron F  
 Floyd JD, Kaplan PA, Sauter ER, Perry MC, Doll DC. Patients With Unusual Bladder Malignancies and a Rare Cause of Splenomegaly. Littoral Cell Angioma of the Spleen in a Patient With Previous Lymphoma, 4460  
 Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of Cancer Therapy, 7685  
 Floyd SR, Pantanowitz L, McDermott DF, Yannucci J, Driver JA, Stevenson MA, Smith BD, Wilson LD, Richardson PG. Plasma Cell Problems: Disseminated Cutaneous Plasmacytomas Treated With Total Skin Electron Radiotherapy, 3138  
 Flynn PJ, *see* Desch CE  
   *see* Witzig TE  
 Focan C, *see* Bruzzi P

## AUTHOR INDEX

- Fodde R, *see* Bian Y
- Fodor MB, *see* Ajani JA
- Foekens JA, *see* Jansen MPH
- Fojo T, *see* Low JA
- Folin A, *see* Praga C
- Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: Long Lasting Benefits From Radiotherapy on Survival and Local Recurrence Rate, 5644
- Folman R, *see* Khalid T
- Folwaczny C, *see* Glas J
- Fong DYT, *see* Chan YW
- Fong KW, *see* Wee J
- Fong L, *see* Kapadia D
- Fong Y, *see* Akhurst T  
*see* Kemeny N
- Fonseca R, *see* Kumar S  
*see* Stewart AK  
*see* Witzig TE
- Fontanesi J, *see* Beebe DW  
*see* Ettinger DS
- Forastiere A, *see* Ang KK  
*see* Burtness B  
*see* Gibson MK
- Ford JM, *see* Kuo T
- Ford LG, *see* Dunn BK  
*see* Parnes HL
- Forman-Hoffman VL, *see* Swenson WT
- Forman SJ, *see* Bhatia R  
*see* Molina A
- Formica V, *see* DePas T
- Fornage B, *see* Hennessy BT
- Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation, 7994
- Forster-Horváth C, *see* Tímár J
- Forster K, *see* Sasaki R
- Forstpointner R, *see* Hiddemann W
- Forsyth P, *see* Roa W
- Fortin A, *see* Bairati I
- Foshag L, *see* Kim J
- Foshag LJ, *see* Kang JC
- Fossa SD, *see* Aass N  
*see* Jones WG  
*see* Stenning SP
- Fosså SD, *see* Hjermstad MJ  
*see* Mykletun A  
*see* Sagstuen H  
*see* Thorsen L
- Fossati-Bellani F, *see* Ferrari A
- Fossati R, *see* Buda A
- Fossella FV, *see* Robert F
- Foster E, *see* Evans TRJ
- Foster RS, *see* Beck SDW  
*see* Cheng L
- Fouladi M, *see* Hinds PS  
*see* Tekautz TM
- Fouladi M, Gilger E, Kocak M, Wallace D, Buchanan G, Reeves C, Robbins N, Merchant T, Kun LE, Khan R, Gajjar A, Mulhern R. Intellectual and Functional Outcome of Children 3 Years Old or Younger Who Have CNS Malignancies, 7152
- Foulkes A, *see* DeMichele A
- Foulkes WD, *see* Eisen A  
*see* Honrado E
- Fountzilias G, *see* Bruzzi P
- Fournel P, Robinet G, Thomas P, Souquet P-J, Léna H, Vergnenégre A, Delhoume J-Y, Le Treut J, Silvani J-A, Dansin E, Bozonnat M-C, Daurés J-P, Mornex F, Pérol M. Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study, 5910
- Fox E, *see* Li J  
*see* Marshall JL  
*see* Warren KE
- Fox EA, *see* Treon SP
- Fox K, *see* Harris EER
- Fracasso PM, *see* Okuno S
- Fraga MF, *see* Agrelo R
- Franchi R, *see* Boccardo F
- Francini G, *see* Correale P  
*see* Sargent DJ
- Francis D, *see* Buzdar AU
- Francis LK. My First American Society of Clinical Oncology Annual Meeting: Inspiration, Education, and Perspective (correspondence), 7245
- Francis S, *see* Dowsett M  
*see* Smith IE
- François E, *see* Conroy T
- Franke C, *see* Stahl M
- Frankel SR, *see* Feldman EJ  
*see* Treon SP
- Franken P, *see* Bian Y
- Franklin J, *see* Josting A
- Franklin WA, *see* Cappuzzo F  
*see* Hirsch FR  
*see* Travis WD
- Franks TJ, *see* Travis WD
- Fransen J, *see* Knols R
- Franssila K, *see* Sihto H
- Frantz C, *see* Bagatell R
- Frappaz D, *see* Oyharcabal-Bourden V
- Frassi E, Gadducci A
- Frasson C, *see* Comoli P
- Frattegiani A, *see* Maranzano E
- Frattini M, Balestra D, Verderio P, Gallino G, Leo E, Sozzi G, Pierotti MA, Daidone MG. Reproducibility of a Semiquantitative Measurement of Circulating DNA in Plasma From Neoplastic Patients (correspondence), 3163
- Fraumeni JF Jr, *see* Kleinerman RA
- Frazier ML, *see* Gritz ER
- Freddo JL, *see* Rugo HS
- Frederiksen K, *see* Boesen EH
- Freedland S. In Reply (correspondence), 2435
- Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC Jr, Kane CJ. Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression After Radical Prostatectomy: A Search Database Study, 7546
- Freedman AS, *see* Brown JR
- Freedman G, *see* Berger AC
- Freeman JL, *see* Geraci JM  
*see* Pratt DA
- Freiberg-Richter J, *see* Bornhäuser M
- Freidlin B, *see* Korn EL

## AUTHOR INDEX

- see* Rubinstein LV
- Freidlin B, Simon R. Evaluation of Randomized Discontinuation Design, 5094
- Freire MF, *see* Arroyo GF
- Freitag E-M, *see* Koch P
- Fresno Vara JA, *see* Espinosa E
- Freund M, *see* Koch P
- Friberg G, *see* Kindler HL
- Frickhofen N, *see* Köhne C-H
- Fridman D, *see* Chung KY
- Fridman WH, *see* Romet-Lemonne J-L
- Fridrik MA. Is the Statistical Difference Clinically Relevant? (correspondence), 8537
- Friebel T, *see* Rebbeck TR
- Friedberg JW, *see* Brown JR
- Friedenberg WR, *see* Witzig TE
- Friedlander ML, *see* Phillips K-A  
*see* Thewes B
- Friedman AH, *see* Quinn JA  
*see* Reardon DA
- Friedman E, *see* Eisen A
- Friedman H, *see* Blaney SM
- Friedman HS, *see* Quinn JA  
*see* Reardon DA
- Frierson GM, *see* Pinto BM
- Fritsch P, *see* Richtig E
- Fritsche HA, *see* Cristofanilli M
- Froger X, *see* Ray-Coquard I
- Frohlich A, *see* Djulbegovic B
- Fröhling S, Scholl C, Gilliland DG, Levine RL. Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications, 6285
- Frohneberg D, *see* Lehmann J
- Fromont G, *see* Catto JWF
- Frontiers MS, *see* Haller DG
- Frontini L, *see* Maione P
- Frost MH, Slezak JM, Tran NV, Williams CI, Johnson JL, Woods JE, Petty PM, Donohue JH, Grant CS, Sloan JA, Sellers TA, Hartmann LC. Satisfaction After Contralateral Prophylactic Mastectomy: The Significance of Mastectomy Type, Reconstructive Complications, and Body Appearance, 7849
- Fruehauf JP, Alberts DS. In Vitro Drug Resistance Versus Chemosensitivity: Two Sides of Different Coins (correspondence), 3641
- Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC. Quality of Life and Sexual Functioning in Cervical Cancer Survivors, 7428
- Frye D, *see* Green MC
- Frye DK, *see* Buzdar AU
- Fu K, *see* Robbins KT
- Fu Q, *see* Chen S
- Fuchs CS, *see* Ayanian JZ  
*see* Meyerhardt JA
- Fuchs R, *see* Köhne C-H
- Fuente N, *see* Fernández-Rodríguez R
- Fujimura S, *see* Hamada C
- Fujita S, *see* Sakane-Ishikawa E
- Fukino K, *see* Weber F
- Fuks ZY, *see* Zelefsky MH
- Fukuhara S, *see* Sakane-Ishikawa E
- Fukuoka M, *see* Bell DW
- Fukuoka M. In Reply (correspondence), 922
- Fulham MJ, McCaughan BC, Boyer MJ, McLean PM, King MT, Pollicino CA, Viney RC. In Reply (correspondence), 1591
- Fuller CE, *see* Tekautz TM
- Fumoleau P, *see* Bonnetterre J  
*see* Praga C
- Fung ASM, *see* Chan YW
- Fung H, *see* Bhatia R
- Fung TT, *see* Kroenke CH
- Funk GF, *see* Yao M
- Funke P-J, *see* Lehmann J
- Fuqua SAW, Cui Y, Lee AV, Osborne CK, Horwitz KB. Insights Into the Role of Progesterone Receptors In Breast Cancer (correspondence), 931
- Furman RR, *see* Leonard JP
- Furman WL, *see* Daw NC  
*see* Hinds PS  
*see* Santana VM
- Furstenberg CT, *see* Ahles TA
- Furuse J, *see* Kawashima M
- Fuso L, Gadducci A
- Fuster J, *see* Ortega JJ
- Füzesi L, *see* Ghadimi BM  
*see* Rödel C
- Fyfe G, *see* Agus DB  
*see* Pegram MD
- ### G
- Gaafar R, *see* van Meerbeeck JP
- Gaarenstroom KN, *see* Madalinska JB
- Gaba A, Mbaoma R, Breining D, Smith RV, Beitler JJ, Haigentz M Jr. Unusual Site of Malignancies: Small-Cell Carcinoma of the Hypopharynx, 2094
- Gabarre J, *see* Boulanger E
- Gabriel M, *see* Warr DG
- Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Maggioni A, Cosio S, Frassi E, LaPresa MT, Fuso L, Cristofani R. Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian Study, 751
- Gademann G, *see* Kaufman M
- Gadgeel S, *see* LoRusso PM
- Gafni A, *see* Simunovic M
- Gagliardi G, *see* Prochazka M
- Gagneja H, *see* Romaguera JE
- Gagnon B, Mayo N. In Reply (correspondence), 2441
- Gagnon P, *see* Gaudreau J-D
- Gahres N, *see* Badros AZ
- Gaiger A, *see* Raderer M
- Gainford MC, Dranitsaris G, Clemons M. Systemic Treatment of Bone Metastases from Breast Cancer: Is It All That It's Cracked Up to Be? (correspondence), 4802
- Gajjar A, *see* Blaney SM  
*see* Fouladi M  
*see* Mulhern RK  
*see* Tekautz TM
- Galani E, *see* Ring AE
- Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ. Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study, 5294
- Galassi P, *see* Boccardo F
- Galbraith S, *see* Leighl NB
- Galimberti V, *see* Colleoni M
- Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM. Profile of Patients With Kaposi's Sarcoma in the Highly Active Antiretroviral Therapy, 1253

## AUTHOR INDEX

- Gallagher A, *see* Stearns V
- Gallagher CJ, *see* Evans TRJ
- Gallardo J, Rubio B, Villanueva L, Barajas O. Gallbladder Cancer, a Different Disease that Needs Individual Trials (correspondence), 7753
- Gallee MPW, *see* Luiten RM
- Gallimidi Z, *see* Stojadinovic A
- Gallino G, *see* Frattini M
- Gallo C, *see* Maione P  
*see* Pignata S
- Galper S, *see* Lyman GH
- Galsky MD, Scher HI. Bladder Cancer “Adjuvant-Lite”: Tastes Great (works as well) and Less Filling (less toxic)?, 4823
- Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, DeLaCruz A, Scher HI, Kelly WK. Multi-Institutional Randomized Phase II Trial of the Etoposide B Analogue Ixabepilone (MS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer, 1439
- Galvão DA, Newton RU. Review of Exercise Intervention Studies in Cancer Patients, 899
- Galvin JR, *see* Travis WD
- Gambhir SS, *see* Quon A
- Gambini C, *see* Manzitti C
- Gameiro C, *see* Lévy M
- Gamelin E, *see* Ducreux M
- Gandara DR, *see* Gaspar LE  
*see* Hirsch FR  
*see* Lara PN Jr  
*see* Williamson SK
- Gandara DR, Gumerlock PH. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Plus Chemotherapy: Case Closed or Is the Jury Still Out? 5856
- Gandhi V, *see* Kurtzberg J
- Gandola L, *see* Ferrari A
- Ganesan TS, *see* Madhusudan S
- Gann PH, *see* Chan JM
- Ganz PA, *see* Levine MN  
*see* Stanton AL  
*see* Wyatt GE
- Ganz PA. A Teachable Moment for Oncologists: Cancer Survivors, 10 Million Strong and Growing! (editorial), 5458
- Garaventa A, *see* Manzitti C
- Garbay J-R, *see* Rouzier R
- Garbe C, *see* Kaufmann R
- Garber JE, *see* Larson PS  
*see* Li FP  
*see* Masciari S  
*see* Rebbeck TR
- Garber JE, Offit K. Hereditary Cancer Predisposition Syndromes, 276
- García-Carbonero R, *see* Hamilton AL
- García-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD. Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study, 5484
- García de Barajas S, *see* Pozo-Rodríguez F
- García del Muro J, *see* Martín J
- García JF. In Reply (correspondence), 3159
- García JJ, *see* Baker KS
- García-Lujan R, *see* Pozo-Rodríguez F
- García M, *see* Tabernero J
- García-Manero G, *see* Bueso-Ramos C  
*see* Cortes J  
*see* Issa J-PJ  
*see* Wierda W
- García P, *see* Martín J  
*see* Ortega JJ
- Garden AS, *see* Ang KK
- Garden AS. Is There Still a Role for Induction Chemotherapy for Head and Neck Cancer? (editorial), 1059
- Gardner GJ, *see* Santillan A
- Gardner TA, *see* Cheng L
- Gardyn J. Thalidomide With Continuous Low-Dose Dexamethasone for Multiple Myeloma (correspondence), 1323
- Garewal H, *see* Schrag D
- Garfield DH. Modern Treatment of Lung Cancer. Response to Erlotinib After Failure of Gefitinib in a Patient with Advanced Non-Small-Cell Lung Carcinoma, 7738
- Garg K, *see* Travis WD
- Garg R, *see* Santillan A
- Garibotti G, *see* Florell SR
- Garrido C, *see* Tabernero J
- Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh Y-C, Barrera E, Klein T, Mori M. Improved Detection of Prostate Cancer Using Classification and Regression Tree Analysis, 4322
- Gascón P, *see* Baselga J
- Gascoyne RD, *see* Farinha P  
*see* Forrest DL  
*see* Sehn LH
- Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB, Gandara DR. Time From Treatment to Subsequent Diagnosis of Brain Metastases in Stage III Non-Small-Cell Lung Cancer: A Retrospective Review by the Southwest Oncology Group, 2955
- Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions, 1295
- Gasparis G, *see* Komotar RJ
- Gasto C, *see* Prieto JM
- Gatsonis C, *see* Hricak H
- Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M. Childhood Cancer Survival Trends in Europe: A EURO CARE Working Group Study, 3742
- Gattinoni L, *see* Bajetta E
- Gatzemeier U, *see* Bissett D  
*see* Leighl NB
- Gaub M-P, *see* Entz-Werlé N
- Gaudreau J-D, Gagnon P, Harel F, Roy M-A, Tremblay A. Psychoactive Medications and Risk of Delirium in Hospitalized Cancer Patients, 6712
- Gaulard P, *see* Feugier P  
*see* Lévy M
- Gawande SR, *see* Sederholm C
- Gayet B, *see* Taïieb J
- Gaynon P, *see* Berg SL
- Gazdar AF, *see* Cappuzzo F
- Gazitt Y, *see* Devine S
- Gazzard B, *see* Stebbing J
- Gazzard BG, *see* Bower M
- Gea-Banacloche J, *see* Dudley ME
- Gebbia N, *see* Colucci G  
*see* Russo M
- Gebbia V, *see* Colucci G
- Geberth M, *see* Kaufman M
- Gebhardt M, *see* Meyers PA  
*see* Pappo AS
- Gebhardt MC, *see* Mankin HJ
- Gebhart W, *see* Richtig E
- Geertsen P, *see* Andersen MH
- Gehan E, *see* Stearns V
- Gehl J, *see* Andersen MH

- Gehling UM, *see* Loges S
- Geiger AM, *see* Herrinton LJ
- Geisler J, *see* Lønning PE
- Geisinger KR, *see* Travis WD
- Geisler J, *see* Lønning PE
- Geismar G, *see* Budach V
- Gelber R, *see* Winer EP
- Gelber RD, *see* Colleoni M  
*see* Dellapasqua S  
*see* Gruber G  
*see* Lipshultz SE
- Gelibter A, *see* Ferretti G
- Gélinas M, *see* Bairati I
- Geling O, Eichler H-G. Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications, 1289
- Gelman R, *see* Burstein HJ
- Gelman RS, *see* Bellon JR
- Gelmann EP, *see* Mani A
- General R, *see* Tu S-M
- Generali D, *see* Berruti A
- Genicot B, *see* Köhne C-H  
*see* Lutz MP
- Gent M, *see* Lee AYY
- Gentet JC, *see* Oyharcabal-Bourden V
- George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT. Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study, 6466
- Georgoulas V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D. Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial, 2937
- Geraci JM, Escalante CP, Freeman JL, Goodwin JS. Comorbid Disease and Cancer: The Need for More Relevant Conceptual Models in Health Services Research, 7399
- Gérard L, *see* Boulanger E
- Gerber B, *see* von Minckwitz G
- Gerbing RB, *see* Johnston DL  
*see* Schmidt ML
- Gerhard-Herman M, *see* Gornik HL
- Germà JR, *see* Aparicio J
- Gerritsen M-JP, *see* de Vries IJM
- Gerritsen WR, *see* Luiten RM
- Gershenson DM, *see* Frumovitz M  
*see* Soliman PT
- Gershenwald JE, *see* Cormier JN  
*see* Pawlik TM
- Gershoni-Baruch R, *see* Eisen A
- Gerszten K, *see* Scheier MF
- Gertz MA, *see* Kumar S
- Geskus RB, *see* Kramer GWPM
- Gesme DH, *see* Neuss MN
- Gessner R, *see* Wu S
- Geyer CE Jr, *see* Tan-Chiu E
- Geyer JR, *see* Blaney SM
- Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW, Heier LA, Johnson D, Mazewski C, Miller DC, Packer R, Puccetti D, Radcliffe J, Tao ML, Shiminski-Maher T. Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children's Cancer Group, 7621
- Geyer R, *see* Blaney SM
- Geyer S, *see* Witzig TE
- Geyer SM, *see* Ghobrial IM  
*see* Witzig TE
- Ghadimi BM, *see* Liersch T
- Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Füzesi L, Langer C, Becker H, Liersch T, Ried T. Effectiveness of Gene Expression Profiling for Response Prediction of Rectal Adenocarcinomas to Preoperative Chemoradiotherapy, 1826
- Ghadirian P, *see* Eisen A
- Ghahramani P, *see* Basegia J
- Gharibyan V, *see* Issa J-PJ
- Ghielmini M, Schmitz S-FH, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T. Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients with Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK), 705
- Ghilezan N, *see* Zielinski C
- Ghobrial I, *see* Witzig TE
- Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larsson TS, Walker RC, Ansell SM, Macon WR, Gores GG, Stegall MD, McGregor CG. Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders, 7574
- Giaccia AJ, *see* Le Q-T
- Giaccio GG, *see* Yao JC
- Giaccone G, *see* Bell DW  
*see* Herbst RS  
*see* van Meerbeek JP
- Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C. Phase III Study of Adjuvant Vaccination With Bc2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study), 6854
- Giaccone G. Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-Small-Cell Lung Cancer, 3235
- Giannarelli D, *see* Ferretti G  
*see* Papaldo P
- Gianni AM, *see* Corradini P
- Gianni L, *see* Sessa C
- Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Puztai L, Shak S. Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer, 7265
- Giannini B, *see* Soverini S
- Giannini C, *see* Tu P-h
- Gibbs IC, *see* Bhat SR
- Gibson MK, Li Y, Murphy B, Hussain MHA, Deconti RC, Ensley J, Forastiere AA. In Reply (correspondence), 8129
- Gibson MK, Li Y, Murphy B, Hussain MHA, DeConti RC, Ensley J, Forastiere AA. Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group, 3562
- Gietema JA, *see* Hoekstra R  
*see* Nijhuis CO  
*see* Nuver J
- Gika D, *see* Bamias A
- Gil S, *see* Sastre J
- Gilbert J, *see* Rudek MA

## AUTHOR INDEX

- Gilbert M, *see* Manon R
- Gilbertson RJ, *see* Tekautz TM
- Giles F, *see* Cortes J  
*see* Keating MJ  
*see* Wierda W
- Giles GG, *see* Phillips K-A  
*see* Southey MC
- Gilger E, *see* Fouladi M
- Gill GW, *see* Austin RM
- Gill H, *see* Patel DA
- Gill K, *see* Sehn LH
- Gill P, *see* Noy A
- Gill S, *see* Alberts SR
- Gilles F, *see* Goy A
- Gilliland DG, *see* Fröhling S
- Gilliland FD, *see* Irwin ML
- Jimenez-Roquepio A-P, *see* Amar L
- Gimotty P, *see* DeMichele A
- Gimotty PA, Botbyl J, Soong S-j, Guerry D. A Population-Based Validation of the American Joint Committee on Cancer Melanoma Staging System, 8065
- Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D. Biologic and Prognostic Significance of Dermal Ki67 Expression, Mitoses, and Tumorigenicity in Thin Invasive Cutaneous Melanoma, 8048
- Giné E, *see* López-Guillermo A
- Ginestet C, *see* Arpin D
- Ginor R, *see* Stojadinovic A
- Ginsberg M, *see* Travis WD
- Gion M, *see* McShane LM
- Giordano S, *see* Hennessy BT
- Giordano SH, *see* Buzdar AU  
*see* Pratt DA
- Giordano SH, Hortobagyi GN, Kau S-WC, Theriault RL, Bondy ML. Breast Cancer Treatment Guidelines in Older Women, 783
- Giorgi G, *see* Correale P
- Giovannucci EL, *see* Chan JM
- Giralt S, *see* Khouri IF  
*see* Pavletic SZ
- Giraud S, *see* Amar L
- Girault J, *see* Rouanet P
- Giri PGS, *see* Urba SG
- Girling DJ, *see* Thatcher N
- Gisselbrecht C, *see* Feugier P
- Gisslinger H, *see* Marchioli R
- Gittelman MC, *see* Smith MR
- Giuliani F, *see* Colucci G
- Giuliani R, *see* Praga C
- Giuliano AE, *see* Lyman GH
- Giuntoli RL II, *see* Santillan A
- Glantz M, *see* Chamberlain MC
- Glare P, *see* Maltoni M
- Glas J, Török, H-P, Folwaczny C, Schneider A, Stolte M, Brännler G, Albert ED, Kopp R. In Reply (correspondence), 5272
- Glaser SL, *see* Keegan THM
- Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf IGH. In Reply (correspondence), 9429
- Glaspy JA, *see* Ribas A
- Glatstein E, *see* Goffman TE
- Gleave M, Kelly WK. High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy, 8186
- Glick J, *see* DeMichele A
- Glimelius B, *see* Birgisson H  
*see* Brigisson H  
*see* Folkesson J  
*see* Sørbye H
- Globe DR, *see* Meeske KA
- Glossmann J-P, *see* Josting A
- Gnad U, *see* Hofheinz R-D
- Gobbi P, *see* Baldini L
- Gobbi PG, Levis A, Chisesi T, Broglio C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M. ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi, 9198
- Göbel U, *see* Einsiedel HG  
*see* Kempf-Bielack B
- Gocke CD, *see* Badros AZ  
*see* Tummala M
- Goddard AD, *see* Eberhard D
- Gödény M, *see* Tímár J
- Godley L, *see* van Besien K
- Goebel FM, *see* Taäieb J
- Goessl C, *see* Kohno N  
*see* Smith MR
- Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes, 9312
- Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C. Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer, 1078
- Goey SH, *see* Bontenbal M
- Goffman TE, Glatstein E. In Reply (correspondence), 1590
- Goggins M, *see* Hansel DE
- Goggins M. Molecular Markers of Early Pancreatic Cancer, 4524
- Goh BC, *see* Chan ATC
- Goh C, *see* Cheung Y-B
- Gojo I, *see* Tummala M
- Gokgoz N, *see* Wunder JS
- Goldaniga M, *see* Baldini L
- Goldberg M, *see* Berger AC
- Goldberg RM, *see* Alberts SR  
*see* Kelly H  
*see* Mahoney MR  
*see* Poplin EA  
*see* Sargent DJ  
*see* Tepper JE
- Goldenberg DM, *see* Leonard JP  
*see* Liersch T
- Goldhirsch A, *see* Colleoni M  
*see* Curigliano G  
*see* Dellapasqua S  
*see* Gruber G
- Golding RP, *see* Hoekstra CJ
- Goldsby R, *see* Sanchez R
- Goldschmidt E, *see* Ulusakarya A
- Goldsmith SJ, *see* Bander NH  
*see* Fisher RI  
*see* Leonard JP
- Goldstein D, *see* Thewes B  
*see* Van Glabbeke M
- Goldstein DP, *see* Yao M
- Goldstein LJ, *see* Winer EP
- Goldstone A, *see* Tauro S

AUTHOR INDEX

- Goldwasser MA, *see* Burtness B
- Goldwein JW, *see* Geyer JR
- Golenkov AK, *see* O'Brien SM
- Gollob JA, *see* McDermott DF
- Goloubeva O, *see* Badros AZ
- Golouh R, *see* Gruber G
- Gómez-García EB, Ambergen T, Blok MJ, van den Wijngaard A. Patients With an Unclassified Genetic Variant in the *BRCA1* or *BRCA2* Genes Show Different Clinical Features From Those With a Mutation, 2185
- Gomez-Navarro J, *see* Ribas A
- Gómez-Reina M-J, *see* Feliu J
- Gönen M, *see* Kemeny N  
*see* Kortmansky J  
*see* Schöder H
- Gonzalez-Angulo A, *see* Cristofanilli M
- Gonzalez-Angulo A, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau S-W, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors Predictive of Distant Metastases in Patients With Breast Cancer Who Have a Pathologic Complete Response After Neoadjuvant Chemotherapy, 7098
- Gonzalez-Angulo A, *see* Rouzier R
- Gonzalez-Angulo A, Morandi P, Cristofanilli M. Inflammatory Breast Cancer and High-Dose Chemotherapy: Back to the Past (correspondence), 3859
- González-Baron M, *see* Feliu J
- Gonzalez D, *see* Soliman PT
- González de Sande JL, *see* Martín J
- Gonzalez J, *see* Lara PN Jr
- González JD, *see* Ortega JJ
- González M, *see* Ortega JJ
- Gonzalez R, *see* Koyanagi K  
*see* Weber RW
- González S, *see* Baselga J
- González U, *see* Puig S
- Good J, *see* Weber RW
- Goodin S, Medina P, Capanna T, Shih WJ, Abraham S, Winnie J, Doyle-Lindrud S, Todd M, DiPaola RS. Effect of Docetaxel in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer, 3352
- Goodman M. Alemtuzumab Until Minimal Residual Disease for Chronic Lymphocytic Leukemia: Is it a New Standard? (correspondence), 7240
- Goodman M. First, Do No Harm  
*see* Second, Make Sure You Are Doing Some Good (correspondence), 1045
- Goodman PH, *see* Klein EA
- Goodwin JS, *see* Geraci JM  
*see* Pratt DA
- Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N. Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer? 6037
- Goodwin PJ, Ennis M. In Reply (correspondence), 1336
- Goodwin PJ. In Reply (correspondence), 5264
- Goodwin TL, *see* Bhat SR
- Goodyear M, *see* Couban S
- Gooley TA, *see* Wallen H
- Goorin AM, *see* Meyers PA
- Gopal AK, *see* Wallen H
- Gorby N, *see* Ferreira MR
- Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II Trial of Individualized Rituximab Dosing for Patients With CD22-Positive Lymphoproliferative Disorders, 1096
- Gordon LI, *see* Czuczman MS
- Gordon M, *see* Vallböhmer D
- Gordon MS, *see* Agus DB  
*see* McDermott DF
- Gordon T, *see* Williamson D
- Gore M, *see* Hancock B  
*see* Keilholz U
- Gore SD, *see* Rudek MA
- Gores GG, *see* Ghobrial IM
- Goris M, *see* Horning SJ
- Gorlick R, *see* Huang H-Y
- Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal Cytology Predicts Poor Prognosis in Cancer Patients With Pericardial Effusion, 5211
- Gorschlüter M, *see* Glasmacher A
- Gospodarowicz M, *see* Abrey LE  
*see* Lukka H
- Gospodarowicz MK, *see* Meyer RM
- Goss G, *see* Butts C  
*see* Garcia-Carbonero R
- Goss P, *see* Pater J
- Goss PE, *see* Cheung AM  
*see* Strasser-Weippl K  
*see* Whelan TJ
- Gotay CC. Behavior and Cancer Prevention, 301
- Gotoda T, *see* Soetikno R
- Gotoh T, Hosoi H, Iehara T, Kuwahara Y, Osone S, Tsuchiya K, Ohira M, Nakagawara A, Kuroda H, Sugimoto T. Prediction of *MYCN* Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain Reaction, 5205
- Gotoh T, Hosoi H, Iehara T, Tsuchiya K, Sugimoto T, Nakagawara A. In Reply (correspondence), 8920
- Götzsche PC, Johansen HK. Misleading Statements in Industry-Sponsored Meta-Analysis of Itraconazole (correspondence), 9428
- Goudier M-J, *see* Bonnetterre J
- Gourgou-Bourgade S, *see* Kramer A
- Gourgou S, *see* Rouanet P
- Gower N, *see* Fennell DA
- Gower NH, *see* Brown J  
*see* Rudd RM
- Goy A, *see* Romaguera JE
- Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemester F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma, 667
- Grabenbauer G, *see* Budach V
- Grabowski P, Scherübl H. Expression of Neuroendocrine Markers in Undifferentiated Carcinomas of the Gastrointestinal Tract (correspondence), 4795
- Gracia GJ, *see* Dudley ME
- Grade M, *see* Ghadimi BM
- Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Metastatic Breast Cancer, 7794
- Graeff H, *see* Amendola MA  
*see* Avril N
- Graf E, *see* Kaufman M
- Graham MM, *see* Juweid ME  
*see* Yao M
- Graham MV, *see* Bradley JD
- Gralla RJ, *see* Warr DG
- Gralow J, *see* Winer EP
- Gralow JR, *see* Pierce LJ
- Gramatzki M, *see* Elter T
- Gramelin E, *see* Lutz MP
- Granath F, *see* Prochazka M

## AUTHOR INDEX

- Grange S, *see* Camidge R
- Grann VR, *see* Doyle JJ
- see* Hershman D
- Grannis FW. Overestimation of Lung Cancer Mortality in a Computed Tomography–Screened Population (correspondence), 2439
- Granowetter L, *see* Saroyan JM
- Grant CS, *see* Frost MH
- Grant SC, *see* Giaccone G
- Grau JJ, *see* Montagut C
- Graubard BI, *see* McGlynn KA
- Graus F, *see* Abrey LE
- Graveland W, *see* ten Tije AJ
- Gray R, *see* Sargent DJ
- Graziano F, Kawakami K. Studying the Predictive/Prognostic Role of *Thymidylate Synthase* Genotypes in Patients With Colorectal Cancer: Is One Polymorphism Enough? (correspondence), 7230
- Graziano F, Ruzzo A. Role of the Interleukin-1 Receptor Antagonist Gene Polymorphism (*IL-1RN\*2*) in Early Gastric Cancer, 5272
- Graziano F, Ruzzo A, Santini D, Humar B, Toninin G, Catalano V, Berardi R, Pizzagalli F, Arduini F, Bearzi I, Scartozzi M, Cascinu S, Testa E, Ficarelli R, Magnani M. Prognostic Role of *Interleukin-1 $\beta$  Gene and Interleukin-1 Receptor Antagonist* Gene Polymorphisms in Patients With Advanced Gastric Cancer, 2339
- Graziano SL, *see* Lilenbaum RC
- Grazziutti ML, *see* Mahfouz T
- Greco A, *see* Hainsworth JD
- Greco FA, *see* Hainsworth JD
- Green D, *see* Schöder H
- Green D. In Reply (correspondence), 3157
- Green DM, *see* Dome JS
- see* Grundy PE
- see* Tomlinson GE
- Green E, *see* Jatoi A
- see* Sargent DJ
- Green M, *see* Baseiga J
- see* Marcucci G
- see* Marty M
- Green MC, *see* Buzdar AU
- Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks, 5983
- Green MR, *see* Lilenbaum RC
- see* Niell HB
- Green RH, *see* Welsh TJ
- Green S. In Reply (correspondence), 1586
- Green SJ, *see* Hutchins LF
- Green SR, *see* Pierce LJ
- Greenberg ML, *see* Mabbott DJ
- Greenblatt J, *see* Carbone DP
- Greene AL, *see* Harlan LC
- Greene MH, *see* Kramer JL
- Greenwald P, *see* Taylor PR
- Greep N, *see* Stearns V
- Gregorc V, *see* Cappuzzo F
- Gregory SA, *see* Kaminski MS
- Gregory WM, *see* Rohatiner AZS
- see* Rudd RM
- Greiner TC, *see* Gross TG
- Greipp PR, *see* Kumar S
- Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Harsousseau J-L, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International Staging System for Multiple Myeloma, 3412
- Grem JL, Morrison G, Guo X-D, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH. Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors, 1885
- Grendys EC Jr, *see* Long HJ III
- Grenier J, *see* Rouanet P
- Gresermann G, *see* Reardon DA
- Grever MR, *see* Bolaños-Meade J
- see* Marcucci G
- see* Raval A
- Grgic M, *see* Zielinski C
- Gridelli C, *see* Maione P
- see* Normanno N
- Gridelli C, Aapro M, Ardizzoni A, Balducci L, De Marinis F, Kelly K, Le Chevalier T, Manegold C, Perrone F, Rosell R, Shepherd F, De Petris L, Di Maio M, Langer C. Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel, 3125
- Grier H, *see* Meyers PA
- Grier HE, *see* Mack JW
- see* Pappo AS
- Griffin S, *see* Dressler LG
- Griffith C, *see* Dowsett M
- Griffith D, *see* Corless CL
- Grigg A. Graft Versus T-Cell–Non-Hodgkin’s Lymphoma Effect (correspondence), 2109
- Grignani G, Perissinotto E, Cavalloni G, Schianca FC, Aglietta M. Clinical Use of AMD3100 to Mobilize CD34+ Cells in Patients Affected by Non-Hodgkin’s Lymphoma or Multiple Myeloma (correspondence), 3871
- Grignon D, *see* Lawton CA
- Grill R, *see* Filipits M
- Grillo-Lopez A, *see* Czuczman MS
- Grimaldi M, *see* Hainsworth JD
- Grimalt R, *see* Montagut C
- Grimaud E, *see* Guibout C
- Grimer RJ, *see* Wunder JS
- Grimes D, *see* Marty M
- Grimshaw R, *see* Dark GG
- Gritz ER, *see* Emmons KM
- Gritz ER, Peterson SK, Vernon SW, Marani SK, Baile WF, Watts BG, Amos CI, Frazier ML, Lynch PM. Psychological Impact of Genetic Testing for Hereditary Nonpolyposis Colorectal Cancer, 1902
- Grochow L, *see* Grem JL
- Groen HJM, *see* Hoekstra R
- see* Nijhuis CO
- Grogan TM, *see* Miller TP
- Grollman F, *see* Grem JL
- Gronchi A, *see* Ferrari A
- see* Fiore M
- Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P, Rosai J. Status of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution, 96
- Groopman JE. A Strategy for Hope: A Commentary on Necessary Collaboration, 3151
- Grosenbach DW, *see* Marshall JL
- Groschen S, *see* Sanderson K
- see* Vallböhmer D
- Gross CP, Herrin J, Wong N, Krumholz HM. Enrolling Older Persons in Cancer Trials: The Effect of Sociodemographic, Protocol, and Recruitment Center Characteristics, 4755

## AUTHOR INDEX

- Gross CP, Krumholz HM. Impact of Managed Care on Cancer Trial Enrollment, 3811
- Gross H, *see* Witzig TE
- Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC. Low-Dose Chemotherapy for Epstein-Barr Virus–Positive-Post-Transplantation Lymphoproliferative Disease in Children After Solid Organ Transplantation, 6481
- Gross-Wieltsch U, *see* Koscielniak E
- Grossi F, *see* Belvedere O
- Grossman HB, *see* Leibovici D
- Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, DeLeo M, Fink K, Sullivan DJ. Efficacy and Safety Analysis of Epoetin Alfa in Patients With Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial, 9377
- Grothey A, *see* Ellis LM  
*see* Sargent DJ
- Grothey A, Sargent D. Overall Survival of Patients With Advanced Colorectal Cancer Correlates With Availability of Fluorouracil, Irinotecan, and Oxaliplatin Regardless of Whether Doublet or Single-Agent Therapy Is Used First Line (correspondence), 9441
- Grothey A, Sargent DJ. FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer, 3311
- Groves M, *see* Cloughesy TF
- Grow WB, *see* Gordan LN
- Grubb G, *see* Southey MC
- Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam C-M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Carbone A, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A. Prognostic Value of Extracapsular Tumor Spread for Locoregional Control in Premenopausal Patients With Node-Positive Breast Cancer Treated With Classical Cyclophosphamide, Methotrexate, and Fluorouracil: Long-Term Observations From International Breast Cancer Study Group Trial VI, 7089
- Grunberg SM, *see* Warr DG
- Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PRM, Macklis R, Tomlinson G, Huff V, Green DM. Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group, 7312
- Gschaidmeier H, *see* Hess G
- Gschnalt F, *see* Richtig E
- Gu J, *see* Leibovici D
- Guadagni S, *see* Fiorentini G
- Guadagnoli E, *see* Ayanian JZ
- Guay S, *see* Dorval M
- Guerci A, *see* de Botton S
- Guerin E, *see* Entz-Werlé N
- Guerin J-C, *see* Arpin D
- Guerry D, *see* Gimotty PA
- Guettier C, *see* Bralet M-P
- Guffanti A, *see* Baldini L
- Guglielmini P, *see* Boccardo F
- Guibout C, Adadj E, Rubino C, Shamsaldin A, Grimaud E, Hawkins M, Mathieu M-C, Oberlin O, Zucker J-M, Panis X, Lagrange J-L, Daly-Schveitzer N, Chavaudra J, de Vathaire F. Malignant Breast Tumors After Radiotherapy for a First Cancer During Childhood, 197
- Guidoboni M, *see* Ferreri AJM
- Guidos BJ, *see* Austin RM
- Guillé F, *see* Patard J-J
- Guillem J, *see* Rengan R
- Guillem JG, Chessin DB, Shia J, Moore HG, Mazumdar M, Bernard B, Paty PB, Saltz, L, Minsky BD, Weiser MR, Temple LKF, Cohen AM, Wong WD. Clinical Examination Following Preoperative Chemoradiation for Rectal Cancer Is Not a Reliable Surrogate End Point, 3475
- Guillém V, *see* Baselga J
- Guillou L, Coindre J-M. In Reply (correspondence), 3639
- Guinet F, *see* Oudard S
- Guiot HFL, *see* van Rooden CJ
- Guix M, *see* Taberero J
- Gulley JL, *see* Marshall JL
- Gulley ML, *see* Keegan THM
- Gumà J, *see* Aparicio J
- Gumerlock PH, *see* Gandara DR  
*see* Hirsch FR
- Gumus Y, *see* Ulusakarya A
- Gunduz E, *see* Altundag O
- Gunduz M, *see* Altundag K
- Gunnarsdóttir K, *see* Knoop AS
- Gunnarsson U, *see* Birgisson H  
*see* Brigisson H  
*see* Folkesson J
- Günther A, *see* Wündisch T
- Guo C, *see* Hussain A
- Guo JJ, *see* Neuss MN
- Guo Q, *see* Sathya JR
- Guo X-D, *see* Grem JL
- Gupta A, *see* Lotan Y
- Gupta T, *see* Laskar S
- Gur D, *see* Stojadinovic A
- Gurney JG, *see* Bowers DC
- Gurney JM, *see* Peoples GE
- Gururangan I, *see* Reardon DA
- Gururangan S, *see* Quinn JA
- Gustafson DL, *see* Thienelt CD
- Guthrie KA, *see* Tomlinson GE
- Gutierrez A, *see* Martín J
- Gutierrez MC, *see* Chang JC  
*see* Mohsin SK
- Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase, 2469
- Gutierrez ME, *see* O'Mahoney D
- Gutkin DW, *see* Lalani M
- Guzman C, *see* Faivre S  
*see* Garcia-Carbonero R
- Gyldenkerne N, *see* Jakobsen A

## H

- Ha CS, *see* Das P
- Haagenson M, *see* Pavletic SZ
- Haaland CF, *see* Mykletun A
- Haase CG, *see* Strumberg D
- Haase GM, *see* Grundy PE
- Habeermann TM, *see* Witzig TE
- Haber DA, *see* Bell DW
- Haber M, *see* Laughton SJ
- Habermann A, *see* Kienle DL
- Habermann TM, *see* Ghobrial IM  
*see* Martin WG
- Habib N, *see* Ayav A
- Habrand JL, *see* Stevens MCG
- Hack T, *see* Chochinov HM
- Hackanson B, *see* Zeiser R

## AUTHOR INDEX

- Haddad RI, *see* Wirth LJ
- Haffty BG, *see* Ahn PH  
*see* Smith BD
- Haffty BG, Pierce L, Harris E, Solin L. In Reply (correspondence), 4241
- Hagemeister F, *see* Goy A  
*see* Romaguera JE
- Hagen AL, *see* Lønning PE
- Hagenbeek A, *see* Rohatiner AZS
- Hagerty RG, Butow PN, Ellis PM, Lobb EA, Pendlebury SC, Leighl N, MacLeod C, Tattersall MHN. Communicating With Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis, 1278
- Hagler KT, Lynch JW Jr. Potential Influence of Health Systems in Accrual to Clinical Trials in Lymphoma (correspondence), 7244
- Hählen K, *see* Einsiedel HG
- Hahn C, *see* Glasmacher A
- Hahn EA, *see* Andrykowski MA
- Haider S, *see* Sachs BA
- Haigentz M Jr, *see* Gaba A
- Hainsworth JD, *see* Hurwitz HI
- Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA. Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular/Non-Hodgkin's Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network, 1500
- Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network, 1088
- Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib, 7889
- Haioun C, *see* Lévy M
- Haken RT, *see* Cao Y
- Hakulinen T, *see* Brenner H
- Halabi S, Small EJ, Vogelzang NJ. Elevated Body Mass Index Predicts for Longer Overall Survival Duration in Men With Metastatic Hormone-Refractory Prostate Cancer (correspondence), 2434
- Halbert CH, Brewster K, Collier A, Smith C, Kessler L, Weathers B, Stopfer JE, Domchek S, Wileyto EP. Recruiting African American Women to Participate in Hereditary Breast Cancer Research, 7967
- Haldoupis M, *see* Burstein HJ
- Hale G, *see* Tauro S  
*see* Tekautz TM
- Haley BB, *see* Patterson AR
- Hall E, *see* Coombes RC
- Hall J, *see* Petros WP
- Hall P, *see* Prochazka M
- Hallek M, *see* Elter T  
*see* Schmid C
- Haller D, *see* Cheson BD  
*see* Poston GJ
- Haller DG, *see* Berger AC  
*see* Poplin EA  
*see* Sargent DJ  
*see* Sun W  
*see* Suntharalingam M
- Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiers MS, Jackson DV, Mayer RJ. Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089, 8671
- Haller DG. Matching the Growth and the Mission of the JCO, 4809
- Hallström M, *see* Öhrling K
- Halmos B, *see* Cho D  
*see* Mayer S
- Halsey J, *see* Kuo T
- Haluschak J, *see* Belani CP
- Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, Wada H. Meta-Analysis of Postoperative Adjuvant Chemotherapy With Tegafur-Uracil in Non-Small-Cell Lung Cancer, 4999
- Hamada K, *see* Onozawa M
- Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. In Reply (correspondence), 4803
- Hambleton J, *see* Hurwitz HI  
*see* Kabbinar FF
- Hamburg S, *see* Choy H
- Hamdy FC, *see* Catto JWF
- Hamid O, *see* Campos S
- Hamilton A, *see* Chung KY
- Hamilton A, Hortobagyi G. Chemotherapy: What Progress in the Last 5 Years?, 1760
- Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM. Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle, 6107
- Hamilton JM, *see* Grem JL
- Hamilton M, *see* Dark GG
- Hamlin P, *see* O'Connor OA
- Hamm JT, *see* Kabbinar FF
- Hammel P, *see* Louvet C
- Hammond I, *see* Paramasivan S
- Hammond S, *see* Perkins JL
- Hamre MR, *see* Chuba PJ
- Han C, *see* Madhusudan S
- Han F, *see* Zhang L
- Han J-Y, *see* Lee H-Y
- Han J-Y, Cho KH, Lee DH, Kim HY, Kim E-A, Lee SY, Lee JS. Phase II Study of Irinotecan Plus Cisplatin Induction Followed by Concurrent Twice-Daily Thoracic Irradiation With Etoposide Plus Cisplatin Chemotherapy for Limited-Disease Small-Cell Lung Cancer, 3488
- Han S-W, Kim T-Y, Hwang PG, Jeong S, Kim J, Choi IS, Oh D-Y, Kim JH, Kim D-W, Chung DH, Im S-A, Kim YT, Lee JS, Heo DS, Bang, Y-J, Kim NK. Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib, 2493
- Hanada R, *see* Igarashi S
- Hanafusa T, *see* Yokote T
- Hanahan D, *see* Pietras K
- Hancock B, Wheatley K, Ives N, Gore M. Adjuvant Interferon Therapy for Melanoma (correspondence), 2431
- Hancock BW, *see* Johnson PWM
- Handgretinger R, *see* Koscielniak E
- Haneda M, *see* Onozawa M
- Hankins J, *see* Vose JM
- Hanks G, *see* Maltoni M
- Hanlon A, *see* Berger AC
- Hanlon C, *see* Rietschel P
- Hann K, *see* Leighl NB
- Hanna E, *see* Urba SG
- Hanna N, *see* Thienelt CD
- Hannemann J, Oosterkamp HM, Bosch CAJ, Velds A, Wessels LFA, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ. Changes in Gene Expression Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer, 3331
- Hans K, *see* Schuette W
- Hansel DE, Maitra A, Lin JW, Goggins M, Argani P, Yeo CJ, Piantadosi S, Leach SD, Biankin AV. Expression of the Caudal-Type Homeodomain

AUTHOR INDEX

- Transcription Factors *CDX 1/2* AND Outcome in Carcinomas of the Ampulla of Vater, 1811
- Hansen EK, Krieg RM, Azar RJ, Jablons DM, Jahan TM, Zaloudek CJ. Unusual Thoracic Problems in Patients With Malignancies. Carcinoid Tumor of the Thymus, 2859
- Hansen H, *see* Schnell R
- Hansen M, *see* Treon SP
- Hansmann M-L, *see* Rummel MJ
- Hanson L, *see* LoRusso PM
- Hara S, *see* Yokote T
- Harari PM, *see* Muss HB
- Hardin SB. Potential Hazards of Necessary Collusion (correspondence), 7242
- Hardisson D, *see* Espinosa E
- Hardy-Bessard AC, *see* Oudard S
- Hardy J, Reymond E, Charles M. Acetaminophen in Cancer Pain (correspondence), 1586
- Harel F, *see* Bairati I  
*see* Gaudreau J-D
- Harford WV, *see* Dowell JE
- Hargraves M, *see* Yates P
- Harisinghani MG, *see* Rockall AG
- Harlan LC, Greene AL, Clegg LX, Mooney M, Stevens JL, Brown ML. Insurance Status and the Use of Guideline Therapy in the Treatment of Selected Cancers, 9079
- Harlos M, *see* Chochinov HM
- Harmon D, *see* Garcia-Carbonero R
- Harousseau J-L, *see* Greipp PR
- Harper P, *see* Harries M
- Harper PG, *see* Rudd RM
- Harrell P, *see* Corless CL
- Harries M, Ellis P, Harper P. Nanoparticle Albumin-Bound Paclitaxel for Metastatic Breast Cancer (editorial), 7768
- Harris E, *see* Haffty BG
- Harris EER, Christensen VJ, Hwang W-T, Fox K, Solin LJ. Impact of Concurrent Versus Sequential Tamoxifen With Radiation Therapy in Early-Stage Breast Cancer Patients Undergoing Breast Conservation Treatment, 11
- Harris EL, *see* Herrinton LJ
- Harris J, *see* Ang KK  
*see* Robbins KT  
*see* Spector NL
- Harris JL, *see* Burriss HA III
- Harris JR, *see* Bellon JR
- Harris JR. Radiation Therapy for Invasive Breast Cancer: Not Just for Local Control (editorial), 1607
- Harris LN, *see* Burstein HJ
- Harris MB, *see* Berg SL  
*see* Meyers PA
- Harris N, *see* Shankier TN
- Harris PL, *see* Bell DW
- Harstrick A, *see* Baselga J
- Hart S, *see* Goy A
- Hartgrink HH, Putter H, van de Velde CJH. In Reply (correspondence), 5405
- Hartgrink HH, van de Velde CJH. In Reply (correspondence), 1593
- Hartke C, *see* Rudek MA
- Hartmann E, *see* Fernández V
- Hartmann JT, *see* Bauer S
- Hartmann LC, *see* Frost MH
- Hartmann LC. Unrealistic Expectations, 4231
- Hartmann O, *see* Valteau-Couanet D
- Hartmann R, *see* Einsiedel HG
- Hartzband PI, *see* Mayer S
- Harvey V, *see* Baseiga J
- Hasan I, *see* Elter T
- Haserlat SM, *see* Bell DW
- Hasford J, *see* Lenz G
- Hashino S, *see* Onozawa M
- Hasleton PS, *see* Travis WD
- Hassard T, *see* Chochinov HM
- Hatch SS, *see* Morgan PB
- Hathaway JC, *see* Vickers KS
- Hatooka S, *see* Mitsudomi T
- Hatton M, *see* Rudd RM
- Haura EB, *see* Ferraro B
- Haus U, *see* Hess G
- Hausmaninger H, *see* Filipits M  
*see* Schmid P
- Hausner P, *see* Edelman MJ
- Haverkamp H, *see* Engert A  
*see* Klimm B  
*see* Shimabukuro-Vornhagen A
- Havrilesky LJ, *see* Cragun JM
- Hawk ET, Levin B. Colorectal Cancer Prevention, 378
- Hawkins DS, *see* Barker LM
- Hawkins DS, Schuetz SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU III, Eary JF. [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors, 8828
- Hawkins HK, *see* Morgan PB
- Hawkins M, *see* Gradishar WJ  
*see* Guibout C
- Hawkins MJ, *see* Nyman DW
- Haworth LR, *see* Attia P
- Hay A, *see* Crawford SC
- Hayashi Y, *see* Igarashi S
- Hayes DF, *see* Cristofanilli M  
*see* Dressler LG  
*see* Stearns V  
*see* van't Veer LJ
- Hayes DF. Prognostic and Predictive Factors for Breast Cancer: Translating Technology to Oncology (editorial), 1596
- Hayes SB, Pollack A. Parameters of Treatment Decisions for Salvage Radiation Therapy, 8204
- Hayman JA, *see* Lyman GH
- Hayman JA, Kabeto MU, Schipper MJ, Bennett JE, Vicini FA, Pierce LJ. Assessing the Benefit of Radiation Therapy After Breast-Conserving Surgery for Ductal Carcinoma-In-Situ, 5171
- Haynes A, *see* Moreton P
- Hayter C, *see* Lukka H
- He P, *see* Rudek MA
- Headlee D, *see* Ryan QC
- Healey J, *see* Meyers PA
- Healey JH, *see* Huang H-Y  
*see* Nathan SS  
*see* Wunder JS
- Heaney M, *see* Kelly WK
- Hebart H, *see* Lengerke C
- Hebbar M, *see* Taäieb J
- Hebert T, *see* Parekh S
- Hecht JR, *see* Kabbinnar FF
- Hecker R, *see* Rummel MJ
- Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG. Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: Disease Progression and Survival Analysis From Four Randomized, Double-Blind, Placebo-Controlled Trials, 6941
- Hedley D, *see* Knox JJ

## AUTHOR INDEX

- Heelan RT, *see* Shah NT
- Hegenbart U, *see* Sorrör ML
- Hehlmann R, *see* Hofheinz R-D
- Hei Y-J, *see* Smith MR
- Hei YJ, *see* Coleman RE
- Heideman R, *see* Blaney SM
- Heidemann E, *see* Lenz G
- Heier LA, *see* Geyer JR
- Heikkilä P, *see* Honrado E
- Heil G, *see* Loges S  
*see* Shimabukuro-Vornhagen A
- Heilmann V, *see* Schmid P
- Heim W, *see* Hurwitz HI
- Heimdal K, *see* Stormorken AT
- Heinecke A, *see* Koch P
- Heinemann M-H, *see* Shah NT
- Heiniger A, *see* Roman-Gomez J
- Heinrich MC, *see* Corless CL  
*see* Li FP  
*see* McArthur GA
- Heinrich PC, *see* Boyle FM
- Heintz APM, *see* van der Lee ML
- Heinze R, *see* Kimmick GG
- Heistein S, *see* Subdø J
- Hejna M, *see* Raderer M
- Helardot P, *see* Cecchetto G
- Heldens SL, *see* Eberhard DA
- Helft PR, Eckles RE, Johnson-Calley CS, Daugherty CK. Use of the Internet to Obtain Cancer Information Among Cancer Patients at an Urban County Hospital, 4954
- Helft PR. In Reply (correspondence), 7242
- Helft PR. Necessary Collusion: Prognostic Communication With Advanced Cancer Patients, 3146
- Helgeson VS, *see* Scheier MF
- Helmke K, *see* Kempf-Bielack B
- Helzlsouer KJ. Contralateral Prophylactic Mastectomy: Quantifying Benefits and Weighing the Harms (editorial), 4251
- Hemery F, *see* Lévy M
- Hemminki K, Bermego JL. In Reply (correspondence), 3637
- Henderson DW, *see* Travis WD
- Henderson IC, *see* Bellon JR  
*see* Dressler LG  
*see* Peters WP  
*see* Sartor CI
- Henderson T, *see* Herbst RS
- Hendrickx BW, van Herpen CML, Bonenkamp JJ, Bulten J, Oyen WJG. Positive Positron Emission Tomography Scan in Sarcoidosis and Two Challenging Cases of Metastatic Cancer: Mediastinal Sarcoidosis in a Melanoma Patient Treated With Interferon, 8906
- Hennesser D, *see* Thuss-Patience PC
- Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy, 9304
- Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, Valera V, Hortobagyi GN. Squamous Cell Carcinoma of the Breast, 7827
- Henrique R, *see* Hoque MO
- Henry-Amar M, *see* Raemaekers JMM
- Henry DH, *see* Grote T
- Henry-Tilman R, *see* Stearns V
- Hensing CA, Timmer-Bonte JN
- Hensley M, *see* Basch E
- Henter J-I, *see* Kreicbergs U
- Henze G, *see* Einsiedel HG  
*see* Wu S
- Heo DS, *see* Han S-W
- Herbert C, *see* Townsley C
- Herbst RS, *see* Bell DW  
*see* Cella D  
*see* Eberhard DA  
*see* Liu G  
*see* Robert F  
*see* Rugo HS  
*see* Sasaki R
- Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck, 5578
- Herbst RS, Giaccone G. In Reply (correspondence), 930
- Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non-Small-Cell Lung Cancer, 2544
- Herbst RS, Onn A, Sandler A. Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications, 3243
- Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer, 5892
- Hermann K, *see* Schmid C
- Hermann R, *see* Herbst RS
- Hernandez-Ilizaliturri F, *see* Czuczman MS
- Herndon JE II, *see* Lilenbaum RC  
*see* Niell HB  
*see* Patz EF Jr  
*see* Quinn JA  
*see* Reardon DA
- Herraiz M, *see* Mazzolini G
- Herrel SD, *see* Smith JA Jr
- Herrera R, *see* LoRusso PM
- Herrero I, *see* Mazzolini G
- Herrero J, *see* Puig S
- Herrin J, *see* Gross CP
- Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW. Efficacy of Prophylactic Mastectomy in Women With Unilateral Breast Cancer: A Cancer Research Network Project, 4275
- Herrmann T, *see* Budach V
- Herrstedt J, *see* Warr DG
- Hersh E, *see* Nyman DW
- Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, Neugut AI. Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer, 6639
- Hershman DL, *see* Doyle JJ
- Hery M, *see* Praga C
- Heseltine D, *see* Meyerhardt JA
- Hesketh PJ, *see* Warr DG
- Hess D, *see* Chan S
- Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T. Sustained Complete Molecular

- Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multi-center Study, 7583
- Hess KR, *see* Rouzier R  
*see* Yao JC
- Hester AL, *see* Spunt SL
- Heyes A, *see* Cella D
- Heyman M, *see* Badros AZ
- Heyman MR, *see* Tummala M
- Hicklin DJ, Ellis LM. Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis, 1011
- Hida T, *see* Mitsudomi T
- Hidalgo M, *see* Adjei AA  
*see* Galanis E
- Hiddemann W, *see* Lenz G
- Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R, Nickenig C, Unterhalt M. Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives, 6394
- Hiddemann W, Lenz G, Dreyling M, Unterhalt M. In Reply (correspondence), 6802
- Hideshima T, *see* Rajkumar SV
- Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma, 6345
- Hietanen P, *see* Meyskens FL Jr
- Higano CS, *see* Smith MR
- Higginson A, *see* Thomas AL
- Highley M, *see* Evans TRJ
- Hijjiya N, *see* Pui C-H
- Hilden JM, *see* Mack JW
- Hilfrich J, *see* von Minckwitz G
- Hilger RA, *see* Strumberg D
- Hill C, Koscielny S
- Hill DA, *see* Dome JS
- Hillan KJ, *see* Eberhard DA
- Hillerdal G, *see* Sederholm C
- Hillman S, *see* Jatoi A
- Hillman SL, *see* Ma CX
- Hillmen P, *see* Moreton P
- Hills M, *see* Dowsett M
- Hilsenbeck SG, *see* Arpino G  
*see* Chang JC  
*see* Mohsin SK
- Hinds PS, Drew D, Oakes LL, Fouladi M, Spunt SL, Church C, Furman WL. End-of-Life Care Preferences of Pediatric Patients With Cancer, 9146
- Hinkelbein M, *see* Koch P
- Hinkelbein W, *see* Budach V
- Hino M, *see* Sakane-Ishikawa E
- Hinrich SH, *see* Gross TG
- Hintner H, *see* Richtig E
- Hirsch F, *see* Travis WD
- Hirsch FR, *see* Cappuzzo F  
*see* Miller VA
- Hirsch FR, Bunn PA Jr. Epidermal Growth Factor Receptor Inhibitors in Lung Cancer: Smaller or Larger Molecules, Selected or Unselected Populations? (editorial), 9044
- Hirsch FR, Lippman SM. Advances in the Biology of Lung Cancer Chemoprevention, 3186
- Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowley J, Gandara DR. Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study, 6838
- Hirt C, *see* Koch P
- Hirte H, *see* Campos S
- Hitt R, *see* Baselga J
- Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chalb C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H. Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer, 8636
- Hjermstad MJ, Fosså SD, Oldervoll L, Holte H, Jacobsen AB, Loge JH. Fatigue in Long-Term Hodgkin's Disease Survivors: A Follow-Up Study, 6587
- Ho C, Davis J, Anderson F, Bebb G, Murray N. Side Effects Related to Cancer Treatment: Hepatitis Following Treatment With Gefitinib, 8531
- Ho WG, *see* Baker KS
- Ho Y-Y, *see* Rubin EH
- Hoang B, *see* Nathan SS
- Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical Model to Predict Survival in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Treated With Third-Generation Chemotherapy Regimens Based on Eastern Cooperative Oncology Group Data, 175
- Hoare S, *see* Madhusudan S
- Hobbie W, *see* Castellino SM
- Hochberg FH, *see* Kirsch DG  
*see* Nguyen PL
- Hochhaus A, *see* Hess G  
*see* Hofheinz R-D
- Hodge JP, *see* Kurtzberg J
- Hodge JW, *see* Marshall JL
- Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJHM, van Zandwijk N, Lammertsma AA, Hoekstra OS. Prognostic Relevance of Response Evaluation Using [<sup>18</sup>F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer, 8362
- Hoekstra HJ, *see* Nuver J
- Hoekstra OS, *see* Hoekstra CJ  
*see* van Tinteren H
- Hoekstra R, de Vos FYFL, Eskens FALM, Gietema JA, van der Gaast A, Groen HJM, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EGE. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer, 5188
- Hoelzer D, *see* Rummel MJ
- Hofer MD, Rubin MA. Platelet-Derived Growth Factor Receptor Inhibitor Imatinib Mesylate and Docetaxel: A Modular Phase I Trial in Androgen-Independent Prostate Cancer (correspondence), 1332
- Hoff PM, *see* Dômont J
- Hoff PM. Is There a Role for Routine p53 Testing in Colorectal Cancer? (editorial), 7395
- Hoffer F, *see* Santana VM
- Hoffman R, *see* Massa M
- Hofheinz R-D, von Gerstenberg-Helldorf B, Wenz F, Gnad U, Kraus-Tiefenbacher U, Müldner A, Hehlmann R, Post S, Hochhaus A, Willeke F. Phase I Trial of Capecitabine and Weekly Irinotecan in Combination With Radiotherapy for Neoadjuvant Therapy of Rectal Cancer, 1350
- Hofstra RMW, *see* Westra JL
- Hogendoorn PCW, *see* Van Glabbeke M
- Hogg D, *see* Lynch HT
- Hogge DE, *see* Forrest DL
- Hohenberger P, *see* Van Glabbeke M
- Hohenberger W, *see* Rödel C

## AUTHOR INDEX

- Højgaard L, *see* Borgwardt L
- Hoksch B, *see* Weber T
- Holland JC, *see* Lilenbaum RC
- Hollema H, *see* Reesink-Peters N  
*see* Westra JL
- Hollenbach KA, *see* Rock CL
- Hollenstein J, *see* Madalinska JB
- Hollis D, *see* Stadler WM
- Hollister D Jr, Lee MS, Eisen RN, Fey C, Portlock CS. Variable Problems in Lymphomas. Sarcoidosis Mimicking Progressive Lymphoma, 8113
- Holmberg SB, *see* Colleoni M  
*see* Gruber G
- Holmes E, *see* Beebe DW
- Holmes FA, *see* Miller KD
- Holmes J, *see* Armstrong K
- Holmes K, *see* Cecchetto G
- Holmes MD, *see* Kroenke CH  
*see* Meyerhardt JA
- Holmes P, *see* Bower M
- Holmgren E, *see* Hurwitz HI
- Holowaty E, *see* Townsley C
- Holsinger FC, *see* Clayman GL
- Holte H, *see* Hjermstad MJ
- Höltje J, *see* Schuch G
- Holtsberg FW, Ascierto PA
- Hon C, Law RW, Shek TW, Au WY. CNS Manifestations of Malignancies. Conjunctival Relapse of Acute Lymphoblastic Leukemia Heraldng Pituitary and CNS Disease, 4225
- Hon C, Ma ESK, Yau K, Au WY. CNS Manifestations of Malignancies. Leukemic Optic Neuropathy Complicating Leukemia Cutis, 4229
- Hong M-H, *see* Chua DTT
- Hong R-L, *see* Chan ATC
- Hong WK, *see* Herbst RS  
*see* Lee H-Y  
*see* Lippman SM  
*see* Lu C
- Honrado E, Osorio A, Palacios J, Milne RL, Sánchez L, Díez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkilä P, Lerma E, Kallioneimi A, Rivas C, Foulkes WD, Nevanlinna H, Benítez J. Immunohistochemical Expression of DNA Repair Proteins in Familial Breast Cancer Differentiate *BCRA1*-Associated Tumors, 7503
- Hood N, *see* Goodwin PJ
- Hoon DSB, *see* Kim J  
*see* Koyanagi K  
*see* Mori T
- Hooper L, *see* Starczynski J
- Hopkins PJ, *see* Petros WP
- Hopper JL, *see* Phillips K-A  
*see* Southey MC
- Hopwood P, *see* Thatcher N
- Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, Westra WH, Sidransky D. Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects, 6569
- Horak ID, *see* Leonard JP  
*see* Liersch T
- Horan N, *see* Lara PN Jr
- Horcher E, *see* Cecchetto G
- Horgan KJ, *see* Warr DG
- Horger MS, *see* Lengerke C
- Horimoto H, *see* Onozawa M
- Horio Y, *see* Mitsudomi T
- Horne H, *see* Leonard JP
- Hornedo J, *see* Colomer R
- Hornicek FJ, *see* Mankin HJ
- Horning SJ, *see* Cheson BD  
*see* Meyer RM
- Horning SJ. In Reply (correspondence), 3162
- Horning SJ. Optimizing Rituximab in B-Cell Lymphoma (editorial), 1056
- Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M. Efficacy and Safety of Tositumomab and Iodine-31 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab, 712
- Hornshien K, *see* Thorsen L
- Horowitz M, *see* Blaney SM
- Horowitz MM, *see* Andrykowski MA  
*see* Baker KS
- Horsfield MA, *see* Thomas AL
- Hortobagyi G, *see* Cristofanilli M  
*see* Hamilton A
- Hortobagyi GN. In Reply (correspondence), 2868
- Hortobagyi GN, *see* Buzdar AU  
*see* Cristofanilli M  
*see* Gianni L  
*see* Giordano SH  
*see* Gonzalez-Angulo A  
*see* Green MC  
*see* Hamaoka T  
*see* Hennessy BT  
*see* Ibrahim NK  
*see* Pratt DA  
*see* Rouzier R
- Hortobagyi GN. Progress in the Management of Bone Metastases: One Continent at a Time? (editorial), 3299
- Horvath WL, *see* Alberts SR
- Horwich A, *see* Jones WG
- Horwitz KB, *see* Fuqua SAW
- Hosch B, *see* Kienle DL
- Hosing C, *see* Khouiri IF
- Hoskin P, *see* Macbeth F
- Hoskin PJ, *see* Rades D
- Hosoi H, *see* Gotoh T
- Hossfeld DK, *see* Loges S  
*see* Schuch G
- Hooster E, *see* Lenz G
- Hotta K, *see* Matsuo K
- Hotta K, Matsuo K, Ueoka H. In Reply (correspondence), 925
- Hotta T, *see* Ogose A
- Hotte SJ, Murgu AJ, Siu LL. In Reply (correspondence), 6273
- Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgu A, Siu LL. Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study, 585
- Hotz S, *see* Gimotty PA
- Hou N, *see* Pasche B
- Houédé-Tchen N, *see* Mar Fan HG
- Houghton J, *see* Dowsett M
- Houghton M, *see* Ajani JA
- Houghton PJ, *see* Santana VM
- Houlston RS, *see* Popat S
- Housman D, *see* Wilson LD
- Howard SC, *see* Krasin MJ  
*see* Pui C-H
- Howell A, *see* Langley RE
- Howell LP, *see* Austin RM
- Howell T, *see* Dowsett M
- Hricak H, *see* Amendola MA  
*see* Dotan A
- Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH,

- Koelliker S, Siegelman ES, Brown JJ, McGhee RB Jr, Iyer R, Vitellas KM, Snyder B, Long HJ III, Fiorica JV, Mitchell DG. Role of Imaging in Pretreatment Evaluation of Early Invasive Cervical Cancer: Results of the Intergroup Study American College of Radiology Imaging Network 6551—Gynecologic Oncology Group 183, 9329
- Hromas B, *see* Bibb J
- Hryniuk W, *see* Banerjee M
- Hsairi M, *see* Abdelkefi A
- Hsi ED, *see* Sup SJ
- Hsieh F-J, *see* Chen C-N
- Hsieh Y-C, *see* Garzotto M
- Hsu C-H, *see* Rubin EH
- Hsu M-M, *see* Chan ATC
- Hu FB, *see* Kroenke CH
- Hu P, *see* Chen S
- Hua A, *see* Conroy T
- Huang AT, *see* Cheng SH
- Huang C-I, Liu D, Nakano J, Ishikawa S, Kontani, Yokomise H, Ueno M. Wnt5a Expression Is Associated With the Tumor Proliferation and the Stromal Vascular Endothelial Growth Factor—An Expression in Non-Small-Cell Lung Cancer, 8765
- Huang EH, *see* Gonzalez-Angulo A
- Huang H-Y, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M. Ewing Sarcomas With *p53* Mutation or *p16/p14ARF* Homozygous Deletion: A Highly Lethal Subset Associated With Poor Chemoresponse, 548
- Huang HQ, *see* Monk BJ  
*see* Wenzel L
- Huang P-Y, *see* Zhang L
- Huang TH, *see* van Doorn R
- Huang W-Y, Pantanowitz L, Dezube BJ. Unusual Site of Malignancies: AIDS-Related Kaposi's Sarcoma of the Gastrointestinal Tract, 2098
- Huber C, *see* Hess G
- Huberman MS, *see* Mayer S
- Hubert M, *see* Rubin EH
- Hubner R, *see* Popat S
- Hudis C, *see* Winer EP
- Hudis C. Testing Chemotherapy for Breast Cancer: Timing Is Everything (editorial), 5434
- Hudson M, *see* Pui C-H
- Hudson MM, *see* Bowers DC  
*see* Castellino SM  
*see* Krasin MJ  
*see* Spunt SL
- Hudson RG, *see* Garzotto M
- Huebner G, *see* Schmid P
- Hueman MT, *see* Peoples GE
- Huertas E, *see* Chacón M
- Huff V, *see* Grundy PE
- Huhn SL, *see* Bhat SR
- Hui EP, *see* Chan ATC  
*see* Mok TSK
- Huiart L, *see* Eisinger F  
*see* Lynch HT
- Huijgens PC, *see* Breems DA
- Huisman MV, *see* van Rooden CJ
- Hulshof MC, *see* Rades D
- Humar B, *see* Graziano F
- Humerickhouse RA, *see* Hoekstra R
- Humphrey JS, *see* Leighl NB
- Hung KN, *see* Au WY
- Hunis B, *see* Charles W
- Hunsberger S, *see* Korn EL  
*see* Rubinstein LV
- Hunt D, *see* Blaney SM
- Hunt KK, *see* Buzdar AU  
*see* Green MC  
*see* Raut CP
- Hunter A, *see* Tauro S
- Huntsman D, *see* Honrado E
- Hupperets P, *see* Nieboer P
- Hurd DD, *see* Peters WP
- Hurwitz H, *see* Spector NL
- Hurwitz HI, *see* Burris HA III  
*see* Kabbinavar FF
- Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F. Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer, 3502
- Hurwitz MY, *see* Chévez-Barrios P
- Hurwitz RL, *see* Chévez-Barrios P
- Hussain A, *see* Smith MR
- Hussain A, Dawson N, Amin P, Engstrom C, Dorsey B, Siegel E, Guo C. Docetaxel Followed by Hormone Therapy in Men Experiencing Increasing Prostate-Specific Antigen After Primary Local Treatments for Prostate Cancer, 2789
- Hussain M, *see* Bhandari MS
- Hussain M, Tangen CM, Lra PN Jr, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED. Ixabepilone (Epothilone B Analogue BMS-247550) Is Active in Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer: A Southwest Oncology Group Trial S0111, 8724
- Hussain MHA, *see* Gibson MK
- Hussein MAH, Bird BR, O'Sullivan MJ, Kalimuthu SG, O'Sullivan GC, O'Reilly S, Breathnach OS. Symptoms in Cancer Patients and an Unusual Tumor: Docetaxel-Related Ischemic Colitis, 9424
- Husseini F, *see* Ducreux M  
*see* Lutz MP
- Husson G, *see* Herrinton LJ
- Hustad CM, *see* Warr DG
- Hutcheon AW, *see* Evans TRJ
- Hutchins L, *see* Jones SE
- Hutchins LF, *see* Pierce LJ
- Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102, 8313
- Hutchinson R, *see* Perkins JL
- Hutchinson RE, *see* Laver JH
- Huvos A, *see* Meyers PA
- Huvos AG, *see* Huang H-Y
- Huy PTB, *see* Duet M
- Hwang J, *see* Marshall JL
- Hwang K, *see* Ryan QC
- Hwang W-T, *see* Harris EER  
*see* Kazak AE
- Hwant PG, *see* Han S-W
- Hyatt MD, *see* Divers SG
- Hyder DJ, *see* Mabbott DJ
- Hylton N. Magnetic Resonance Imaging of the Breast: Opportunities to Improve Breast Cancer Management, 1678

## I

- Iacona RB, *see* Bell DW
- Iacono I, *see* Combaret V

## AUTHOR INDEX

- Iacono LC, *see* Daw NC
- Iacopetta B, *see* Elsaleh H  
*see* Russo M
- Iarussi T, *see* Marchetti A
- Ibrahim NK, *see* Buzdar AU  
*see* Green MC
- Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer, 6019
- Iehara T, *see* Gotoh T
- Igarashi K, *see* Sakane-Ishikawa E
- Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, Kamijo T, Isoyama K, Kajiwara M, Sotomatsu M, Sugita K-i, Sugita K, Maeda M, Yabe H, Kinoshita A, Kaneko T, Hayashi Y, Ikuta K, Hanada R, Tsuchida M No Advantage of Dexamethasone Over Prednisolone for the Outcome of Standard- and Intermediate-Risk Childhood Acute Lymphoblastic Leukemia in the Tokyo Children's Cancer Study Group L95-14 Protocol, 6489
- Iino Y, *see* Kohno N
- Ikeda K, *see* Ajani JA
- Ikenaga M, *see* Morita T
- Ikuta K, *see* Igarashi S
- Ilariucci F, *see* Baldini L
- Illei PB, *see* Huang H-Y
- Illiger H-J, *see* Chan S
- Illmer T, *see* Bornhäuser M
- Ibson D, *see* Shah MA
- Ibson D. Just When You Thought the Fluorouracil Debate Was Over: S-1 and Gastric Cancer (editorial), 6826
- Ibson DI, *see* Kortmansky J
- Im S-A, *see* Han S-W
- Im Y-h, *see* Rhee J-Y
- Imaizumi M, *see* Hamada C
- Imberti D, *see* Verso M
- Imisch P, *see* Weber A
- Inagaki K, *see* Matsuzaki H
- Inbar M, *see* Zielinski C
- Ince WL, *see* Eberhard DA
- Ingle J, *see* Pater J
- Ingle JN, *see* Goetz MP  
*see* Whelan TJ  
*see* Winer EP
- Intini D, *see* Agnelli L
- Intra M, *see* Colleoni M
- Intrivici C, *see* Correale P
- Inui A, *see* Kamikawa S
- Invernizzi R, *see* Malcovati L
- Inwards DJ, *see* Witzig TE
- Ioannides CG, *see* Peoples GE
- Iqbal S, *see* Vallböhmer D
- Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R. Changes in Body Fat and Weight After a Breast Cancer Diagnosis: Influence of Demographic, Prognostic, and Lifestyle Factors, 774
- Isaacs C, *see* Eisen A  
*see* Peshkin BN  
*see* Rebbeck TR  
*see* Schwartz MD  
*see* Stearns V
- Isaacs WB, *see* Freedland SJ
- Ishihara S, *see* Watanabe T
- Ishii H, *see* Kawashima M
- Ishikawa S, *see* Huang C-I
- Ishizuka N, *see* Yamamoto N
- Isla D, *see* Hitt R
- Isoyama K, *see* Igarashi S
- Issa B, *see* Jayson GC
- Issa J-PJ, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate, 3948
- Issell B, *see* Ezzo J
- Ito M, *see* Okada K
- Itoi E, *see* Okada K
- Ivers H, *see* Savard J
- Ives N, *see* Hancock B
- Ivy SP, *see* Rubinstein LV
- Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K. Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling, 422
- Iyer R, *see* Hricak H
- Izumiyama K, *see* Onozawa M
- Izzo B, *see* Soverini S
- Izzo F, *see* Ascierto PA
- J**
- Jablons DM, *see* Hansen EK
- Jack AS, *see* Johnson PWM
- Jackisch C, *see* von Minckwitz G
- Jackson A, *see* Jayson GC
- Jackson DV, *see* Haller DG
- Jackson E, *see* Liu G
- Jackson G, *see* Tauro S
- Jackson M, *see* Rischin D
- Jacky E, *see* Breems DA
- Jacob J-H, *see* Conroy T  
*see* Ducreux M
- Jacobs I. Screening for Familial Ovarian Cancer: The Need for Well-Designed Prospective Studies (editorial), 5443
- Jacobs JJ, *see* Menon U  
*see* Rockall AG
- Jacobs MI, *see* Mantha S
- Jacobs MS, *see* Schuch G
- Jacobsen AB, *see* Hjermstad MJ
- Jacobsen PB, *see* Andrykowski MA
- Jacobsohn DA, *see* Bolaños-Meade J
- Jacobson F, *see* Travis WD
- Jacobson JO, *see* Neuss MN
- Jacobson JS, *see* Doyle JJ  
*see* Hershman D
- Jacques DP, *see* Allen PJ
- Jaeck D, *see* Dömönt J
- Jaeckle K, *see* Blaney SM  
*see* Galanis E
- Jaeger U, *see* Raderer M
- Jäger U, *see* Kienle DL
- Jagsi R, DeLaney TF, Donelan K, Tarbell NJ. In Reply (correspondence), 2438
- Jahan TM, *see* Hansen EK
- Jahanzeb M, *see* Neuss MN
- Jahnke K, *see* Budach V  
*see* Shankier TN
- Jain RK, *see* Willett CG
- Jain V, *see* Horning SJ
- Jakesz R, *see* Filipits M
- Jaklitsch MT, *see* Mamon HJ

AUTHOR INDEX

- Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. In Reply (correspondence), 7231
- Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. *Thymidylate Synthase* and *Methylenetetrahydrofolate Reductase* Gene Polymorphism in Normal Tissue As Predictors of Fluorouracil Sensitivity, 1365
- Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J, Reece D, Chen C, Stewart AK. Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance, 7069
- James LE, *see* Rudd RM
- Janjan N, *see* Ajani JA
- Janka-Schaub G, *see* Einsiedel HG
- Jänne PA, *see* Cho D  
*see* Eberhard DA  
*see* Johnson BE  
*see* Mamon HJ
- Jänne PA, Engelman JA, Johnson BE. Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology, 3227
- Jansen EPM, Boot H, Verheij M, van de Velde CJH. Optimal Locoregional Treatment in Gastric Cancer, 4509
- Jansen JBMJ, *see* van Kouwen MCA
- Jansen MPH, Foekens JA, van Staveren IL, Dirkszwaiger-Kiel MM, Ritscher K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LCJ, Klijn JGM, Berns EMJJ. Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling, 732
- Jansen SJT, Otten W, Baas-Thijssen MCM, van de Velde CJH, Nortier JWR, Stiggelbout AM. Explaining Differences in Attitude Toward Adjuvant Chemotherapy Between Experienced and Inexperienced Breast Cancer Patients, 6623
- Janssen EAM, *see* Baak JPA
- Janssen JT, *see* Bontenbal M
- Januario T, *see* Eberhard DA
- Janvier M, *see* Ferman J-P
- Janz NK, *see* Katz SJ
- Jaques DP, *see* Allen PJ
- Jarnagin W, *see* Akhurst T  
*see* Kemeny N
- Järvelä I, *see* Ollikainen M  
*see* Renkonen ET
- Järvinen HJ, *see* Renkonen ET
- Jass JR, *see* Southey MC
- Jassem J, *see* Leigh NB
- Jatoi A, Hillman S, Stella P, Green E, Adjei A, Nair S, Perez E, Amin B, Schild SE, Castillo R, Jett JR. Should Elderly Non-Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group, 9113
- Jatoi A, Loprinzi C, Rowland K, Dakhil S. In Reply (correspondence), 2872
- Jatoi A, Loprinzi CL, Rowland K, Dakhil S. In Reply (correspondence), 3854
- Jatoi I, Anderson WF, Rao SR, Devesa SS. Breast Cancer Trends Among Black and White Women in the United States, 7836
- Jayson G, *see* Dark GG
- Jayson GC, Parker GJM, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B, Buckley DL, Cheung S, Davies K, Watson Y, Zinkewich-Péotti K, Rolfe L, Jackson A. Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume, 973
- Jeanne-Pasquier C, *see* Entz-Werlé N
- Jeffery DD, *see* Bellizzi KM
- Jeha S, *see* Pui C-H
- Jelinek J, *see* Issa J-PJ
- Jenke A, *see* Bornhäuser M
- Jenkins J, *see* Calzone KA  
*see* Pappo AS
- Jenkins MA, *see* Southey MC
- Jenkins RB, *see* Galanis E
- Jennings K, *see* Southey MC
- Jennings M, *see* Geyer JR
- Jensen M, *see* Elter T
- Jeong S, *see* Han S-W
- Jeremić B, Milčić B, Acimović L, Milisavljević S. Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin/Paclitaxel in Patients With Early-Stage (I/II) Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study, 6873
- Jeremić B, Milčić B, Acimovic L, Milisavljević S. Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin and Paclitaxel in Patients With Stage III Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study, 1144
- Jernigan JC, *see* Trauth JM
- Jett JR, *see* Jatoi A  
*see* Ma CX
- Jeunemaitre X, *see* Amar L
- Jeyarajah A, *see* Menon U  
*see* Rockall AG
- Jhingran A, *see* Frumovitz M
- Jiang C, *see* Chen S
- Jiao LR, *see* Ayav A
- Jimenez D, *see* Puig S
- Jiménez M, *see* López-Guillermo A
- Jimenez RE, Panageas K, Busam KJ, Brady MS. Prognostic Implications of Multiple Lymphatic Basin Drainage in Patients With Truncal Melanoma, 518
- Jimenez-Velasco A, *see* Roman-Gomez J
- Jimeno J, *see* Faivre S  
*see* Garcia-Carbonero R  
*see* Le Cesne A  
*see* Sessa C
- Jirstrom K, *see* Rydén L
- Jodrell D, *see* Camidge R
- Joensuu H, *see* Sihto H
- Johansen C, *see* Boesen EH
- Johansen HK, *see* Gotzsche PC
- John MJ, *see* Suntharalingam M
- Johnson BE, *see* Carbone DP  
*see* Eberhard DA  
*see* Herbst RS  
*see* Jänne PA  
*see* Travis WD
- Johnson BE, Jänne PA. Selecting Patients for Epidermal Growth Factor Receptor Inhibitor Treatment: A FISH Story or a Tale of Mutations? (editorial), 6813
- Johnson-Calley CS, *see* Helft PR
- Johnson D, *see* Geyer JR
- Johnson DH, *see* Belani CP  
*see* Bell DW  
*see* Eberhard DA  
*see* Herbst RS  
*see* Hoang T  
*see* Miller VA
- Johnson JL, *see* Frost MH  
*see* Kimmick GG
- Johnson MR, *see* Saif MW
- Johnson PJ, *see* Mok TSK
- Johnson PT, *see* Vickers KS
- Johnson PWM, *see* Rudd RM

## AUTHOR INDEX

- Johnson PWM, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW. Comparison of ABVD and Alternating or Hybrid Multi-drug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519), 9208
- Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Risk Factors and Therapy for Isolated Central Nervous System Relapse of Pediatric Acute Myeloid Leukemia, 9172
- Johnston PG, *see* Allen WL
- Johnston S, *see* Chan S  
*see* Gutierrez MC
- Johnstone DW, *see* Bradley JD
- Jonat W, *see* Kaufman M
- Jones A, *see* Ring AE
- Jones AL, *see* Evans TRJ  
*see* Langley RE
- Jones CU, *see* Ang KK
- Jones D, *see* van Besien K
- Jones DA, *see* Samlowski WE
- Jones DH, Silberstein PT, Lynch H, Ternet C. Regression of Colorectal Adenomas With Intravenous Cytotoxic Chemotherapy in a Patient With Familial Adenomatous Polyposis (correspondence), 6278
- Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW. Randomized Trial of Hyperthermia and Radiation for Superficial Tumors, 3079
- Jones L, *see* Rock CL
- Jones R, *see* Khouri IF
- Jones RB, *see* Petros WP
- Jones S, *see* Morrison C
- Jones SA, *see* Dudley ME
- Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM. Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer, 5542
- Jones SF, *see* Burris HA III
- Jones WG, *see* Stenning SP
- Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP. Randomized Trial of 30 Versus 20 Gy in the Adjuvant Treatment of Stage I Testicular Seminoma: A Report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328), 1200
- Jones-Jackson L, *see* Mahfouz T
- Jönsson P-E, *see* Rydén L
- Joos S, *see* Mendrzyk F
- Joosten FBM, *see* Brouwers AH
- Jordan C, *see* Campos S
- Jordan VC. Chemoprevention in the 21st Century: Is a Balance Best or Should Women Have No Estrogen at All? (editorial), 1598
- Joseph G, *see* Charles W
- Joshi V, *see* Bagatell R  
*see* Wirth LJ
- Joshua AM, *see* Vardy J
- Joshua AM, Adams D, McKenzie P, Solomon M, Clarke SJ. Small Blue Cell Tumors of the Rectum. Small-Cell Carcinoma of the Rectum, 912
- Joshua AM, Cotroneo A, Clarke S. Humor and Oncology, 645
- Josten K-M, *see* Rummel MJ
- Josting A, *see* Elter T  
*see* Engert A  
*see* Klimm B  
*see* Shimabukuro-Vornhagen A
- Josting A, Nogová L, Franklin J, Glossmann J-P, Eich HT, Sieber M, Schober T, Boettcher H-D, Schulz U, Müller R-P, Diehl V, Engert A. Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin's Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group, 1522
- Jourdan E, Boiron J-M, Dastugue N, Vey N, Marit G, Rigal-Huguet F, Molina L, Fegueux N, Pigneux A, Recher C, Rossi J-F, Attal M, Scotto J-J, Maraninchi D, Reiffers J, Bardou V-J, Esterni B, Blaise D. Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience, 7676
- Jourkiv O, *see* Calzone KA
- Joy AA, *see* Verma S
- Ju DW, *see* Chen S
- Judkins AR, *see* Tu P-h
- Judson I, *see* Banerji U  
*see* Le Cesne A
- Judson IR, *see* Van Glabbeke M
- Julian JA, *see* Lee AYY  
*see* Lukka H  
*see* Sathya JR
- Julian T, *see* Mamounas EP
- Juliar B, *see* Li J
- Juliar BE, *see* Cheng L
- Junck L, *see* Cloughesy TF
- Jundt G, *see* Kempf-Bielack B
- Junggeburst JMC, *see* Peeters KCMJ
- Jüngling F, *see* Weber T
- Jurcic JC, *see* Feldman EJ
- Jürgens H, *see* Kempf-Bielack B
- Juweid ME, Cheson BD. Role of Positron Emission Tomography in Lymphoma (editorial), 4577
- Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD. Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography, 4652

## K

- Kaasa S, *see* Maltoni M
- Kaatsch P, *see* Gatta G
- Kabbinavar F, *see* Hurwitz HI  
*see* Smith MR
- Kabbinavar FF, Hambleton J, Mass R, Hurwitz HI, Bergsland E, Sarkar S. Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer, 3706
- Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass RD, Perrou B, Nelson B, Novotny WF. Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial, 3697
- Kabeto MU, *see* Hayman JA
- Kabish H, *see* Kempf-Bielack B
- Kachnic L, *see* Suntharalingam M
- Kadan-Lottick NS, *see* Vanderwerker LC
- Kahan JP, *see* Poston GJ
- Kahan Z, *see* Zielinski C
- Kaine EM, *see* Livestro DP
- Kaiserling E, *see* Lengerke C
- Kajiwarra M, *see* Igarashi S
- Kakinuma R, *see* Travis WD
- Kakkar AK, *see* Lee AYY  
*see* Levine M  
*see* Levine MN
- Kaklamani V, *see* Bian Y

- see Pasche B*  
 Kakolyris S, *see* Georgoulis V  
 Kalaycio M, *see* Feldman EJ  
 Kälble T, *see* Lehmann J  
 Kaldjian EP, *see* Campos S  
 Kalemkerian G. Trastuzumab in the Treatment of Advanced Non–Small-Cell Lung Cancer: Is There a Role? (correspondence), 1325  
 Kalemkerian GP. Commentary on “Unrealistic Expectations,” 4233  
 Kalemkerian GP. Is Collusion Necessary? A Commentary on Necessary Collusion, 3153  
 Kalidas M, *see* Chang JC  
 Kalifa C, *see* Entz-Werlé N  
     *see* Oyharcabal-Bourden V  
 Kalimuthu SG, *see* Hussein MAH  
 Kallioniemi A, *see* Honrado E  
 Kalnitskiy M, *see* Ryan QC  
 Kalra K, *see* Edelman MJ  
 Kaltenbach T, *see* Soetikno R  
 Kalva SP, *see* Willett CG  
 Kam AW, *see* Pingpank JF  
 Kam BL, *see* Kwekkeboom DJ  
 Kamijo T, *see* Igarashi S  
 Kamikawa S, Inui A. Pediatric Malignancies. Craniopharyngioma in a 4-Year-Old Girl: Neuroendoscopic Diagnosis, 4793  
 Kaminski MS, *see* Fisher RI  
 Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL. Re-Treatment With I-131 Tositumomab in Patients with Non-Hodgkin’s Lymphoma Who Had Previously Responded to I-131 Tositumomab, 7985  
 Kaminsky DB, *see* Austin RM  
 Kammoun L, *see* Abdelkefi A  
 Kammula US, *see* Attia P  
     *see* Dudley ME  
 Kammula US, Coit DG. In Reply (correspondence), 3864  
 Kamps WA, *see* Nijhuis CO  
     *see* Pession A  
 Kanakura Y, *see* Sakane-Ishikawa E  
 Kanamaru A, *see* Sakane-Ishikawa E  
 Kanayama N, *see* Matsuzaki H  
 Kanazawa S, Muramatsu M, Kinoshita Y, Yamaguchi K, Nomura S. Gefitinib Has the Potential of Activating Cell Immunity Against Malignant Cells (correspondence), 3865  
 Kanazawa T, *see* Watanabe T  
 Kane CJ, *see* Freedland SJ  
 Kaneko T, *see* Igarashi S  
 Kang JC, Wanek LA, Essner R, Faries MB, Foshag LJ, Morton DL. Sentinel Lymphadenectomy Does Not Increase the Incidence of In-Transit Metastases in Primary Melanoma, 4764  
 Kang S, Badger J  
 Kang WK, *see* Rhee J-Y  
 Kantarjian H, *see* Bueso-Ramos C  
     *see* Cortes J  
     *see* Keating MJ  
     *see* Wierda W  
 Kantarjian HM, *see* Issa J-PJ  
 Kanz L, *see* Lengerke C  
 Kapadia D, Fong L. CTLA-4 Blockade: Autoimmunity As Treatment (editorial), 8926  
 Kaplan PA, *see* Floyd JD  
     *see* Sachs BA  
 Karagorgis P, *see* Athanassiou S  
 Karakiewicz PI, *see* Lotan Y  
 Karim R, *see* Lim S-T  
     *see* Lim ST  
 Kariola R, *see* Ollikainen M  
 Karlan B, *see* Agus DB  
 Karlin JD, Nguyen D, Yang SX, Lipkowitz S. Epidermal Growth Factor Receptor Expression in Breast Cancer (correspondence), 8118  
 Karlsson MO, *see* Sandström M  
 Karpf AR, *see* Samlowski WE  
 Karrison T, *see* Kindler HL  
 Kasimis B, *see* Nagaria NC  
 Kásler M, *see* Tímár J  
 Kasper CE, *see* Bowers DC  
 Kaste S, *see* Castellino SM  
     *see* Krasin MJ  
 Kastritis E, *see* Bamias A  
 Kates TJ, *see* Akhurst T  
 Kato K, *see* Iwao-Koizumi K  
 Katsahian S, *see* Fermand J-P  
 Katsaros D, *see* Buda A  
 Kattan MW, Ferrone CR, *see* Dotan ZA  
     *see* Saranchuk JW  
     *see* Stephenson AJ  
 Katz A. Does Neoadjuvant/Adjuvant Chemotherapy Change the Natural History of Classic Invasive Lobular Carcinoma? (correspondence), 6796  
 Katz A. The Sounds of Silence: Sexuality Information for Cancer Patients, 238  
 Katz RL, *see* Romaguera JE  
 Katz SJ, Lantz PM, Janz NK, Fagerlin A, Schwartz K, Liu L, Deapen D, Salem B, Lakhani I, Morrow M. Patient Involvement in Surgery Treatment Decisions for Breast Cancer, 5526  
 Katz SJ, Lantz PM, Janz NK, Fagerlin A, Schwartz K, Liu L, Deapen D, Salem B, Lakhani I, Morrow M. Patterns and Correlates of Local Therapy for Women With Ductal Carcinoma-in-Situ, 3001  
 Kau S-W, *see* Cristofanilli M  
     *see* Gonzalez-Angulo A  
 Kau S-WC, *see* Giordano SH  
 Kau SW, *see* Hennessy BT  
 Kaubisch A, *see* Kortmansky J  
 Kaufman HL. Integrating Bench With Bedside: The Role of Vaccine Therapy in the Treatment of Solid Tumors (editorial), 659  
 Kaufman M, Graf E, Jonat W, Eiermann W, Geberth M, Albert U-S, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M. Tamoxifen Versus Control After Adjuvant, Risk-Adapted Chemotherapy in Postmenopausal, Receptor-Negative Patients With Breast Cancer: A Randomized Trial (GABG-IV D-93)—The Terman Adjuvant Breast Cancer Group, 7842  
 Kaufman SS, *see* Gross TG  
 Kaufmann M, *see* von Minckwitz G  
 Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, Linse R, Tilgen W, Schadendorf D, Becker JC, Sebastian G, Krenzel S, Kretschmer L, Garbe C, Dummer R. Temozolomide in Combination With Interferon- $\alpha$  Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group, 9001  
 Kaufmann SH, *see* Witzig TE  
 Kaur K, *see* Madhusudan S  
 Kavanaugh D, *see* Carbone DP  
 Kavoussi LR, *see* Link RE  
 Kawakami K, *see* Graziano F  
 Kawashima H, *see* Ogose A  
 Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, Nagase M, Nihei K, Ogino T. Phase II Study of Radiotherapy Employing Proton Beam for Hepatocellular Carcinoma, 1839  
 Kawauchi A, *see* Mizutani Y  
 Kay A, *see* Thomas AL  
 Kay AC, *see* Cella D

AUTHOR INDEX

- Kaye S, *see* Banerji U  
*see* Dark GG
- Kaye SB, *see* Crawford SC
- Kazak AE, Boeving CA, Alderfer MA, Hwang W-T, Reilly A. Posttraumatic Stress Symptoms During Treatment in Parents of Children With Cancer, 7405
- Kazama Y, *see* Watanabe T
- Keating A, *see* Baker KS
- Keating M, *see* Wierda W
- Keating MJ, *see* Kurtzberg J  
*see* Wierda WG
- Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia, 4079
- Keating NL, *see* Malin JL
- Keefe D, *see* Tan-Chiu E
- Keegan THM, Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA, Dorfman RF, Mann RB, Ambinder RF. Epstein-Barr Virus As a Marker of Survival After Hodgkin's Lymphoma: A Population-Based Study, 7604
- Kefauver C, *see* Marcucci G
- Keilholz U, *see* Voit C
- Keilholz U, Punt CJA, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suci S, Eggermont AMM. Dacarbazine, Cisplatin, and Interferon- $\alpha$ -2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organization for Research and Treatment of Cancer Melanoma Group, 6747
- Kelaghan JW, *see* Buchanan DR
- Kelbick N, *see* Morrison C
- Kelcz F, *see* Liu G
- Keler T, *see* Sanderson K
- Keller AM. In Reply (correspondence), 6261
- Keller ET, *see* Loberg RD
- Kelley MJ, *see* Carbone DP
- Kelley SK, *see* Herbst RS
- Kelly DG, *see* Moynihan T
- Kelly H, Goldberg RM. Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence, 4553
- Kelly JK, *see* Olivotto IA
- Kelly JS, *see* Olivotto IA
- Kelly K, *see* Gridelli C  
*see* Muss HB  
*see* Niell HB  
*see* Thienelt CD
- Kelly KW, *see* Dotan ZA
- Kelly MD, *see* Schroen AT
- Kelly WK, *see* Galsky MD  
*see* Gleave M
- Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients with Advanced Cancer, 3923
- Kelsen DP, *see* Chung KY  
*see* Klimstra DS  
*see* Kortmansky J  
*see* Shah MA
- Kelsey A, *see* Williamson D
- Kelsey MI, *see* Carbone DP
- Kelsey SM, *see* Agus DB
- Kemeny N, *see* Kortmansky J
- Kemeny N, Jarnagin W, Paty P, Gönen M, Schwartz L, Morse M, Leonard G, D'Angelica M, DeMatteo R, Blumgart L, Fong Y. Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal Cancer, 4888
- Kemeny NE, *see* Chung KY  
*see* Leonard GD
- Kemeny NE. In Reply (correspondence), 2106
- Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K. Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS), 559
- Kendall J, *see* Edelman MJ
- Kenley E, *see* Powell CB
- Kennedy B, *see* Moreton P
- Kennedy J, *see* Marty M
- Kenny L, *see* Rischin D
- Kenny PM, *see* Fulham MJ
- Kepner J, *see* Laver JH
- Kerber R, *see* Florell SR
- Kerbrat P, *see* Bonnetterre J  
*see* Praga C
- Keri G, *see* Schwab R
- Kerkhofs LG, *see* Bontenbal M
- Kerr D, *see* Russo M  
*see* Sargent DJ
- Kerr K, *see* Travis WD
- Keshaviah A, *see* Burstein HJ
- Kessler L, *see* Halbert CH
- Kessler ML, *see* Cao Y
- Ketas J, *see* Leonard JP
- Ketterer N, *see* Ghilmini M
- Ketterer P, *see* Koch P
- Kevric M, *see* Kempf-Bielack B
- Khalid T, Folman R. Symptoms in Cancer Patients and an Unusual Tumor: Follicular Dendritic Cell Sarcoma, 9425
- Khalil A, *see* Andre F
- Khammari A, *see* van Baren N
- Khamtsov D, *see* Zielinski C
- Khan J, *see* Bilke S
- Khan R, *see* Fouladi M
- Khatri VP, Petrelli NJ, Belghiti J. Extending the Frontiers of Surgical Therapy for Hepatic Colorectal Metastases: Is There a Limit? 8490
- Khawli LA, *see* Chen S
- Khokhar AR, *see* Lu C
- Khoo K-S, *see* Cheung Y-B
- Khouri IF, *see* Pavletic SZ
- Khouri IF, Saliba RM, Hosing C, Okoroji G-J, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Chaqmplin RE. Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin's Lymphomas, 2240
- Khoury HJ, DiPersio JF. In Reply (correspondence), 6262
- Khawja A, *see* Tauro S
- Kicielinski KP, *see* Reardon DA
- Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A, Kröber A, Jäger U, Lichter P, Döhner H, Stilgenbauer S. Evidence for Distinct Pathomechanisms in Genetic Subgroups of Chronic Lymphocytic Leukemia Revealed by Quantitative Expression Analysis of Cell Cycle, Activation, and Apoptosis-Associated Genes, 3780
- Kieran M, *see* Blaney SM

AUTHOR INDEX

- Kies MS, *see* Herbst RS  
*see* Rugo HS
- Kievit J, *see* van den Brink M
- Kim A-Y, *see* Roh J-L
- Kim B-T, *see* Choi JY
- Kim D-W, *see* Han S-W
- Kim E-A, *see* Han J-Y
- Kim ES, *see* Herbst RS
- Kim G, *see* Philip PA  
*see* Sanchez R
- Kim H, *see* Brown JR
- Kim HY, *see* Han J-Y
- Kim J, *see* Han S-W  
*see* Tu S-M
- Kim J, Takeuchi H, Lam ST, Turner RR, Wang H-J, Kuo C, Foshag L, Bilchik AJ, Hoon DSB. Chemokine Receptor *CXCR4* Expression in Colorectal Cancer Patients Increases the Risk for Recurrence and for Poor Survival, 2744
- Kim JH, *see* Han S-W
- Kim NK, *see* Han S-W
- Kim S-Z, *see* Rummel MJ
- Kim-Sing C, *see* Eisen A
- Kim SJ, *see* Iwao-Koizumi K
- Kim T-Y, *see* Han S-W
- Kim TD, *see* Wündisch T
- Kim TY, *see* Lyman GH
- Kim YT, *see* Han S-W
- Kimby E, *see* Treon SP
- Kimler BF, *see* Fabian CJ
- Kimnick GG, Peterson BL, Kornblith AB, Mandelblatt J, Johnson JL, Wheeler J, Heinze R, Cohen HJ, Muss HB. Improving Accrual of Older Persons to Cancer Treatment Trials: A Randomized Trial Comparing an Educational Intervention With Standard Information: CALGB 360001, 2201
- Kimnick GG, Peterson BL, Kornblith AB, Mandelblatt J, Johnson JL, Wheeler J, Heinze R, Cohen HJ, Muss HB. In Reply (correspondence), 7752
- Kinchla N, *see* Hamilton AL
- Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE. Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer, 8033
- Kindler T, *see* Hess G
- King CR, *see* Patel DA
- King MT, *see* Fulham MJ
- King RJ, *see* Pavletic SZ
- Kingreen D, *see* Thuss-Patience PC
- Kinoshita A, *see* Igarashi S
- Kinoshita T, *see* Kawashima M
- Kinoshita Y, *see* Kanazawa S
- Kipps TJ, *see* Raval A  
*see* Wierda WG
- Kirk EN, *see* Stirling D
- Kirkwood JM, *see* McDermott DF  
*see* Moschos SJ
- Kirkwood JM. Building Upon the Standard of Care in Adjuvant Therapy of High-Risk Melanoma (editorial), 8559
- Kirsch DG, Ledezma CJ, Mathews CS, Bhan AK, Anckiewicz M, Hochberg FH, Loeffler JS. Survival After Brain Metastases From Breast Cancer in the Trastuzumab Era (correspondence), 2114
- Kirsch IR, *see* Calzone KA
- Kisor DF, *see* Kurtzberg J
- Kiss R, *see* Lefranc F
- Kissane DW. In Reply (correspondence), 5263
- Kitago M, *see* Mori T
- Kizawa Y, *see* Morita T
- Klasa R, *see* Sehn LH
- Kleeberg U, *see* Keilholz U
- Klein-Cabral M, *see* DeMichele A
- Klein EA, *see* Small EJ  
*see* Stephenson AJ  
*see* Thompson IM
- Klein EA, Tangen CM, Goodman PH, Lippman SM, Thompson IM. Assessing Benefit and Risk in the Prevention of Prostate Cancer: The Prostate Cancer Prevention Trial Revisited, 7460
- Klein P, *see* Calzone KA  
*see* Eberhard DA  
*see* Herbst RS  
*see* Pegram MD
- Klein T, *see* Garzotto M
- Kleinberg L, *see* Choy H
- Kleinerman ES, *see* Meyers PA
- Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni JF Jr. Risk of New Cancers After Radiotherapy in Long-Term Survivors of Retinoblastoma: An Extended Follow-Up, 2272
- Klenke R, *see* Blaney SM
- Klepp O, *see* Mykletun A  
*see* Sagstuen H
- Klerk CPW, Smorenburg SM, Otten H-M, Lensing AWAQ, Prins MH, Piovella F, Prandoni P, Bos MMEM, Richel DJ, van Tienhoven G, Büller HR. The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy, 2130
- Klevesath MB, *see* Purushotham AD
- Klijn J, *see* Eisen A
- Klijn JGM, *see* Jansen MPH
- Klimm B, *see* Behringer K
- Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A. Role of Hematotoxicity and Sex in Patients With Hodgkin's Lymphomas: An Analysis From the German Hodgkin Study Group, 8003
- Klimpfinger M, *see* Rödel C
- Klimstra DS, *see* Chung KY
- Klimstra DS, Shia J, Tang L, Brenner B, Kelsen DP. In Reply (correspondence), 4796
- Klingebliel T, *see* Einsiedel HG  
*see* Kempf-Bielack B  
*see* Koscielniak E
- Klinger G, *see* Warr DG
- Klippenstein D, *see* Czuczman MS
- Klisovic MI, *see* Marcucci G
- Klisovic RB, *see* Marcucci G
- Klotz L. Active Surveillance for Prostate Cancer: For Whom? 8165
- Kluin-Nelemans HC, *see* van Imhoff GW
- Kluin PM, *see* van Imhoff GW
- Klump B, *see* Stahl M
- Klumpp TR. R-CHOP for Mantle Cell Lymphoma (correspondence), 6802
- Knapp J, *see* Scheier MF
- Knaus WA, *see* Schroen AT
- Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly Occurring Toxicity That May Influence Academic and Social Development, 8588
- Knight RA, *see* Hoekstra R
- Knipp H, *see* Pink D
- Knisely J, *see* Manon R
- Knol J, *see* Ben-Josef E
- Knols R, Aaronson NK, Uebelhart D, Franssen J, Aufdemkampe G. Physical

- Exercise in Cancer Patients During and After Medical Treatment: A Systematic Review of Randomized and Controlled Clinical Trials, 3830
- Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B. Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions as Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group, 7483
- Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ. Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial, 2332
- Knox JJ. In Reply (correspondence), 7754
- Knox SJ, *see* Fisher RI  
*see* Kaminski MS
- Knudsen H, *see* Knoop AS
- Kobayashi H, *see* Matsuzaki H
- Kobbe G, *see* Hess G
- Kocak M, *see* Fouladi M  
*see* Mulhern RK
- Koch KM, *see* Burris HA III  
*see* Spector NL
- Koch MO, *see* Cheng L
- Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, Breitsprecher R, Schmits R, Freund M, Fietkau R, Ketterer P, Freitag E-M, Hinkelbein M, Heinecke A, Parwaresch R, Tiemann M. Treatment Results in Localized Primary Gastric Lymphoma: Data of Patients Registered Within the German Multicenter Study (GIT NHL 02/96), 7050
- Kocher O, *see* Cho D  
*see* Mayer S
- Kodama K, *see* Hamada C
- Kodama T, *see* Yamamoto N
- Koduru PRK, *see* Farag SS
- Koerberle D, *see* Ruhstaller T
- Koehler MT, *see* Baselga J
- Koehne CH, *see* Lutz MP
- Koelliker S, *see* Hricak H
- Kofahl-Krause D, *see* Rummel MJ
- Koh J, *see* Mok TSK
- Kohara H, *see* Morita T
- Kohli M, *see* Alikhan M
- Köhne C-H, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Rüdke-Lanz H, Frickhoven N, Fuchs R, Merghenthaler H-G, Langenbuch T, Vanhoef U, Rougier P, Voigtmann R, Müller L, Genicot B, Anak Ö, Nordlinger B. Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986, 4856
- Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S. Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial, 3314
- Kohonen-Corish MRJ, Daniel JJ, Chan C, Lin BPC, Kwun LSY, Dent OF, Dhillon VS, Trent RJA, Chapuis PH, Bokey EL. Low Microsatellite Instability Is Advanced With Poor Prognosis in Stage C Colon Cancer, 2318
- Kok J, *see* Townsley C
- Kokocinski F, *see* Mendrzyk F
- Kolb H-J, *see* Schmid C
- Kölbeck K, *see* Sederholm C
- Kolia S, *see* Spentzos D
- Kolitz JE, *see* Farag SS  
*see* Marcucci G
- Kolkman-Uljee SM, *see* Sieben NLG
- Koller C, *see* Cortes J  
*see* Keating MJ  
*see* Wierda W
- Komaki R, *see* Bradley JD  
*see* Movsas B  
*see* Sasaki R
- Komaki R, Sasaki R, Allen PK. In Reply (correspondence), 6800
- Komaki R. What Should the Optimal Timing Be for Amifostine Administration Relative to Radiation and Chemotherapy? (correspondence), 7232
- Komaromy M, *see* Powell CB
- Kömer M, *see* Weber T
- Komiya A, *see* Bhatia R
- Komminoth P, *see* Dannenberg H
- Komotar RJ, Zacharia BE, Mocco J, Ransom ER, Davis JP, Gasparis G, Bruce JN. Internet-Based Approach to Multi-Institutional Patient Recruitment in the Medico-Legal Age (correspondence), 4471
- Kondagunta GV, *see* Ronnen EA
- Kondagunta GV, Bacik J, Bajorin D, Dobrzynski J, Motzer RJ, Bosl GJ. Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors, 9290
- Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, Bosl GJ, Motzer RJ. Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors, 6549
- Kondo T, *see* Matsuzaki H  
*see* Onozawa M
- Kong C, *see* Le Q-T
- Kong S, *see* Chan S
- Konishi M, *see* Kawashima M
- Konstantinovic ML, *see* Timmerman D
- Kontani K, *see* Huang C-I
- Koo J, *see* Goodwin PJ
- Kooij PP, *see* Kwekkeboom DJ
- Koomen M, Pisano ED, Kuzmiak C, Pavic D, McLelland R. Future Directions in Breast Imaging, 1674
- Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ. Imatinib-Induced Regression of AIDS-Related Kaposi's Sarcoma, 982
- Koon KP, *see* Epplein M
- Koong AC, *see* Le Q-T
- Koong HN, *see* Choo SP
- Kopp R, *see* Glas J
- Kopper L, *see* Schwab R
- Korbling M, *see* Khouri IF
- Korfee S, *see* Strumberg D
- Korfel A, *see* Abrey LE
- Körholz D, *see* Schellong G
- Korn EL, *see* Rubinstein LV
- Korn EL, Hunsberger S, Freidlin B, Smith MA, Abrams JS. Preliminary Data Release for Randomized Clinical Trials of Noninferiority: A New Proposal, 5831
- Kornblith AB, *see* Kimmick GG
- Korshunov A, *see* Mendrzyk F
- Kortmansky J, Shah MA, Kaubisch A, Weyerbacher AQ, Yi S, Tong W, Sowers, Gonen M, O'Reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors, 1875

- Koryzna A, *see* Czuczman MS
- Korz C, *see* Kienle DL
- Kosaka T, *see* Mitsudomi T
- Koscielniak E, *see* Carli M
- Koscielniak E, Gross-Wieltch U, Treuner J, Winkler P, Klingebiel T, Lang P, Bader P, Niethammer D, Handgretinger R. Graft-Versus-Ewing Sarcoma Effect and Long-Term Remission Induced by Haploidentical Stem-Cell Transplantation in a Patient With Relapse of Metastatic Disease (correspondence), 242
- Koscielny S, Michiels S, Boige V, Hill C. Validation of Microarray Data by Quantitative Reverse-Transcriptase Polymerase Chain Reaction (correspondence), 9439
- Kostakoglu L, *see* Bander NH  
*see* Leonard JP
- Kosty MP, *see* Muss HB
- Kotasek D, *see* Hedenus M
- Kotz R, *see* Kempf-Bielack B
- Kouroussis C, *see* Georgoulas V
- Koutsoukou V, *see* Bamias A
- Kovacs A, *see* Tasci S
- Kovács AF. In Reply (correspondence), 2875, 4804
- Kovacs J, *see* Leonard JP  
*see* Liersch T
- Koyama H, *see* Noguchi S
- Koyanagi K, *see* Mori T
- Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang H-J, Elashoff RM, Takeuchi H, Umetani N, Hoon DSB. Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multi-center Trial, 8057
- Kozin SV, *see* Willett CG
- Kozinetz C, *see* Chévez-Barríos P
- Kozloff M, *see* Kindler HL
- Kraak MMJ, *see* Westra JL
- Kraemer DF, *see* Knight KRG
- Krag C, *see* Boesen EH
- Krag LE, *see* Lønning PE
- Kragstrup J, *see* Aabom B
- Krailo M, *see* Berg SL  
*see* Daw NC  
*see* Meyers PA  
*see* Whitlock JA
- Kramer A, *see* Rouanet P
- Kramer A, Gourgou-Bourgade S, Ychou M. Relationship of Serum Bilirubin to Toxicity in Patients With Metastatic Colorectal Cancer Treated With Single-Agent High-Dose Irinotecan (correspondence), 650
- Kramer BS, *see* Brawley OW
- Kramer GWPM, Wanders SL, Noordijk EM, Vonk EJA, van Houwelingen HC, van den Hout WB, Geskus RB, Scholten M, Leer J-WH. Results of the Dutch National Study of the Palliative Effect of Irradiation Using Two Different Treatment Schemes for Non-Small-Cell Lung Cancer, 2962
- Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up of *BRCA1* Mutation Carriers, 8629
- Kramer K, *see* Kushner BH
- Krams M, *see* Claviez A
- Kranenbarg EK, *see* Marijnen CAM  
*see* Peeters KCMJ
- Krasin MJ, *see* Spunt SL  
*see* Tekautz TM
- Krasin MJ, Rai SN, Kun LE, Merchant TE, Metzger ML, Kaste SC, Howard SC, Hudson MM. Patterns of Treatment Failure in Pediatric and Young Adult Patient With Hodgkin's Disease: Local Disease Control With Combined-Modality Therapy, 8406
- Krasna MJ, *see* Suntharalingam M
- Kraus-Tiefenbacher U, *see* Hofheinz R-D
- Krause C, *see* Desch CE
- Kraut M, *see* Okuno S
- Kraveka JM, *see* Laver JH
- Krebs AD, *see* Bell DW
- Kreicbergs U, Valdimarsdóttir U, Onelöv E, Björk O, Steineck G, Henter J-I. Care-Related Distress: A Nationwide Study of Parents Who Lost Their Child to Cancer, 9162
- Kreisberg JJ, *see* Galanis E
- Kreisman H, *see* Choy H
- Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJP, Wilson WH, Pastan I. Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B Cell Malignancies, 6719
- Krengel S, *see* Kaufmann R
- Krenitsky T, *see* Kurtzberg J
- Krenning EP, *see* Kwekkeboom DJ
- Kretschmar C, *see* George RE
- Kretschmer L, *see* Kaufmann R
- Kretzschmar A, *see* Pink D  
*see* Thuss-Patience PC
- Krieg RM, *see* Hansen EK
- Kripke ML, *see* Clayman GL
- Kris MG, *see* Bell DW  
*see* Cella D  
*see* Herbst RS  
*see* Shah NT
- Krishna MC, *see* Camphausen K
- Krishnamurthy S, *see* Hennessy BT
- Krishnan A, *see* Bhatia R
- Kristjansson LJ, *see* Chochinov HM
- Kröber A, *see* Kienle DL
- Krober SM, *see* Lengerke C
- Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, Weight Gain, and Survival After Breast Cancer Diagnosis, 1370
- Kroenke CH, Fung TT, Hu FB, Holmes MD. Dietary Patterns and Survival After Breast Cancer Diagnosis, 9295
- Kroll S, *see* Fisher RI  
*see* Horning SJ  
*see* Kaminski MS  
*see* Leonard JP
- Kron M, *see* Voit C
- Krook JE, *see* Witzig TE
- Krop IE, Winer EP. Ovarian Suppression for Breast Cancer: An Effective Treatment in Search of a Home (editorial), 5869
- Krown SE, *see* Su YB
- Krown SE. In Reply (correspondence), 2433
- Krug LM, *see* Kelly WK
- Kruhøffer M, *see* Eschrich S
- Kruit W, *see* Keilholz U
- Krull K, *see* Mulhern RK
- Krumholz HM, *see* Gross CP
- Krupnick JL, *see* Stanton AL
- Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and Socioeconomic Variation in the Treatment of Prostate Cancer, 7881
- Kubista E, *see* Filipits M
- Kuehl WM, *see* Bergsagel PL
- Kuerer H, *see* Cristofanilli M  
*see* Gonzalez-Angulo A  
*see* Hennessy BT  
*see* Newman LA  
*see* Raut CP

## AUTHOR INDEX

- Kuerer HM, Newman LA. Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer: Developments and Resolving Controversies, 1698
- Kueter EWM, *see* Luiten RM
- Kuhl CK, Schrading S, Leutner CC, Morakkbati-Spitz N, Wardelmann E, Fimmers R, Kuhn W, Schild HH. Mammography, Breast Ultrasound, and Magnetic Resonance Imaging for Surveillance of Women at High Familial Risk for Breast Cancer, 8469
- Kuhn J, *see* Cloughesy TF
- Kuhn W, *see* Amendola MA  
*see* Avril N  
*see* Kuhl CK
- Kulkarni KG, *see* Lightdale CJ
- Kulke MH, *see* Meyerhardt JA
- Kulle B, *see* Liersch T
- Kumagai M, *see* Igarashi S
- Kumar P, *see* Robbins KT
- Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE. Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance, 5668
- Kummar S, *see* O'Mahoney D
- Kun L, *see* Blaney SM  
*see* Mulhern RK
- Kun LE, *see* Fouladi M  
*see* Krasin MJ  
*see* Tekautz TM
- Kung M, *see* Vordermark D
- Kunitoh H, *see* Takano T  
*see* Yamamoto N
- Kunstlinger F, *see* Poston DJ
- Kuntz KM, *see* Punglia RS
- Kuo C, *see* Kim J  
*see* Mori T
- Kuo M-L, *see* Chen C-N
- Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. Phase II Study of Gefitinib, Fluorouracil, Leucovorin, and Oxaliplatin Therapy in Previously Treated Patients With Metastatic Colorectal Cancer, 5613
- Kuo Y-F, *see* Pratt DA
- Küppers R, *see* Re D
- Kure E, *see* Stormorken AT
- Kurita N, *see* Matsuzaki H
- Kuroda H, *see* Gotoh T
- Kurtin P, *see* Witzig TE
- Kurtin PJ, *see* Witzig TE
- Kurtycz DF, *see* Austin RM
- Kurtzberg J, *see* Berg SL
- Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, Mitchell BS. Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies, 3396
- Kurzrock R, *see* Cortes J
- Kushner BH, Kramer K, Laquaglia MP, Modak S, Yataghene K, Cheung N-KV. In Reply (correspondence), 6263
- Kuter I, *see* Taghian AG
- Kutti J, *see* Marchioli R
- Kuwahara Y, *see* Gotoh T
- Kuzmiak C, *see* Koomen M
- Kwan E, *see* Laughton SJ
- Kwan L, *see* Krupski TL  
*see* Stanton AL
- Kwan W, *see* Lukka H
- Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Fielders RA, van Eijck CH, Esser J-P, Kam BL, Krenning EP. Radiolabeled Somatostatin Analog [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors, 2754
- Kwok Y, Patchell RA, Regine WF. In Reply (correspondence), 8272
- Kwok Y, Regine WF, Patchell RA. Radiation Therapy Alone for Spinal Cord Compression: Time to Improve Upon a Relatively Ineffective Status Quo (editorial), 3308
- Kwon ED, *see* Webster WS
- Kwon GY, *see* Rhee J-Y
- Kwon OJ, *see* Choi JY
- Kwong D, Sham J. In Reply (correspondence), 2865
- Kwong KY, *see* Eschrich S
- Kwun LSY, *see* Kohonen-Corish MRJ
- Kyle RA, *see* Dimopoulos MA  
*see* Greipp PR  
*see* Kumar S

## L

- La Placa M, *see* Correale P
- Laack E, *see* Schuch G
- Labianca R, *see* Louvet C
- Labirio M, *see* Comoli P
- Lablanca R, *see* Sargent DJ
- Lackey VL, *see* Hainsworth JD
- Lacourciere J, *see* Wright J
- Lacy MQ, *see* Kumar S
- Ladányi A, *see* Tímár J
- Ladanyi M, *see* Huang H-Y
- Ladanyi M. Correlates of SYT-SSX Fusion Type in Synovial Sarcoma: Getting More Complex But Also More Interesting? (correspondence), 3638
- Ladeb S, *see* Abdelkefi A
- Laden G. Hyperbaric Oxygen Therapy for Radionecrosis: Clear Advice From Confusing Data (correspondence), 4465
- Ladewski L, *see* Ferreira MR
- Laff RE, *see* Vanderwerker LC
- LaFleur B, *see* Rothenberg ML
- Lagattuta TF, *see* Reardon DA
- Lager JJ, *see* Kurtzberg J
- Lagman R, *see* Davis MP  
*see* Yavuzsen T
- Lagomasino I, *see* Ell K
- Lagrange J-L, *see* Guibout C
- Lahuerta JJ, *see* Greipp PR
- Lai P, *see* Mok TSK
- Lai WS, *see* Dowell JE
- Laínez N, *see* Martín J
- Laird PW, *see* Cote RJ
- Lairson DR, *see* Du XL
- Lakhal A, *see* Abdelkefi A
- Lakhani I, *see* Katz SJ
- Lakhani S, *see* Banerji U
- Lal A, *see* Schmidt ML
- Lalani M, Rhee JC, Gutkin DW, Matin K, Ahmad J. Uncommon Presentations of Some Common Malignancies: Chronic Lymphocytic Leukemia Involving the Colon and Presenting With Perforation, 1315
- Laloo FI, *see* Stirling D
- Lally BE, *see* Smith BD
- Lam DSC, *see* Chan W-M
- Lam P, *see* Au WY
- Lam ST, *see* Kim J
- Lamb D, *see* Rischin D
- Lamberg K, *see* Sederholm C

AUTHOR INDEX

- Lamborn K, *see* Cloughesy TF  
 Lamerato L, *see* Hershman D  
 Lammert I, *see* Budach V  
 Lammertsma AA, *see* Hoekstra CJ  
 Lamont E, *see* Hotte SJ  
 Lampe D, *see* von Minckwitz G  
 Lampkin TA, *see* Berg SL  
 Lamps LW, *see* Dye DW  
 Lancashire L, *see* Mian S  
 Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA III, Moore DH, Monk BJ, O'Connor DM. Randomized Comparison of Weekly Cisplatin or Protracted Venous Infusion of Fluorouracil in Combination With Pelvic Radiation in Advanced Cervix Cancer: A Gynecologic Oncology Group Study, 8289  
 Land S, *see* Moschos SJ  
 Landberg G, *see* Rydén L  
 Landolfi R, *see* Marchioli R  
 Landoni F, Gadducci A, *see* Buda A  
 Lang H, *see* Bauer S  
 Lang P, *see* Koscielniak E  
 Langbein S, *see* Lehmann J  
 Lange BJ, *see* Johnston DL  
 Langenbuch T, *see* Köhne C-H  
 Langer AS, *see* Winer EP  
 Langer C, *see* Ghadimi BM  
   *see* Gridelli C  
   *see* Liersch T  
   *see* Movsas B  
 Langer CJ. In Reply (correspondence), 1326  
 Langer CJ, Mehta MP. Current Management of Brain Metastases, With a Focus on Systemic Options, 6207  
 Langer SL, *see* Syrjala KL  
 Langley RE, Carmichael J, Jones AL, Cameron DA, Qian W, Uscinska B, Howell A, Parmar M. Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01, 8322  
 Langmuir V, *see* Miller KD  
 Langnas AN, *see* Gross TG  
 Langston A, *see* Sorrow ML  
 Lannin D, *see* Ahn PH  
 Lansdale MF, *see* Bhat SR  
 Lantz PM, *see* Katz SJ  
 Lao L, *see* Ezzo J  
 Laperriere NJ, *see* Loblaw DA  
 Laplanche A, *see* Dromain C  
   *see* Ducreux M  
 LaPresa MT, Gadducci A  
 Laquaglia MP, *see* Kushner BH  
 Lara PN Jr, *see* Hussain M  
   *see* Williamson SK  
 Lara PN Jr, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara DR, Wun T, Beckett LA, Chen MS Jr. Evaluation of Factors Affecting Awareness of and Willingness to Participate in Cancer Clinical Trials, 9282  
 Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC. Etiology of Solitary Extrapulmonary Positron Emission Tomography and Computed Tomography Findings in Patients With Lung Cancer, 6846  
 Larkin P, *see* Maltoni M  
 Larsimont D, *see* Colozza M  
 Larson PS, Schlechter BL, de las Morenas A, Garber JE, Cupples LA, Rosenberg CL. Allele Imbalance, or Loss of Heterozygosity, in Normal Breast Epithelium of Sporadic Breast Cancer Cases and *BRCA1* Gene Mutation Carriers Is Increased Compared With Reduction Mammoplasty Tissues, 8613  
 Larson RA, *see* Farag SS  
   *see* Marcucci G  
   *see* van Besien K  
 Larson SM, *see* Akhurst T  
   *see* Schöder H  
 Larson TS, *see* Ghobrial IM  
 Laskar S, Gupta T, Muckaden MA. In Reply (correspondence), 246  
 Lasser P, *see* Ducreux M  
 Lastowska M, *see* Vandesompele J  
 Laszlo D, *see* Martrinelli G  
 Laszlo D, Agazzi A, Pruneri G, Bertoni F, Calabrese L, Martinelli G. In Reply (correspondence), 7362  
 Latini P, *see* Maranzano E  
 Lau CY, *see* Chang J  
 Lau DHM, *see* Williamson SK  
 Lau JT, *see* Lee AWM  
 Lau JWY, *see* Mok TSK  
 Lau WH, *see* Lee AWM  
 Laufman L, *see* Jones SE  
 Laughton SJ, Ashton LJ, Kwan E, Norris MD, Haber M, Marshall GM. Early Responses to Chemotherapy of Normal and Malignant Hematologic Cell Are Prognostic in Children With Acute Lymphoblastic Leukemia, 2264  
 Laurent D, *see* Thomas AL  
 Laurent-Puig P, *see* Lièvre A  
 Laureys G, *see* De Preter K  
   *see* Vandesompele J  
 Laurie F, *see* Sartor CI  
 Laursen H, *see* Borgwardt L  
 Lautenschlaeger C, *see* Schuette W  
 Lauwers GY, *see* Willett CG  
 Laver JH, Kravaka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB. Advanced-Stage Large Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating Intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial, 541  
 Laverdière C, Lussier D. What Health Care Providers Learn As Caregivers, 5260  
 Laviano A, Fanelli FR, Meguid MM. Serotonin and Cancer Anorexia: Myths or Facts? (correspondence), 2111  
 Lavoie JC, *see* Forrest DL  
 Law RW, *see* Hon C  
 Law SCK, *see* Lee AWM  
 Lawrance J, *see* Jayson GC  
 Lawrence TS, *see* Ben-Josef E  
   *see* Cao Y  
 Lawson S, *see* Stirling D  
 Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen Suppression Plus Radiation Versus Radiation Alone for Patients With Stage D<sub>1</sub>/Pathologic Node-Positive Adenocarcinoma of the Prostate: Updated Results Based on National Prospective Randomized Trial Radiation Therapy Oncology Group 85-31, 800  
 Lax S, *see* Filipits M  
 Lazarus HM, *see* Manon R  
 Lazzarino M, *see* Malcovati L  
   *see* Vallisa D  
 Lazzaro A, *see* Vallisa D  
 Le Cesne A, *see* Van Glabbeke M  
 Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS. Phase II Study of ET-743 in

- Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (ORTC) Soft Tissue and Bone Sarcoma Group Trial, 576
- Le Chevalier T, *see* Gridelli C  
*see* Pisters KMW
- Le Gall JR, *see* Thiéry G
- Le Nestour E, *see* Rouanet P
- Le Q-T, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O'Byrne KJ, Giaccia AJ, Koong AC. Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege, 8932
- Le T, *see* Dark GG
- Le Treut J, *see* Fournel P
- Leach M, *see* Moreton P
- Leach SD, *see* Hansel DE
- Leachman SA, *see* Florell SR  
*see* Samlowski WE
- LeBlanc M, *see* Fisher RI  
*see* Urba SG
- Leblond V, *see* Ferman J-P
- Leclere J, *see* Thuret R
- Ledderose G, *see* Hess G  
*see* Schmid C
- Ledezma CJ, *see* Kirsch DG
- Lee AK, D'Amico AV. Utility of Prostate-Specific Antigen Kinetics in Addition to Clinical Factors in the Selection of Patients for Salvage Local Therapy, 8192
- Lee AV, *see* Cui X  
*see* Fuqua SAW
- Lee AWM, Lau WH, Tung SY, Chua DTT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JST, Ngan RKC, Law SCK, Yau TK, Au JSK, O'Sullivan B, Pang ESY, O SK, Au GK, Lau JT. Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group, 6966
- Lee AYY, *see* Levine MN
- Lee AYY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism, 2123
- Lee DH, *see* Han J-Y
- Lee DP, Skolnik JM, Adamson PC. Pediatric Phase I Trials in Oncology: Analysis of Study Conduct Efficiency, 8431
- Lee FT Jr, *see* Liu G
- Lee H-Y, Chang YS, Han J-Y, Liu DD, Lee JJ, Lotan R, Spitz MR, Hong WK. Effects of 9-*cis*-Retinoic Acid on the Insulin-Like Growth Factor Axis in Former Smokers, 4439
- Lee J, *see* Noy A
- Lee JC, *see* Cho D  
*see* Wirth LJ
- Lee JE, *see* Cormier JN
- Lee JJ, *see* Clayman GL  
*see* Herbst RS  
*see* Lee H-Y  
*see* Lotan R  
*see* Low JA
- Lee JJ, Feng L. Randomized Phase II Designs in Cancer Clinical Trials: Current Status and Future Directions, 4450
- Lee JS, *see* Han J-Y  
*see* Han S-W
- Lee K-A, *see* Coleman RE
- Lee K-H, *see* Choi JY
- Lee KM, *see* Wee J
- Lee KS, *see* Choi JY  
*see* Wee J
- Lee L, *see* Thomas AL
- Lee MS, *see* Hollister D Jr
- Lee P, *see* Sanderson K
- Lee P-H, *see* Chen C-N
- Lee P-J, *see* Ell K
- Lee PWH, *see* Chan YW
- Lee SM, *see* Rudd RM
- Lee SY, *see* Han J-Y
- Lee W-J. No Therapeutic Effect of Extended Lymph Node Dissection for Gastric Cancer (correspondence), 1592
- Lee WC, *see* Smith MR
- Leedham B, *see* Stanton AL
- Leer J-WH, *see* Kramer GWPM  
*see* Marijnen CAM
- Leer JWH, *see* Peeters KCMJ
- Lefaix J-L, *see* Delanian S
- Lefranc F, Brotchi J, Kiss R. Possible Future Issues in the Treatment of Glioblastomas: Special Emphasis on Cell Migration and the Resistance of Migrating Glioblastoma Cells to Apoptosis, 2411
- LeGales C, *see* Oyharcabal-Bourden V
- Legha SS. Treatment of Brain Metastases From Melanoma (correspondence), 3155
- Legrand C, *see* Giaccone G  
*see* van Meerbeek JP
- LeGrand S, *see* Yavuzsen T
- Lehman F, *see* Keilholz U
- Lehmann J, Retz M, Wiemers C, Beck J, Thüroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke P-J, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kälble T, Sternberg D, Wellek S, Stöckle M. Adjuvant Cisplatin Plus Methotrexate Versus Methotrexate, Vinblastine, Epirubicin, and Cisplatin in Locally Advanced Bladder Cancer: Results of a Randomized, Multicenter, Phase III Trial (AUO-AB 05/95), 4963
- Lehmann N, *see* Stahl M
- Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival, 5746
- Leigh BR, *see* Czuczman MS
- Leighl N, *see* Hagerty RG
- Leighl NB, *see* D'Addario G
- Leighl NB, Paz-Ares L, Douillard J-Y, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA. Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination with Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18, 2831
- Leis A, *see* Brundage M
- Leis J, *see* Sorrow ML
- Leiter U, *see* Kaufmann R
- Lembersky B, *see* Mamounas EP
- Lemoine NR. Antithrombotic Therapy in Cancer (editorial), 2119
- Léna H, *see* Fournel P
- Lenahan PF, *see* Campos S
- Lengerke C, Wirths S, Kanz L, Hebart H, Kaiserling E, Krober SM, Horger MS, Soennichsen K. Unusual Leukemia Presentations: Pulmonary Chloroma Preceded by Leukemia Cutis 7 Years Earlier, 5837
- Lenihan DJ, *see* Ewer MS  
*see* Hennessy BT
- Lenington S, *see* Stojadinovic A
- Lensing AWA, *see* Klerk CPW
- Lenz G, Hiddemann W, *see* Hiddemann W
- Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S,

- Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W. Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG), 1984
- Lenz G, Dreyling M, Unterhalt M, Hiddemann W. In Reply (correspondence), 6264
- Lenz H-J, *see* Vallböhmer D
- Lenz H-J. First Amsterdam, Then Bethesda, Now Melbourne? (editorial), 6445
- Leo E, *see* Frattini M
- Leonard G, *see* Kemeny N
- Leonard GD, *see* Traina TA
- Leonard GD, Brenner B, Kemeny NE. Neoadjuvant Chemotherapy Before Liver Resection for Patients With Unresectable Liver Metastases From Colorectal Carcinoma, 2038
- Leonard JP, *see* Czuczman MS  
*see* Fisher RI  
*see* Kaminski MS
- Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM. Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma, 5044
- Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ. Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma, 5696
- Leonard RCF, *see* Evans TRJ
- Leong LA, *see* Faynsod M
- Leong SS, *see* Wee J
- Leong T, *see* Lim L
- Leoni V, *see* Spinola M
- Lepage E, *see* Feugier P
- Lepere C, *see* Louvet C
- Leray E, *see* Patard J-J
- Lerma E, *see* Honrado E
- Lerman C, Patterson F, Berrettni W. Treating Tobacco Dependence: State of the Science and New Directions, 311
- Lerner S, *see* Keating M  
*see* Leibovici D  
*see* Wierda W
- Lerner SP, *see* Lotan Y  
*see* Ziari M
- Leroy K, *see* Lévy M
- Lesinski GB, *see* Eisenbeis CF
- Lesterhuis WJ, *see* de Vries IJM
- Lettini AA, *see* Ferreri AJM
- Leu KM, *see* Chugh R
- Leu M, *see* Worden FP
- Leung N, *see* Mok TSK
- Leung TW, *see* Lee AWM
- Leutner C, *see* Tasci S
- Leutner CC, *see* Kuhl CK
- Levenback CF, *see* Frumovitz M
- Levin B, *see* Hawk ET  
*see* Lippman SM
- Levin J, *see* Kurtzberg J
- Levine AM, *see* Lim S-T  
*see* Lim ST
- Levine AM, Lim S-T. In Reply (correspondence), 8540
- Levine DA, *see* Spentzos D
- Levine M, *see* Lukka H  
*see* Parulekar WR  
*see* Sathya JR  
*see* Simunovic M  
*see* Whelan T
- Levine M, Kakkak AK. Catheter-Associated Thrombosis: Thromboprophylaxis or Not? (editorial), 4006
- Levine MN, *see* Lee AYY
- Levine MN. In Reply (correspondence), 7244
- Levine MN, Lee AYY, Kakkak AK. In Reply (correspondence), 7250
- Levine MN, Mamounas EP, Ganz PA, Piccart-Gebhart MJ. Preface to Special Edition on Breast Cancer, 1595
- Levine MN, Pritchard KI, Bramwell VHC, Shepherd LE, Tu D, Paul N. Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5, 5166
- Levine MN. Trastuzumab Cardiac Side Effects: Only Time Will Tell (editorial), 7775
- Levine P, *see* Robbins KT
- Levine RL, *see* Fröhling S
- Levis A, *see* Gobbi PG
- Levitt R, *see* Alberts SR  
*see* Witzig TE
- LeVoyer T, *see* Berger AC
- Levy C, *see* Attia P
- Levy DE, *see* Rothenberg ML
- Levy E, *see* Scotté F
- Lévy M, Copie-Bergman C, Gameiro C, Chaumette M-T, Delfau-Larue M-H, Haioun C, Charachon A, Hemery F, Gaulard P, Leroy K, Delchier J-C. Prognostic Value of Translocation t(11;18) in Tumoral Response of Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue Type to Oral Chemotherapy, 5061
- Lévy V, *see* Thiéry G
- Lew D, *see* Hutchins LF
- Lew DL, *see* Pierce LJ
- Lewis I, *see* Nathan SS
- Lewis K, *see* Koyanagi K
- Lewis S, *see* Menon U
- Lewis MT, *see* Chang JC
- Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandis S, Manikhas G, Makh son A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study, 5960
- Leys RB, *see* Bontenbal M
- Li FP, *see* Emmons KM  
*see* Kleinerman RA  
*see* Park ER
- Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C, Duensing A, van de Rijn M, Schnipper LE, Demetri GD. Familial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred, 2735
- Li G, *see* Dai DL
- Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, Einhorn LH, Sweeney CJ. Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study, 1185
- Li S, *see* Chen S  
*see* Grundy PE  
*see* Tomlinson GE

## AUTHOR INDEX

- Li SM, *see* Dome JS
- Li X, *see* Herbst RS
- Li Y, *see* Gibson MK
- Li YN, *see* Mizutani Y
- Liao G, *see* Chen S
- Liberati M, *see* Gobbi PG
- Liberman TA, *see* Spentzos D
- Libertella N, *see* Oktay K
- Libucha M, *see* Warren KE
- Libutti SK, *see* Pingpank JF
- Licht JD, *see* Melnick AM
- Lichter P, *see* Kienle DL  
*see* Mendrzyk F
- Licitra L, Bossi P, Locati LD, Bergamini C. Is Restoring Platinum Sensitivity the Best Goal for Cetuximab in Recurrent/Metastatic Nasopharyngeal Cancer? (correspondence), 7757
- Lidbrink E, *see* Sandström M
- Lie AKW, *see* Chim CS
- Liebel SA, *see* Zelefsky MH
- Lieberman FS, *see* Cloughesy TF
- Lieberman G, *see* Agus DB
- Liebes L, *see* Hamilton AL
- Lien EA, *see* Lønning PE
- Lienard D, *see* Keilholz U
- Liénard D, *see* van Baren N
- Liersch R, *see* Koch P
- Liersch T, *see* Ghadimi BM  
*see* Rödel C
- Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, Ghadimi BM, Wegener WA, Kovacs J, Horak ID, Becker H, Goldenberg DM. Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy With <sup>131</sup>I-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results, 6763
- Liesveld JL, *see* Baker KS
- Lièvre A, Chapusot C, Bouvier A-M, Zinzindohoué F, Piard F, Roignot P, Arnould L, Beaune P, Faivre J, Laurent-Puig P. Clinical Value of Mitochondrial Mutations in Colorectal Cancer, 3517
- Liewehr DJ, *see* Calzone KA
- Lightdale CJ, Kulkarni KG. Role of Endoscopic Ultrasonography in the Staging and Follow-Up of Esophageal Cancer, 4483
- Lilenbaum RC, Herndon JE II, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks, JC, Holland JC, Green MR. Single-Agent Versus Combination Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730), 190
- Lim CH, *see* Choo SP
- Lim DWT, *see* Choo SP
- Lim L, Michael M, Mann GB, Leong T. Adjuvant Therapy in Gastric Cancer, 6220
- Lim S-T, *see* Levine AM
- Lim S-T, Karim R, Nathwani BN, Tulpule A, Levine AM. In Reply (correspondence), 8133
- Lim S-T, Karim R, Tulpule A, Nathwani BN, Levine AM. Prognostic Factors in HIV-Related Diffuse Large-Cell Lymphoma: Before Versus After Highly Active Antiretroviral Therapy, 8477
- Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre-Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemotherapy, 4430
- Lin BPC, *see* Kohonen-Corish MRJ  
*see* Vardy J
- Lin J-J, *see* Chen C-N
- Lin JW, *see* Hansel DE
- Lin R-K, *see* Wang Y-C
- Lin S-H, *see* Tu S-M
- Lin SS, *see* Chan JK
- Lin TS, Grever MR, Byrd JC. Changing the Way We Think About Chronic Lymphocytic Leukemia (editorial), 4009
- Lin X, *see* Chan ATC
- Lin Y-C, *see* Chen JJW
- Linares-Cruz G, *see* Rouanet P
- Linassier C, *see* Oudard S
- Lind M, *see* Baka S
- Lindeberg J, *see* Jakobsen A
- Lindeman NI, *see* Wirth LJ
- Lindenberg J, *see* Wolf MS
- Lindman H, *see* Sandström M
- Lindner T, *see* Pink D
- Lindroos A, *see* Ollikainen M
- Lindsey JC, *see* Ellison DW
- Lindtner J, *see* Colleoni M  
*see* Gruber G
- Linehan WM, *see* Srinivasan R
- Lingenfeller T, *see* Lutz MP
- Lingle WL, *see* Goetz MP
- Link BK, *see* Juweid ME  
*see* Swenson WT
- Link M, *see* Meyers PA
- Link RE, Allaf ME, Pili R, Kavoussi LR. Modeling the Cost of Management Options for Stage I Nonseminomatous Germ Cell Tumors: A Decision Tree Analysis, 5762
- Linnartz R, *see* Smith MR
- Linse R, *see* Kaufmann R
- Lioté F, *see* Duet M
- Liotta LA, *see* Petricoin EF III
- Lipkowitz S, *see* Calzone KA  
*see* Karlin JD
- Lippman M, *see* Petricoin EF III
- Lippman SM, *see* Clayman GL  
*see* Dannenberg AJ  
*see* Ewer MS  
*see* Hirsch FR  
*see* Klein EA  
*see* Lotan Y  
*see* Thompson IM
- Lippman SM, Levin B. Cancer Prevention: Strong Science and Real Medicine (editorial), 249
- Lippman SM, Sudbø J, Hong WK. Oral Cancer Prevention and the Evolution of Molecular-Targeted Drug Development, 346
- Lipshultz SE, *see* Adams MJ
- Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia, 2629
- Lipsitz S, *see* Sun W
- Lipsitz SR, *see* Lipshultz SE
- Lipton A, *see* Coleman RE
- Lissoni A, *see* Buda A
- List MA, *see* Lilenbaum RC
- Lister TA, *see* Rohatiner AZS
- Lister TA. Improved Survival for Patients With Follicular Lymphoma, 4830
- Litchy S, *see* Hainsworth JD
- Littler JAH, *see* Rudd RM
- Littlewood T, *see* Tauro S
- Litwin A, *see* Cheewakriangkrai R
- Litwin MS, *see* Krupski TL
- Liu D, *see* Arshad M

AUTHOR INDEX

- see Ferreira MR  
 see Huang C-I  
 see Sanderson K  
 Liu DD, *see* Herbst RS  
 see Lee H-Y  
 Liu DTL, *see* Chan W-M  
 Liu ET, *see* Dressler LG  
 Liu G, *see* Rugo HS  
 Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study, 5464  
 Liu H, *see* Wündisch T  
 Liu J, *see* Eisenbeis CF  
 Liu L, *see* Katz SJ  
 see Spector NL  
 Liu S, *see* Marcucci G  
 see Whelan TJ  
 Liu T-W, *see* Chan ATC  
 Liu WM, Baird R, Sarker D, Powles T. Antiapoptotic Effect of Growth Factors in Leukemia (correspondence), 649  
 Liu X, *see* Leyland-Jones B  
 Liu Y, *see* Bowers DC  
 see Park ER  
 see Perkins JL  
 Livestro DP, Muzikansky A, Kaine EM, Flotte TJ, Sober AJ, Mihm MC Jr, Michaelson JS, Cosimi AB, Tanabe KK. Biology of Desmoplastic Melanoma: A Case-Control Comparison With Other Melanomas, 6739  
 Livingston PO, *see* Su YB  
 Livingston RB, *see* Gaspar LE  
 see Pierce LJ  
 Liyanarachchi S, *see* Raval A  
 Lledo G, *see* Louvet C  
 Llombart-Bosch A, *see* Martín J  
 Llosa F, *see* Feliu J  
 Lluch A, *see* Baselga J  
 see Marty M  
 Lo CPL, *see* Choo SP  
 Lo SS, *see* Nagda SN  
 Lo Vullo S, *see* Fiore M  
 see Gronchi A  
 Lobb EA, *see* Hagerty RG  
 Lobel B, *see* Patard J-J  
 Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype, 8232  
 Loberiza FR Jr, *see* Baker KS  
 Lobins RL, *see* Floyd JD  
 Loblaw DA, Laperrriere NJ, Perry J. In Reply (correspondence), 7751  
 Loblaw DA, Perry J, Chambers A, Laperrriere NJ. Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group, 2028  
 Lobo F, *see* Hitt R  
 Locasciulli A, *see* Corradini P  
 Locatelli F, *see* Comoli P  
 see Pession A  
 Locati LD, *see* Licitra L  
 Locker G, *see* Kindler HL  
 Loeb TB, *see* Wyatt GE  
 Loeffler JS, *see* Kirschg D  
 see Nguyen PL  
 Loehrer PJ Sr, Bosl GJ. Carboplatin for Stage 1 Seminoma and the Sword of Damocles (editorial), 8566  
 Logan TF, Ascierto PA, *see* McDermott DF  
 Logan W, *see* Stojadinovic A  
 Loge JH, *see* Hjerstad MJ  
 Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, Gehling UM, Schuch G, Hossfeld DK, Fiedler W. Analysis of Concerted Expression of Angiogenic Growth Factors in Acute Myeloid Leukemia: Expression of Angiopoietin-2 Represents an Independent Prognostic Factor Overall Survival, 1109  
 Logothetis CJ, *see* Loberg RD  
 see Tu S-M  
 Loken MR, *see* Sorror ML  
 Lombardi L, *see* Agnelli L  
 London WB, *see* Bagatell R  
 see George RE  
 London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorne P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group, 6459  
 Long HJ III, *see* Hricak H  
 see Monk BJ  
 Long HJ III, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV. Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study, 4626  
 Long K, *see* Nyman DW  
 Long ME, *see* Thienelt CD  
 Longarini R, *see* Bajetta E  
 Longhi A, *see* Ferrari S  
 Longmate J, *see* Faynsod M  
 Longo L, *see* Rossi G  
 Longo R, *see* Gasparini G  
 Lo Nigro L, *see* Pession A  
 Lønning PE, Geisler J. In Reply (correspondence), 8917  
 Lønning PE, Geisler J. In Reply (correspondence), 9434  
 Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Øfjord ES, Paolini J, Polli A, Massimini G. Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer, 5126  
 Lonser RR, *see* Weil RJ  
 Loo C, *see* Hannemann J  
 Look, MP, *see* Jansen MPH  
 Look AT, *see* Armstrong SA  
 see Bagatell R  
 see George RE  
 see London WB  
 Looker SA, *see* Vickers KS  
 Loong F, *see* Chim CS  
 Loong S, *see* Wee J  
 Lopez-Berestein G, *see* Lu C  
 see Ribas A  
 López-Brea M, *see* Aparicio J  
 López de Argumedo G, *see* Fernández-Rodríguez R  
 Lopez-Encuentra A, *see* Pozo-Rodríguez F  
 Lopez-Gómez L, *see* Feliu J  
 López-Guerrero JA, *see* Martín J  
 López-Guillermo A, *see* Moreno C  
 López-Guillermo A, Colomo L, Jiménez, M, Bosch F, Villamor N, Arenillas L, Muntañola A, Montoto S, Giné E, Colomer D, Beá S, Campo E, Montserrat E. Diffuse Large B-Cell Lymphoma: Clinical and Biological

- Characterization and Outcome According to the Nodal or Extranodal Primary Origin, 2797
- Lopez-Lazaro L, *see* Faivre S
- Lopez M, *see* Colucci G  
*see* Papaldo P
- López-Pousa A, *see* Hitt R
- Lopez R, *see* Feliu J
- Lopez T, *see* Garcia-Carbonero R
- López-Vivanco G, *see* Fernández-Rodriguez R
- Loprinzi C, *see* Jatoi A  
*see* Whelan TJ
- Loprinzi CL, *see* Alberts SR  
*see* Desch CE  
*see* Jatoi A  
*see* Ryan M  
*see* Steensma DP  
*see* Vickers KS  
*see* Witzig TE
- Lorenz M, *see* Köhne C-H
- Loria FS, *see* Chacón M  
*see* Chacón R
- Lorigan P, *see* Baka S  
*see* Le Cesne A
- LoRusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB. Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies, 5281
- Losa F, *see* Martín J
- Loscalzo MJ, *see* Muss HB
- Lossos IS. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma, 6351
- Lotan R, *see* Lee H-Y
- Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM. Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes, 1911
- Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI. Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy, 6533
- Loud P, *see* Czuczman MS
- Louvet C, *see* Taïieb J
- Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïieb J, Faroux R, Lepere C, de Gramont A. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial, 3509
- Low, JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T, Swain SM. Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer, 2726
- Löwenberg B, *see* Breems DA
- Lower E, *see* Jones SE
- Lozahic S, *see* Faivre S
- Lozza L, *see* Fiore M  
*see* Gronchi A
- Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM. Phase II Study of a Liposome-Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally and Pathologic Response Rates in Patients With Malignant Pleural Mesothelioma, 3495
- Lu KH, *see* Soliman PT
- Lu L-X, *see* Zhang L
- Lu T-X, *see* Chua DTT
- Lu Y-J, *see* Williamson D
- Luatti S, *see* Soverini S
- Lubaroff DM, *see* Lutgendorf SK
- Lubinski J, *see* Eisen A
- Luboiniski M, *see* Ducreux M
- Lucas D, *see* Chuba PJ
- Lucas DM, *see* Bolaños-Meade J  
*see* Raval A
- Lucas G, *see* Moreton P
- Lucas J, *see* Horning SJ
- Lucassen AM, *see* Stirling D
- Lucci JA III, *see* Lanciano R
- Lucena F, *see* Mazzolini G
- Lucesole M, *see* Corradini P
- Lüderitz B, *see* Tasci S
- Lüders H, *see* Claviez A  
*see* Schellong G
- Ludovini V, *see* Cappuzzo F
- Ludwig H, *see* Greipp PR
- Ludwig W-D, *see* Einsiedel HG
- Luini A, *see* Colleoni M
- Luiten RM, Kueter EWM, Mool W, Gallee MPW, Rankin EM, Gerritsen WR, Clift SM, Nooijen Wj, Weder P, van de Kastele WF, Sein J, van den Berk PCM, Nieweg OE, Berns AM, Spits H, de Gast GC. Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF–Transduced Tumor Cells in Metastatic Melanoma Patients, 8978
- Lukanich JM, *see* Mamon HJ
- Lukits J, *see* Tímár J
- Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W. Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer, 6132
- Lukka HR, *see* Sathya JR
- Luksch R, *see* Ferrari A
- Lumbroso J, *see* Dromain C
- Luminari S, *see* Baldini L
- Lunagomez S, *see* Ajani JA
- Lund E, *see* Bakken K
- Lunec J, *see* De Preter K
- Lupattelli M, *see* Maranzano E
- Lurkin A, *see* Ray-Coquard I
- Lusher ME, *see* Ellison DW
- Lussier D, *see* Laverdière
- Lust JA, *see* Kumar S
- Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiser H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM. Social Support, Psychological Distress, and Natural Killer Cell Activity in Ovarian Cancer, 7105
- Lutterbach J, Ostertag C. What Is the Appropriate Radiotherapy Protocol for Older Patients With Newly Diagnosed Glioblastoma? (correspondence), 2869
- Lutz D, *see* Zach O
- Lutz MP, *see* Köhne C-H
- Lutz MP, Van Cutsem E, Wagener T, Van Laethem J-L, Vanhoef U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mityr E, Husseini F, Reichardt P, El-Serafi M, Etienne P-L, Lingenfeller T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP. Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group, 9250
- Lutz P, *see* Entz-Werlé N

## AUTHOR INDEX

- Luyun R, *see* Witzig TE  
Lyerly HK, *see* Disis ML  
Lyman GH, *see* Basu SK  
*see* Clark OAC  
Lyman GH, Giuliano AE, Somerfield MR, Benson AB III, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS III, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer, 7703  
Lynch CE, *see* Swenson WT  
Lynch H, *see* Jones DH  
Lynch HT, *see* Bian Y  
*see* Eisen A  
*see* Rebbeck TR  
Lynch HT, Watson P, Tarantolo S, Wiernik PH, Quinn-Laquer B, Bergsagel KI, Huiart L, Olopade OI, Sobol H, Sanger W, Hogg D, Weisenburger D. Phenotypic Heterogeneity in Multiple Myeloma Families, 685  
Lynch JC, *see* Gross TG  
*see* Vose JM  
Lynch JW, *see* Gordan LN  
Lynch JW Jr, *see* Hagler KT  
Lynch PM, *see* Ajani JA  
*see* Gritz ER  
Lynch TJ, *see* Bell DW  
*see* Cella D  
Lynn A, *see* Keating MJ  
Lyons EA, *see* McKoy JM  
Lyss AP, *see* Hutchins LF